Antiviral purine derivatives

ABSTRACT

Chemical compounds comprising nucleoside phosphoramides, their preparation and their therapeutic use in treating viral infections, particularly HIV and HBV are disclosed. The compounds contain a substituted adenine analogue moiety comprising 2-amino-6-(cyclopropylamino)-9H-purin-9-yl. The compounds show both anti-viral activity and acid stability. Salts and esters of the phosphoramidates are included. A representative compound is (1S, 4R), -4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol1 O-[phenyl-(methoxy-L-alaninyl)]-phosphate.

[0001] The present invention relates to a chemical compound. In particular the present invention relates to a chemical compound suitable for use as an anti-viral agent. The present invention also relates to the therapeutic use of the present chemical compound, to a pharmaceutical composition containing the present compound and to use of the present compound in the manufacture of a medicament.

[0002] Since the recognition of human acquired immunodeficiency syndrome (AIDS) much interest and research activity has been directed to its understanding and to attempting to provide a means of treatment. The human immunodeficiency virus (HIV) has been identified as the presumed aetological agent in AIDS. A large literature now exists related to the use of a wide variety of chemical compounds having as their object a demonstration of anti-viral activity with respect to HIV, hepatitus B virus (HBV), herpes and other viruses.

[0003] A class of compounds which has demonstrated anti-viral activity and which has been the subject of a large amount of research are nucleoside analogues.

[0004] An example of such a compound is “Abacavir” which is a substituted adenine analogue (Foster R. H. & Faulds D. Drugs 1998 55 729-736). This compound has entered clinical use due to the potential activity and stability of the compound displayed in preliminary work.

[0005] PCT/GB96100580 relates to a class of nucleoside analogues said to be highly active with respect to HIV. In particular PCT/GB96/00580 addresses the problem of providing compounds which are said to be highly potent in vitro viral inhibitors in both TK⁻ and TK⁺ cells. The compounds disclosed in PCT/GB96/00580 are phosphoramidates of purine or pyrimidine nucleoside analogues. Such compounds can however display chemical, for example acid, or biological, for example nucleoside phosphorylase, instability towards glycoside bond cleavage. Consequential deactivation may limit their potential clinical efficacy.

[0006] A compound however to be potentially useful in a clinical setting needs to exhibit a number of other properties as well as demonstrating, at least in in vitro tests, a sufficient and desired anti-viral activity. Primarily, these other properties comprise good pharmacokinetic properties, sufficient stability in the compound to permit its ease of handling and supply, and sufficiently low toxicity to permit its administration with an acceptable level of side effects to a patient in need of treatment for the viral infection in question.

[0007] In practice however it is frequently found that attempts to modify a compound demonstrating anti-viral activity in vitro, in order to improve its other properties, can have a detrimental effect on the anti-viral activity it displays. Ideally moreover any compound proposed for clinical trials needs also to have a ready means of administration and to be prepareable by an economically viable route.

[0008] It is an object of the present invention to provide a novel class of compounds exhibiting potent anti-viral, in particular anti HIV and/or HBV activity, in combination with good pharmacokinetic and stability properties and exhibiting sufficiently low toxicity so as to provide a compound having beneficial properties for clinical use.

[0009] According to the present invention there is provided a compound according to the following formula (1):

[0010] wherein

[0011] Ar is an aryl group,

[0012] R¹ and R² are independently selected from the group comprising H, alkyl and aryl groups;

[0013] X is selected from the group comprising O, NH, NR⁴ and S wherein R⁴ is selected from the group comprising alkyl and aryl groups;

[0014] R⁵ is selected from the group comprising H, alkyl and aryl groups, wherein when R¹ and R⁵ are each alkyl they may be linked to form a 5- or 6- membered ring;

[0015] and R³ is selected from the group comprising H, al, aryl, heterocyclic and polycyslic groups,

[0016] or a pharmaceutically acceptable derivative or metabolite thereof.

[0017] The present invention includes salts and physiologically functional derivatives of the presently defined compounds.

[0018] Reference in the present specification to an alkyl group means a branched or unbranched, cyclic or acyclic, saturated or unsaturated (e.g. alkenyl or alkynyl) hydrocarbyl radical. Where cyclic, the alkyl group is preferably C₃ to C₁₂, more preferably C₅ to C₁₀, more preferably C₅ to C₇. Where acyclic, the alkyl group is preferably C₁ to C₁₆, more preferably C₁ to C₆, more preferably methyl or ethyl.

[0019] Reference in the present specification to an aryl group means an aromatic group, such as phenyl or naphthyl, or a heteroaromatic group containing one or more, preferably one, heteroatom for example O, N and/or S, such as pyridyl, pyrrolyl, furanyl and thiophenyl. Preferably, the aryl group comprises phenyl or substituted phenyl.

[0020] The alkyl and aryl groups may be substituted or unsubstituted, preferably unsubstituted. Where substituted, there will generally be 1 to 3 substituents present, preferably 1 substituent. Substituents may include halogen atoms and halomethyl groups such as CF₃ and CCl₃; oxygen containing groups such as oxo, hydroxy, carboxy, carboxyalkyl, alkoxy, alkoyl, alkoyloxy, aryloxy, aryloyl and aryloyloxy; nitrogen containing groups such as amino, alkylamino, dialkylamino, cyano, azide and nitro; sulphur containing groups such as thiol, alkylthiol, sulphonyl and sulphoxide, heterocyclic groups which may themselves be substituted; alkyl groups, which may themselves be substituted; and aryl groups, which may themselves be substituted, such as phenyl and substituted phenyl. Alkyl includes substituted and unsubstituted benzyl. Reference in the present specification to alkoxy and aryloxy groups means alkyl-O—and aryl-O— groups, respectively. Reference to alkoyl and aryloyl groups means alkyl-CO—and aryl-CO—, respectively.

[0021] Reference in the present specification to heterocyclic groups means groups containing one or more, optionally bridged, rings containing 1 to 6 heteroatoms in total. Each ring in the group may contain 3 to 12, preferably I to 6, atoms in total. At least one ring present contains 1 to 2 heteroatoms. Where two or more rings are present they may be fused or unfused. The rings can contain unsaturation. Heteroatoms includes 0, S and N. Examples of such heterocyclic groups containing one or more pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, yrazolidinyl, tetrahydrofuranyl, pyranyl, pyronyl, pyridyl, pyrazinyl, pyridazinyl, piperidyl, piperazinyl, morpholinyl, thionaphthyl, benzofuiranyl, isobenzofiyl, indolyl, oxyindolyl, isoindolyl, indazolyl, indolinyl, 7-azaindolyl, isoindazolyl, benzopyranyl, coumarinyl, isocoumarinyl, quinolyl, isoquinolyl, napthridinyl, cinnolinyl, quinazolinyl, pyridopyridyl, benzoxazinyl, quinoxadinyl, chromenyl, chromanyl, isochromanyl and carbolinyl.

[0022] References in the present specification to polycyclic groups means a group comprising two or more non-aromatic carbocyclic or heterocyclic rings which may themselves be substituted. Preferably the group contains 2 to 4 fused or non-fuised rings, each ring suitably containing 3 to 12 atoms, more suitably 4 to 10, more suitably 5 to 7, and even more suitably 5 to 6 atoms. The definitions of cyclic alkyl and heterocyclic rings given above also apply to the rings in the polycyclic groups.

[0023] Reference in the present specification to halogen means a fluorine, chlorine, bromine or iodine radical, preferably fluorine or chlorine radical.

[0024] The group Ar comprises a substituted or unsubstituted aryl group, wherein the term “aryl group” and the possible substitution of said group is as defined above. Preferably, Ar is a substituted or unsubstituted phenyl group. Particularly preferred substituents are electron withdrawing groups such as halogen (preferably chlorine or fluorine), trihalomethyl (preferably trifluoromethyl), cyano and nitro groups. Preferably, Ar is phenyl, 3,5-dichloro-phenyl, p-trifluoromethyl-phenyl, p-cyano-phenyl, or p-nitro-phenyl.

[0025] R³ is selected from hydrogen, alkyl, aryl, heterocyclic and polycyclic groups.

[0026] Preferably, R³ is a substituted or unsubstituted alkyl group. Preferably, R³ is a substituted or unsubstituted C₁₋₆ alkyl group, more preferably an ethyl or methyl group.

[0027] Preferably, at least one of R¹ and R² is hydrogen. It will be appreciated that if R¹ and R² are different, the carbon atom to which they are bonded is an asymmetric centre. Preferably this carbon atom is chiral. When this carbon atom is chiral, the stereohemistry at this site may be D or L or mixed, with L-stereochemistry being preferred. R⁵ and R¹ can be linked to form an alkylene bridge comprising 3 to 4 carbon atoms so as to form a 5- or 6- membered ring. Preferably R⁵ is hydrogen.

[0028] It will be appreciated that the group —NH—CHR¹—CO₂R³ corresponds to a carboxy-protected α-amino acid. Preferably, the group R¹ corresponds to the side chain of a naturally occurring amino acid such as Alanine, Arginine, Asparagine, Aspartic Acid, Cysteine, Cystine, Glycine, Glutanic Acid, Glutamine, Histidine, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Proline, Serine, Threonine, Tryptophan, Tyrosine, Valine. Preferably, R¹ is Me or PhCH₂ corresponding to the side chain of alanine or phenylalanine, respectively. Preferably, the stereochemistry at the asymmetrc centre —CHR¹— corresponds to an L-amino acid.

[0029] It is a feature of the aryl ester phosphate compounds of the present invention that they exhibit significantly enhanced anti-viral efficacy in in vitro tests, in comparison to their corresponding nucleoside analogue, (1S,4R)-4-[2-anino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol, which is known as Abacavir and which has the following structural formula:

[0030]

[0031] According to a further aspect of the present invention there is provided a compound of formula (II):

[0032] wherein R¹, R², R³, R⁵ and X are as defined above, or a pharmaceutically acceptable derivative or metabolite thereof. Preferably X is O.

[0033] The intracellular generation of such anti-viral metabolites is an important feature of the invention for several reasons. In cases where the nucleoside is not a good substrate for host nucleotide kinases, activation will be poor and anti-viral efficacy low, even if the triphosphate is an excellent RT inhibitor. In such cases, the generation of the present metabolites may lead to a very significant enhancement in anti-viral action.

[0034] By “a pharmaceutically acceptable derivatives” is meant any pharmaceutically acceptable salt, ester or salt of such ester or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) a compound of the present formula or present metabolite. Preferred “pharmaceutically acceptable derivatives” include sodium, succinate, fumarate, glutarate and D-tartrate salts.

[0035] By “pharmaceutically acceptable metabolite” is meant a metabolite or residue of a compound of the present formula or present metabolite which gives rise to reverse transcriptase inhibition exhibited by the present compounds.

[0036] According to a fuirther aspect of the present invention there is provided a compound according to the present invention for use in a method of treatment, preferably in the prophylaxis or treatment of viral infection.

[0037] According to a further aspect of the present invention there is provided use of a compound according to the present invention in the manufacture of a medicament for the prophylaxis or treatment of viral infection.

[0038] According to a furter aspect of the present invention there is provided a method of prophylaxis or treatment of viral infection comprising administration to a patient in need of such treatment an effective dose of a compound according to the present invention.

[0039] The viral infection may comprise any viral infection such as HIV and herpes vinis, including HSV I and HSV 2, CMV, VZV, EBV, HAV, HBV, HCV, HDV, HHV6, HHV7, HHV8, papilloma, adenoviruses, rabies and influenza.

[0040] Preferably, the viral infection comprises HIV or HBV infection, more preferably HIV-I or HIV-II. It is a feature of the present invention that the compounds exhibit good activity against HIV-I and HIV-II, and HBV.

[0041] According to a fiurther aspect of the present invention there is provided a pharmaceutical composition comprising a compound of the present invention in combination with a pharmaceutically acceptable excipient.

[0042] According to a filrther aspect of the present invention there is provided a method of preparing a pharmaceutical composition comprising the step of combining a compound of the present invention with a pharmaceutically acceptable excipient.

[0043] Compounds of the present invention can demonstrate significant stability towards acid-mediated hydrolytic decomposition. The present compounds can thus be particularly suitable for oral administration under typical dosing conditions in humans as they can retain stability under the highly acidic environment of the stomach.

[0044] As the purine in compounds of formula (I) is a weak base (pKa=5.0) and the compounds of formula (a) demonstrate stability to acids, salts can be formed of compounds of formula (1) with acids, such as carboxlic acids and dicarboxlic acids. Such salts can be stable, crstalline solids, which can be beneficial in terms of improved shelf-life and ease of handling during manufacture into pharmaceutical compositions. Preferred carboxylic and dicarboxylic acids include malonic, succinic, glutaric, fumaric and tartaric acids. In contrast to the salts of compounds of formula (I), the free bases of compounds of formula (I) can be in a non-crystalline amorphous form which can be hygroscopic.

[0045] The P-OH group of compounds of formula (II) is a weak acid and can therefore form monobasic salts with bases to give, for example, sodium, potassium, ammonium, and triethylanmmonium salts. In. compounds of fonnula (II) when X is OH, dibasic salts can be formed. Such dibasic salts can be in the form of stable solids, which can provide benefits of improved shelf-life and ease of handling during manufacture into pharmaceutical compositions.

[0046] Compounds of the present invention can also demonstrate enhanced stability in biological media, for example, in human plasma. The increased half-life of compounds embodying the present invention in media such as human plasma may permit a pharamacokinetic advantage in dosing in humans in need of treatment.

[0047] The medicament employed in the present invention can be administered by oral or parenteral routes, including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.

[0048] For oral administration, the compounds of the invention will generally be provided in the form of tablets or capsules, as a powder or granules, or as an aqueous solution or suspension.

[0049] Tablets for oral use may include the active ingredients mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouing agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.

[0050] Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent, and soft gelatin capsules wherein the active ingredients is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.

[0051] Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.

[0052] Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

[0053] For intramuscular, intraperitoneal, subcutaneous and intravenous use, the compounds of the invention will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Aqueous suspensions according to the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinyl-pyrrolidone and gum tragacanth, and a wetting agent such as lecithin. Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate.

[0054] The compounds of the invention may also be presented as liposome formulations.

[0055] In general a suitable dose will be in the range of 0.01 to 10 mg per kilogram body weight of the recipient per day, preferably in the range of 0.2 to 1.0 mg per kilogram body weight per day. The desired dose is preferably presented once daily, but may be dosed as two, three, four, five or six or more sub-doses administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dosage forms, for example, containing 10 to 1500 mg, preferably 20 to 1000 mg, and most preferably 50 to 700 mg of active ingredient per unit dosage form.

[0056] According to a further aspect of the present invention there is provided a process for the preparation of the present compound comprising reaction of a compound of formula

[0057] with a compound of formula

[0058] wherein R¹, R², R³, R⁵ and X have the meanings given above.

[0059] The reaction may be carried out under dry conditions at ambient temperature in tetrahydrofuran in the presence of N-methylimidazole, or by using t-butyl magnesium chloride and an excess of the appropriate phosphorochlorideate reagent.

[0060] Compounds embodying the present invention wherein Ar is replaced by H may be prepared from the acid form by treatment of the ester with an aqueous base.

[0061] Compounds wherein X is NH or NR₄ can be prepared by treating the acid form (X═O and R³=H) with amine.

[0062] The above starting material, (1S, 4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin9H-yl]-2-cyclopentenel-methanol, is known as Abacavir and may be made by any procedure known in the art, for example by procedures described in European Patent Specification Number 0434450, PCT Patent Application No. PCT/GB95/02014, and PCT Patent Application No. PCTIEP98/02835, all of which are incorporated by reference thereto.

[0063] The invention will now be described with reference to the following Examples. It will be appreciated that what follows is by way of example only and that modifications to detail may be made whilst still falling within the scope of the invention.

EXPERIMENTAL PROCEDURES General Methods

[0064] The following anhydrous solvents and reagents were bought dry from Aldrich with sure seal stoppers: Dichloromethane (DCM), diethyl ether (Et₂O), tetrahydrofuran (A), N-methyl imidazole (NMI), methanol (MeOH), dimethylformamide (DMF), pyridine (pyr), dioxane, and tBuMgCl. Triethylamine (NEt₃) was dried by refluxing over CaH₂ for several hours and then distilled off for immediate use.

Chromatography

[0065] Thin layer chromatography (tic) was performed on commercially available Merck Kieselgel 60F₂₅₄ plates and the separated components were visualised using ultra violet light (254nm and 366nm), or by treatment with a 5% ethanolic solution of dodeca-molybdo-phosphoric acid (MPA) followed by heating. Column chromatography was performed using Woelm silica (32-63mm) as the stationary phase.

Spectral Characterisation

[0066] All NMR spectral data, unless otherwise stated, were obtained in CDCl₃. Proton and Carbon-13 nuclear magnetic resonance were recorded on a Bruker Avance DPX300 spectrometer with operating frequencies of 300 MHz and 75 MHz respectively. Phosphorous-31 NMR spectra were recorded on a Bruker Avance DPX300 spectrometer operating at 121MHz, and are reported in units of δ relative to 85% phosphoric acid as the external standard, positive shifts are downfield. The following abbreviations are used in the assignment of NMR signals: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), bs (broad signal), dd (double of doublets), dt (double of triplets).

[0067] Low resolution mass spectra were run on a VG Platform II Fisons instrument (Fisons, Altrincham, UK) (atmospheric pressure ionization, electrospray mass spectrometry) in either negative or positive ion mode.

[0068] High Performance Liquid Chromatography (HPLC) was performed on an SSODS2 reverse phase column with an eluent of water/acetonitrile. 100% water (0 mins), 20% water (35 mins), 20% water (45 mins), 100% water (55 mins), with a flow rate of I ml/min and detection by UV at 254 mn. Standards: acetone (t_(R) 4.54 mins), toluene (tR 10.21 mins). Final products showed purities >99%, with undetectable amounts of the parent nucleoside.

Nomenclature and Numbering of Compounds

[0069] IUPAC nomenclature is used where possible, but for ease some compounds are abbreviated. Numbering is by conventional nucleoside numbering.

Standard Procedures

[0070] For practical purposes, standard procedures are given where applicable.

Standard Procedure 1

[0071] To a stirring solution of anhydrous alcohol (10 mol eq) was added thionyl chloride (2 mol eq) dropwise at 0° C., and the resulting solution stirred for Ihr. Upon rising to room temperature, the appropriate amino acid (1 mol eq) was added and the reaction heated at reflux for 6-16 hrs. Removal of the solvent and recrystallisation from methanol:ether gave the amino ester hydrochloride salts.

Standard Procedure 2

[0072] The appropriate amino acid (1 mol eq), para-toluene sulfonic acid (1.1 mol eq) and the appropriate alcohol (Imol eq) were heated under reflux in toluene (100 ml), under Dean and Stark conditions, for 6-16 hrs. On cooling to room temperature the solvent was removed under reduced pressure to give an oil. This was solubilised in dichloromethane (50 ml) and washed with 10% K₂CO₃ (50 ml), and water (50 ml), filtered and the filtratee reduced to dryness to give an oil. This was solubilised in the minimum amount of acetone and neutralised with 2M HCl, and then lyophilised to give the amino acid ester hydrochloride salts.

Standard procedure 3

[0073] Phenyl dichlorophosphate (1 mol eq) and the appropriate amino acid ester hydrochloride salt (1 mol eq) were suspended in anhydrous dichloromethane (30-60 ml). Anhydrous triethylamine (2 mol eq) in anhydrous dichloromethane (30 ml) was added dropwise at −80° C., and the reaction lefi to rise to room temperature overnight. The solvent was removed under reduced pressure, and under nitrogen, to give white solids. This was washed with anhydrous ether (2×25 ml), filtered and the filtrate reduced to dryness to give the products as crude oils. These were stored in anhydrous THF and used without any firther purification.

Standard Procedure 4

[0074] (1 S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (Imol eq) was dried by azeotroping with anhydrous pyridine (3×5 ml), and then suspended in anhydrous THF (5-30 ml). To the suspension was added tBuMgCl (1-2 mol eq, 1.0M solution in THF) dropwise, and the resulting suspension stirred for 10 mins. The phosphorochloridate species (3 mol eq, solution in THF) was then added dropwise and the resulting solution stirred at room temperature for 24-96 hrs. The reaction was then uenched by the addition of sat.NC₄Cl (0.1 ml), and after 10 mins the solvent was removed under reduced pressure. The crude product was purified by silica column chromatography.

[0075] L-Alanine methyl ester hydrochloride.

[0076] C₄H₁₀O₂N₁Cl₁, MW=139.38.

[0077] This was synthesised according to Standard Procedure 1, using anhydrous methanol (34 ml, 0.84 mol), thionyl chloride (8.2 ml, 0.1 12 mol) and L-alanine (5.0 g, 0.056 mol). The product was isolated as a white solid (2.87 g, 36.7%).

[0078]¹H NMR (D₂O): δ4.074.00 (1H,q,CH,J=7.22 Hz), 3.83 (3H,s,OCH₃), 1.39-1.37 (3H,t,CH₃).

[0079]¹³C NMR (D2O): δ171.5 (CO), 53.9 (O CH₃), 49.1 (CH), 15.4 (CH₃).

[0080] Phenyl-(methoxy-L-alaninyl)-phosphorochloridate.

[0081] C₁₀H₁₃O₄N₁Cl₁P₁, MW=277.65.

[0082] This was synthesised according to Standard Procedure 3, using L-Alanine methyl ester hydrochloride (2.0 g, 14.34 mmol), phenyl phosphorodichloridate (3.02 g, 2.14 ml, 14.34 mmol) and anhydrous triethylamine (2.90 g, 4.0 ml, 28.68 mmol). The product (3.91 g, 98.2%) was isolated as a colourless crude oil which was stored in anhydrous THF (40 ml) to give a 0.47M solution.

[0083]³¹p NMR: δ9.28, 8.97 (1:1).

[0084]¹H NMR: δ7.39-7.34 (2H,m,‘o’-Ph), 7.29-7.20 (3H,m,‘m’+‘p’-Ph), 4.494.37 (1H,q,NHala), 4.27-4.09 (1H,m,CHala), 3.78 (3H,d,OCH₃), 1.52-1.49 (3H,dd,CH₃).

[0085]¹³C NMR: 173.6 (CO), 150.1 (‘ipso’-Ph), 130.25 (‘m’-Ph), 126.4 (‘p’-Ph), 120.9 (‘o’-Ph), 53.2 (OCH₃), 51.0 (CH), 20.9 (CH₃ala).

[0086] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-[phenyl-(methoxy-L-alaninyl)]-phosphate. Cf1490.

[0087] C₂₄H₃₀O₅N₇P₁, MW=527.53.

[0088] This was synthesised according to Standard Procedure 4, using (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (500 mg, 1.75 mmol), tBuMgCl (1.0M solution in THF) (1.75 ml, 1.75 mmol) and phenyl-(methoxy-L-alaninyl)-phosphorochloridate (0.47M solution in THF) (1 1.17 ml, 5.24 mmol), in THF (30 ml) and stirring at room temperature for 70 hrs. The crude product was purified by column chromatography eluting with 3% MeOH in DCM and then 2% MeOH in DCM to give the roduct as a white foam (442 mg, 48%).

[0089]³¹P NMR (MeOH-d₄): δ3.97, 3.88.

[0090]¹H N : δ7.41 (1H,d,C8), 7.24-7.19 (2H,m,‘o’-Ph), 7.13-7.03 (3H,m,‘m’+‘p’-Ph), 6.08 (1H,bs,NH), 5.98 (1H,q,H2′), 5.78 (t,H3′), 5.44 (1H,t,H1′), 5.09 (2H,bs,NH₂), 4.22-4.02 (3H,m,NHala+H5′), 3.99-3.87 (1H,m,CHala), 3.59 (3H,t,OCH₃), 3.05 (1H,d,H4′), 2.92 (1H,bs,CHcPr), 2.73-2.62 (1H,m,‘o’H6′), 1.62-1.53 (1H,m,‘o’H6′), 1.30-1.25 (3H,t,CH₃ala), 0.78-0.71 (2H,q,2H of CH₂cPr), 0.54-0.49 (2H,t,2H of CH₂cPr).

[0091]¹³C NMR: δ174.6 LCO), 160.3 (C2), 156.6 (C4), 151.3 (C6), 151.1 (‘ipso’-Ph), 136.8 (C8), 135.9 (C2′), 131.5 (C3′), 130.0 (‘m’-Ph), 125.2 (‘p’-Ph), 120.5 (‘o’-Ph), 115.0 (C5), 69.2 (C5′), 59.2 (C1′), 52.8 (OCH₃), 50.5 (CHala), 46.0 (C4′), 34.9 (C6′), 24.2 (CHcPr), 21.2 (CH₃ala), 7.7 (CH₂cPr).

[0092] MS ES⁺: m/z 527.86 (100%) (M)⁺, 546.84 (M+K)⁺.

[0093] MS FAB: For C₂₄H₃₁O₅N₇P, requires 528.212431, found 528.213848.

[0094] HPLC: tR 30.33 (100%)-(100% water (Omins), 20% water (35 mins), 20% water (45 mins), 100% water (55 mins)).

[0095] IR: 3328.6 (N-Hstr.), 2922.1, 2862.9 (C-Hstr.), 1734.4 (C═Ostr.), 1590.9 (aromatic C-Cstr.), 1462.9 (C-Hdef), 1376.8 (-CH₃syM.def.), 1207.1 (P-O-aryl), 1154.0 (C-Ostr.), 1027.7 (P-O-alkyl), 933.4 (olefiric C-Hdef.), 721.8 (monosub.aromatic C-Hdef.).

[0096] Phenyl-(methoxy-D-alaninyl)-phosphorochloridate.

[0097] C₁₀H₁₃O₄N₁Cl₁P₁, MW=277.65.

[0098] This was synthesised according to Standard Procedure 3, using D-alanine methyl ester hydrochloride (1.Og, 7.17 mmol), PhOP(O)Cl₂ (1.51 g, 1.07 ml, 7.17 mmol) and NEt₃ (1.45 g, 2.0 ml, 14.Ommol) to yield 1.66 g (83.4%) of crude product that was stored in anhydrous THF (10ml), to give a 0.60 mmol/ml solution that was used without fuirther purification.

[0099]³¹P NMR: δ9.38, 9.18 (1:1).

[0100]¹H NMR: δ7.39-7.30 (2H,t,‘o’-Ph), 7.29-7.09 (3H,m,‘m’+‘p’-Ph), 4.85-4.80 (1H,d,NHala), 4.19-4.11 (1H,m,CHala), 3.75 (3H,d,OCH₃), 1.52-1.49 (3H,dd,CH₃ala).

[0101]¹³C NMR: δ173.6 (CO), 150.1 (‘ipso’-Ph), 130.3 (‘o’-Ph), 126.4 (‘p’-Ph), 120.9 (‘m’-Ph), 53.2 (OCH₃), 50.9 (CHala), 21.0 (CH₃ala).

[0102] (1 S,4R)-4-(2-amino6cyclopropyiamin o-9H-purin-9-yl)-2-cyclopentene-1-methanol O-[phenyl-(methoxy-D-alaninyl)]-phosphate. Cf1583.

[0103] C₂₄H₃₀O₅N₇P₁, MW=527.53.

[0104] This was synthesised according to Standard Procedure 4, using (1S,4R)1(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (400 mg, 1.4 mmol), tBuMgCl (1.0M solution in THF) (2.1 ml, 2.lmmol), and phenyl-(methoxy-D-alaninyl)-phosphorochloridate (0.6M solution in THF) (7.0 ml, 4.19 mmol) in THF (25 ml) stiTring at room temperature for 36hrs. The crude product was purified by eluting with 3% MeOH in CHCl₃ and then 2.5% MeOH in CHCl₃ to give the product as a white foam (318.6 mg, 43.2%).

[0105]³¹p NR: 3.93, 3.70.

[0106]¹H NMR: δ7.56+7.51 (1H,d,H8), 7.37-7.32 (2H,m,‘o’-Ph), 7.29 (1H,d,‘p’-Ph), 7.25-7.15 (2H,m,‘m’-Ph), 6.10 (1H,t,J=5.28 Hz,H2′), 6.03 (1H,bs,NHcPr), 5.94-5.89 (1H,m,H3′), 5.54 (1H,bs,H1′), 5.01 (2H,bs,NH₂), 4.26-3.83 (4H,m,CHala,NHala+H5′), 3.72 (3H,d,OCH₃), 3.18 (1H,s,CHcPr), 3.02 (1H,bs,H4′), 2.86-2.75 (1H,m,1 of H6′), 1.78-1.64 (1H,m,1 of H6′), 1.39-1.36 (3H,dd,CH₃ala), 0.90-0.83 (2H,q,J=6.13 Hz,2H of CH₂cPr), 0.63 (2H,bs, 2H of CH₂cPr).

[0107]¹³C NMR: δ174.5 (CO), 160.3 (C2), 156.6 (C4) 151.2 (C6), 151.0 (‘ipso’-Ph), 13608 (C2′), 136.1 (C8), 131.5 (C3′), 130.0 (‘m’-Ph), 125.3 (‘p’-Ph), 120.5 (‘o’-Ph), 115.2 (C5), 69.3 (C5′), 59.3 (Cl′), 52.9 (CHala), 50.5 (OCH₃), 46.0 (C4′), 34.9 (C6′), 24.1 (CHcPr), 21.4 (CH₃ala), 7.8 (CH₂cPr).

[0108] MS ES⁺: m/z 527.86 (100%) (M)⁺, 546.84 (M+K)⁺.

[0109] MS FAB: For C₂₄H₃₁O₅N₇P requires 528.212431, found 528.211505.

[0110] HPLC: tR 29.807 (100%)-(100% water (0 mins), 20% water (35 mins), 20% water (45 mins), 100% water (55 mins)).

[0111] IR: 3333.6 (N-Hstr.), 2923.4, 2853.4 (C-Hstr.), 1734.1 (C═Ostr.), 1591.1 (aromatic C-Cstr.), 1458.3 (C-Hdef.), 1376.7 (-CH₃syM.def.), 1208.3 (P-O-aryl), 1153.3 (C-Ostr.), 1026.9 (P-O-alkyl), 931.9 (olefinic C-Hdef), 721.6 (monosub.aromatic C-Hdef).

[0112] Phenyl-(methoxy-L-phenylalaninyl)-phosphorochloridate.

[0113] C₁₆H₁₇O₄N₁C₁, P₁, MW=353.74.

[0114] This was synthesised according to Standard Procedure 3, using L-phenylalanine methyl ester (1.Og, 4.64 mmol), PhOP(O)Cl₂ (0.98 g, 0.70 ml, 4.64 mmol) and NEt₃ (0.94 g, 1.30 mi, 9.28 mmol) to yield 1.45 g (88.4%) of crude product as an oil that was stored in anhydrous THF (10 ml), to give a 0.41 mmol/ml solution that was used without farther purification. 31p NMR: 6 9.37, 9.23 (1:1).

[0115]¹H NMR: δ7.60-7.16 (10H,m,2xPh), 4.704.49 (1H,m,CHala), 4.38-4.16 (1H,m,NHala), 3.89 (3H,d,OCH₃), 3.23 (2H,m,CHPh).

[0116] (1,S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentee-1-methain O-[phenyl-(methoxy-L-phenylalaninyl)]-phosphate. Cf 1585.

[0117] C₃₁H₃₄O₅N₇P, MW=603.6.

[0118] This was synthesised according to Standard Procedure 4, using (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (300 mg, 1.05 mmol), tBuMgCl (1.0M solution in THF) (1.57 ml, 1.57 mmol) and phenyl-(methoxy-L-phenylalaninyl)-phosphorochloridate (0.41M solution in THF) (7.66 ml, 3.14 mmol) in THF (20 ml) stirring at room temperature for 48 hrs. The crude product was purified by eluting with 3% MeOH in CHCl₃ and then 2.5% MeOH in CHCl₃ to give the product as a white foam (272.9 mg, 43.15%).

[0119]³¹p NMR: δ3.91, 3.80.

[0120]¹H NMR: δ7.47+7.43 (1H,d,H8), 7.31-7.06 (IOH,m,2xPh), 6.25 (1H,d,NHcPr), 6.00-5.95 (1H,q,H2′), 5.87-5.81 (1H,t,H3′), 5.49 (1H,s,H1′), 5.19 (2H,bs,NH₂), 4.31-3.92 (4H,m,CHala,NHala+H5′), 3.64 (3H,d,OCH₃), 3.02-2.89 (4H,m,CH₂Ph,CHcPr+H4′), 2.78-2.63 (1H,m,1 of H6′), 1.63-1.49 (1H,m,l of H6′), 0.86-0.80 (2H,q,J=6.24 Hz,2H of CH₂cPr), 0.60 (2H,d,2H of CH₂cPr).

[0121]¹³C NMR: δ74.3 (CO), 161.5 (C2), 157.7 (C4), 152.4 (C6) 152.1 (‘ipso’-OPh), 137.7 (‘ipso’-Bn), 137.1 (C2′), 136.9 (C8), 132.4 (C3′), 130.9 (‘o’+‘m’-Bn), 129.9 (‘m’-mOPh), 128.4 (‘p’-Bn), 126.2 (‘p’-OPh), 121.5 (‘o’-OPh), 116.1 (C5), 70.1 (C5′), 60.1 (Cl′), 57.2 (CHala), 53.6 (OCH₃), 46.9 (C6′), 41.7 (C4′), 35.9 (CH₂Ph), 25.1 (CHcPr), 8.7 (CH₂cPr).

[0122] MS ES⁺: m/z 603.8 (100%, M+), 604.8 (35%, M+H⁺), 625.7 (15%, M+Na⁺).

[0123] MS FAB: For C₃₁H₃₄O₅N₇P requires 604.243731, found 604.242585.

[0124] HPLC: t_(R) 34.707, 35.020 (100%)-(100% water (0 mins), 20% water (35 mins), 20% water (45 mins), 100% water (55mins)).

[0125] IR: 3331.7 (N-Hstr.), 3007.2, 2952.2 (C-Hstr.), 1741.1 (C═Ostr.), 1595.6, 1487.7 (aromatic C-Cstr.), 1455.0 (C-Hdef), 1393.9 (—CH₃sym.def.), 1252.5 (P═O), 1214.3 P-0-my1), 1125.3 (C-Ostr.), 1025.6 (P-O-alkyl), 935.8 (olefinic C-Hdef.), 754.8 (monosub.aromatic C-Hdef.).

[0126] Phenyl-(methoxyglycinyl)-phosphorochloridate.

[0127] C₉H₁₁O₄N₁C₁,P₁, MW=263.62.

[0128] This was synthesised according to Standard Procedure 3, using glycine methyl ester (1.5 g, 11.9 mmol), PhOP(O)Cl₂ (2.52 g, 1.79 ml, 11.9 mmol) and NEt₃ (2.42 g, 3.33 ml, 23.9 mmol) to yield 3.07 g (97.15%) of crude product as an oil that was stored in anhydrous THF (15 ml), to give a 0.774 mmol/ml solution that was used without further purification.

[0129]³¹p NMR: δ10.43.

[0130]¹H NMR: δ7.43-7.38 (2H,m,‘o’-Ph), 7.31-7.25 (3H,m,‘m’+‘p’-Ph), 4.67 (1H,bs,NHala), 3.94 (2H,dd,CH₂), 3.83 (3H,s,OCH₃).

[0131]¹³C NMR: δ170.4 (CO), 150.1 (‘ipso’Ph), 130.2 (‘m’-Ph), 126.4 (‘p’-Ph), 120.8 (‘o’-Ph), 53.1 (OCH₃), 43.4 (CH₂).

[0132] (1 S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-[phenyl-(methoxy-glycinyl)]-phosphate. Cf1588.

[0133] C₂₃H₂₈O₅N₇P₁, MW=513.49.

[0134] This was synthesised according to Standard Procedure 4, using (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (300 mg, 1.05 mmol), tBuMgCl (1.0M solution in THF) (1.57 ml, 1.57 mmol) and phenyl-(methoxy-glycinyl)-phosphorochloridate (0.774M solution in THF) (4.06 ml, 3.14 mmol) in THF (20 ml) stirring at room temperature for 96hrs. The crude product was purified by eluting with 3% MeOH in CHCl₃ and then with 2.5% MeOH in CHCl₃ to give the product as a white foam (82.6 mg, 15.4%).

[0135]³¹p NMR: δ4.79, 4.67 (1:1).

[0136]¹H NMR: δ7.40+7.36 (1H,dH8), 7.24-7.19 (2H,t,‘o’-Ph), 7.15-7.10 (2H,t,‘m’-Ph), 7.07-7.02 (1H,t,‘p’-Ph), 6.00-5.96 (2H,m,H2′+NHcPr), 5.80-5.76 (1H,m,H3′), 5.45-5.41 (1H,tH1′), 4.99 (2H,bs,NH₂), 4.14-4.00 (3H,m,NHala+H5′), 3.62 (3H,s,OCH₃), 3.03 (1H,d,H4′), 2.91 (1H,d,CHcPr), 2.73-2.62 (1H,m,1of H6′), 1.62-1.51 (1H,m,1 of H6′), 1.45-1.43 (6H,t,2xCH₃), 0.78-0.71 (2H,q,2H of CH₂cPr), 0.54-0.49 (2H,t,2H of CH₂cPr).

[0137]¹³C NMR: δ172.1 (CO), 160.2 (C2), 156.6 (C4), 152.0 (C6), 151.7 (‘ipso’-Ph), 137.7 (C8), 137.1 (C2′), 132.0 (C3′), 130.8 (‘m’-Ph), 126.0 (‘p’-Ph), 121.2 (‘o’-Ph), 115.5 (C5), 69.9 (C5′), 60.0 (Cl′), 53.5 (OCH₃), 46.7 (C4′), 43.9 (CH₂), 35.4 (C6′), 25.0 (CHcPr), 8.5 (CH₂cPr).

[0138] MS ES⁺: m/z 513.9 (100%, M⁺), 514.8 (25%, M+H⁺), 535.8 (40%, M+Na⁺).

[0139] MS FAB: For C₂₃H₂₉O₅N₇P requires 514.196781, found 514.195321.

[0140] HPLC: t_(R) 28.419 (99.9%)-(100% water (Omins), 20% water (35 mins), 20% water (45 mins), 100% water (55 mins)).

[0141] IR: 3342.0 (N-Hstr.), 1749.8 (C═Ostr.), 1596.2, 1488.4 (aromatic C-Cstr.), 1451.9 (C-Hdef.), 1394.7 (-CH₃sym.def), 1259.6 (P═O), 1212.1 (P-O-aryl), 1151.6 (C-Ostr.), 1026.8 (P-O-alkyl), 937.8 (olefinic C-Hdef), 760.7 (monosub.aromaiic C-Hdef.).

[0142] Methyl-2-amino-2-methylpropanoate hydrochloride

[0143] C₅H,₂O₂N₁Cl, MW=153.61.

[0144] This was synthesised according to Standard Procedure 1, using 2-amino-isobutyric acid (4 g, 0.039 mol) with thionyl chloride (5.66 ml, 0.078 mol) and anhydrous methanol (23.5 ml, 0.58 mol). This gave the product as a white solid (5.805 g, 97.4%)

[0145]¹H NMR (DMSO): δ8.85 (3H,s,NH+Cl), 3.72 (3H,s,OMe), 1.48 (6H,s,2xMe).

[0146]¹³C NMR (DMSO): δ172.8 (COOMe), 56.6 (OMe), 53.9 (CMe₂), 24.1 (2xMe).

[0147] MS ES⁺: m/z 117.71 M+H⁺, 142.88 M+Na⁺.

[0148] Phenyl-(methyl-2-amino-2-methylpropanoate)-phosphorochloridate.

[0149] C₁₁I H₁₅O₄N₁C₁P₁, MW=291.67.

[0150] This was synthesised according to Standard Procedure 3, using 2-amino-isobutate methyl ester hydrochloride (1.0 g, 6.51 mmol), PhOP(O)Cl₂ (1.37 g, 0.97 ml, 6.51 mmol) and NEt₃ (1.32 g, 1.18 ml, 13.02 mmol), to yield 1.73 g (91%) of the crude product as an oil. This was stored in anhydrous THF (10 ml) to give a solution of 0.593mmol/ml, and used without flirther purification.

[0151]³¹P NMR: δ6.86.

[0152] 1H NMR: δ7.43-7.38 (2H,t,‘o’-Ph), 7.32-7.21 (3H,m,‘m’+‘p’-Ph), 4.84 (1H,d,NHala), 3.83 (3H,s,OCH₃), 1.72 (6H,d,2xCH₃).

[0153]¹³C NMR: δ175.7 (CO), 150.3 (‘ipso’-Ph), 130.3 (‘m’-Ph), 126.3 (‘p’-Ph), 121.0 (‘o’-Ph), 58.8 (OCH3), 53.6 (C[CH₃]₂), 27.3+27.0 (2xCH₃).

[0154] (1S,4R)-4-(2-amino-6-yclopropylamino-9H-puri-9-yl)-2-cyclopentene-1-methanol

[0155] O-[phenyl-(methoxy-α,αdimethylglycinyl)]-phosphate. Cf 1584.

[0156] C₂₅H₃₂O₅N₇P₁, MW=542.23.

[0157] This was synthesised according to Standard Procedure 4, using (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (300 mg, 1.05 mmol), tBuMgCl (1.0M solution in THF) (1.57 ml, 1.57 mmol) and phenyl-(methoxy-dimethylglycinyl)-phosphorochloridate (0.59M solution in THF) (5.3 ml, 3.14 mmol) in THF (20 ml) stirring at room temperature for 96 hrs. The crude product was purified by eluting with 3% MeOH in CHCl₃ and then with 2.5% MeOH in CHCl₃ to give the product as a white foam (193.7 mg, 34.14%).

[0158]³¹p NMR: δ2.49. ¹H NMR: δ7.40+7.36 (1H,d,H8), 7.24-7.19 (2H,t,‘o’-Ph), 7.15-7.10 (2H,t,‘m’-Ph), 7.07-7.02 (1H,t,‘p’-Ph), 6.00-5.96 (2H,m,H2′+NHcPr), 5.80-5.76 (1H,m,H3′), 5.45-5.41 (1H,t,H1′), 4.99 (2H,bs,NH₂), 4.14-4.00 (3H,m,NHala+H5′), 3.62 (3H,s, OCH₃), 3.03 (1H,d, H4′), 2.91 (1H,d,CHcPr), 2.73-2.62 (1H,m,1 of H6′), 1.62-1.51 (1H,m,1of H6′), 1.45-1.43 (6H,t,2xCH₃), 0.78-0.71 (2H,q,2H of CH₂cPr), 0.54-0.49 (2H,t,2H of CH₂cycl.).

[0159] MS ES⁺: m/z 541.9 (100%, M⁺), 563.8 (30%, M+Na⁺).

[0160] MS FAB: For C₂₅H₃₃O₅N₇P requires 542.228081, found 542.228428.

[0161] HPLC: t_(R) 28.347 (100%)-(100% water (0 mins), 20% water (35 mins), 20% water (45 mins), 100% water (55mins)).

[0162] IR: 3346.0 (N-Hstr.), 2923.0, 2853.5 (C-Hstr.), 1734.0 (COstr.), 1590.2 (aromatic C-Cstr.), 1458.4 (C-Hdef.), 1376.8 (-CH₃syn.def.), 1261.3 (P═O), 1152.7 (C-Ostr.), 1028.0 (P-O-allcyl), 936.0 (olefinic C-Hdef.), 721.7 (monosub.aromatic C-Hdef.).

[0163] L-Aspartic acid dimethyl ester hydrochloride.

[0164] C₆H₁₂O₄N₁C₁, MW=197.62.

[0165] This was synthesised according to Standard Procedure 1, using L-asparagine (2.5 g, 0.019 mol) with thionyl chloride (3.67 ml, 0.042 mol) and anhydrous methanol (12.86 ml, 0.32 mol). This gave L-aspartic acid dimethyl ester hydrochloride in 3.70 g, 99% yield. ¹H NMR (MeOH-d₄): 5 4.53-4.50 (1H,t,CH), 3.94 (3H,s,OCH₃), 3.85 (3H,s,OCH₃), 3.18 (2H,d,CH₂).

[0166]¹³C NMR (MeOH-d): δ170.4, 168.4 (CO), 53.0+52.0 (2xOMe), 49.4 (CH), 33.8 (CH₂).

[0167] Phenyl-(dimethoxy-L-aspartyl)-phosphorochloridate.

[0168] C₁₂H₁₅O₆N₁C₁P₁, MW=335.68.

[0169] This was synthesised according to Standard Procedure 3, using L-Aspartic acid dimethyl ester (1.0 g, 5.04 mmol), PhOP(O)Cl₂ (1,06 g, 0.75 ml, 5.04 mmol) and NEt₃ (1.02 g, 1.40 ml, 10.1 mmol) to yield 0.55 g (32.4%) of crude product as an oil that was stored in anhydrous THF (5 ml), to give a 0.33mmol/ml solution that was used without further purification.

[0170]³¹P NMR: δ9.74,9.59 (1:1).

[0171] (1S,4R)-4-(2-amino- 6-cyclopropylamin9H-purin-9-yl)-2-cyclopentene-1-methanol O-[phenyl-(L-asparic acid dimethyl ester)]-phosphate. Cf1589.

[0172] C₂₄H₃₀O₅N₇P), MW=527.53.

[0173] This was synthesised according to Standard Procedure 4, using (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (250 mg, 0.87 mol),

[0174] tBuMgCl (1.0M solution in THF) (0.87 ml, 0.87 mmol) and phenyl-(L-aspartic acid dimethyl ester)-phosphorochloridate (0.50M solution in THF) (5.20 ml, 2.62 mmol) in THF (15 ml) and stirring at room temperature for 48 hrs. The crude product was purified by eluting with 2.5% MeOH in CHCl₃ ((2) to give the product as a pale yellow foam (163.5 mg, 32.0%).

[0175]³¹p NMR: δ4.19, 3.76 (1:1).

[0176]¹H NMR: 8 7.40 (1H,d,H8), 7.24-7.19 (2H,t,‘o’-Ph), 7.12-7.03 (3H,m,‘m’+p -Ph), 6.05-5.95 (2H,m,H2′+NHcPr), 5.79 (1H,d,H3′), 5.44 (1H,s,H′), 5.02 (2H,bs,NH₂), 4.384.07 (4H,m,H5′,NHala+CHala), 3.61 (3H,s,OCH₃), 3.54 (3H,d,OCH₃), 3.05-2.52 (5H,m,CH₂aa,H4′,CHcPr,+1of H6′), 1.64-1.52 (1′H,m,1of H6′), 0.77-0.73 (2H,t,J=5.49 Hz,2Hof CH₂cPr), 0.51 (2H,bs,2Hof CH₂CPr).

[0177]¹³C NMR: δ173.3 (CO), 172.4 (CO), 161.5 (C2), 157.7 (C4), 152.3 (C8), 152.1 (‘ispo’-Ph), 137.8 (C2′), 137.0 (C6), 132.6 (C3′), 131.1 (‘m’-Ph), 126.4 (‘p’-Ph), 121.6 (‘o’-P3), 116.2 (C5), 70.5 (C5′), 60.3 (Cl′), 54.3 (OCH₃), 53.5 (OCH₃), 52.6 (CHala), 47.1 (C4′), 39.7 (CH₂ala), 36.0 (C6′), 25.1 (CHcPr), 8.8 (CH₂cPr).

[0178] MS ES⁺: m/z 585.8 (100%, M⁺), 607.7 (30%, M+Na⁺.

[0179] MS FAB: For C₂₆H₃₃O₅N₇P requires 586.217910, found 586.217510.

[0180] HPLC: t_(R) 29.261 (100%)-(100% water (Omins), 20% water (35 mins), 20% water (45 mins), 100% water (55 mins)).

[0181] IR: 3347.5 (N-Hstr.), 2850.7 (C-Hstr.), 1739.9 (C═Ostr.), 1596.1 (aromatic C-Cstr.), 1461.9 (C-Hdef.), 1376.6 (—CH₃sym.def.), 1262.4 (P═O), 1211.2 (P-O-aryl), 1158.3 (C-Ostr.), 1027.0 (P-O-alkyl), 935.6 (olefinic C-Hdef), 761.5, 722.0 (monosub.aromatic C-Hdef.).

[0182] 3-cyclohexyl-L-alanine methyl ester hydrochloride salt

[0183] C₉H₁₉N₁o₂Cl₁, MW=221.75

[0184] This was synthesised according to Standard Procedure 1, using 3-cyclohexyl-L-alanine (3.0 g, 17.5mmol), methanol (30 ml), and thionyl chloride (2.56 ml, 35 mmol). The product was isolated as a white solid (3.23 g, 83.9%).

[0185]¹H NMR (MeOH-d₄): δ4.124.07 (3H,t,CHala), 3.85 (3H,s,OCH₃), 1.741.68 (6H,m,CH2+0-CH2), 1.56-1.43 (1H,m,CH), 1.36-1.15 (4H,m,m-CH₂), 1.05-0.90 (2H,q,p-CH₂)

[0186]¹³C NMR: δ170.15 (CO), 52.7 (OCH₃), 50.8 (CHala), 38.2 (CH₂), 33.6 (CH), 33.0+32.7 (2xCH₂-o), 26.3 (p-CH₂), 26.0+25.9 (2xCH₂-m).

[0187] Phenyl-(methoxy-3-cyclohexyl-L-alaninyl)-phosphorochloridate

[0188] C₁₆H₂₃N₁O4P₁Cl₁, MW=359.82

[0189] This was synthesised according to Standard Procedure 3, using 3-Cyclohexyl-L-alanine methyl ester hydrochloride salt (0.7 g, 316 mmol), PhOP(O)Cl₂ (0.47 ml, 3.16mmol), triethylamine (0.88 ml. 6.31mmol) in DCM (60 ml). The usual workup yielded the crude product as a yellow oil (1.18 g, 100%), which was stored in THF (7 ml) to give a 0.45M solution.

[0190]³¹p NMR. δ9.79, 9.49 (1:1).

[0191]¹H NMR: δ7.49-7.43 (2H,m,‘o’-Ph), 7.37-7.19 (3H,m,‘m’+‘p’-Ph), 4.464.35 (1H,q,NHala), 4.32-4.20 (1H,m,CHala), 3.88-3.85 (3H,dd,OCH₃), 1.94-1.90 (1H,d,CHcHx), 1.76-1.60

[0192] (1 S,4R)-4-(2-amino-6cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-Phenyl-(meth oxy-3-cyclohexane-L-alaninyl)-phosph ate. Cf1709.

[0193] C₃₀H₄₀N₇O₅P₁, MW=609.66

[0194] This was synthesised according to Standard Procedure 4, using (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (150 mg, 0.52 mmol), tBuMgCl (1.05 ml, 1.05 mmol, of a 1.0M solution in THF), in THF (4 ml) and phenyl-(methoxy-3-cyclohexane-L-alaninyl)-phosphorochloridate (3.5 ml, 1.57 mmol, of a 0.45M solution in THF), at room temperature for 24 hrs. Afler 24 hrs, additional phenyl-(methoxy-3-cyclohexane-L-alaninyl)-phosphorochloridate (2.5 ml, 1.12 mmol, of a 0.45M solution in THF) was added and the reaction stirred for another 24 hrs. The crude product was purified by eluting with 3% MeOH in CHCl₃, and then 2.5% MeOH in CHCl₃ to give the pure product as a pale yellow foamy solid (79.6 mg, 24.9%).

[0195] 31P NMR: δ4.14, 3.98 (1:1).

[0196]¹H NMR: δ7.50 (1H,d,H8), 7.34-7.13 (5H,t,OPh), 6.20 (1H,s,NHcPr), 6.08 (1H,t,H2′), 5.89 (1H,q,H3′), 5.53 (1H,bs,H1′), 5.16 (2H,bs,NH₂), 4.24-3.84 (4H,m,H5′,NHala+CHala), 3.66 (3H,s,OCH₃), 3.34 (1H,bs, ), 3.11 (1H,d, ), 3.03 (1H,bs, ), 2.84-2.72 (1H,m,1of H6′), 1.98-1.36 (8H,m, ), 1.11 (3H,bs, ), 0.89-0.83 (4H,m,2Hof cPr+4CH2-‘p’), 0.63 (2H,d,2Hof cPr).

[0197]¹³C NMR: δ174.8CO 160.2 (C2), 156.5 (C4), 151.3 (C6), 151.2 (‘ipso’-Ph), 136.8 (C2′), 135.9 (C8), 131.5 (C3′), 130.0 (‘m’-Ph), 125.2 (‘p’-Ph), 120.5 (‘o’-Ph), 115.1 (C5), 69.4 (C5′), 59.3 (Cl′), 52.7 (CHala), 46.1 (C4′), 42.5 (CH₂), 34.9 (C6′), 33.8 (CHcHx), 32.7 (CH2-‘o’), 26.7 (CH₂-‘m’), 26.4 (CH₂-p′), 24.2 (CHcPr), 7.8 (CH₂cPr).

[0198] MS ES⁺: m/z 610.3 (40%, M⁺), 632.3 (100%, M+Na⁺), 633.3 (25%, M+H+Na⁺).

[0199] MS FAB: For C₃₀H₄₀O₅N₇NaP requires 632.2726, found 632.2727.

[0200] HPLC: t_(R) 42.154 (100%)-(100% water (0 mins), 20% water (35 mins), 20% water (45 mins), 100% water (55 mins)).

[0201] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-(L-alaninyl)-phosphate diammonium salt Cf1540.

[0202] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-[phenyl-(methoxy-L-alaninyl)]-phosphate (125 mg, 0.24 mmol) was stirred in H₂O: NEt₃ (10 ml, 1:1 v/v), at 25-35° C. for 5 hrs. The reaction mixture was extracted with DCM (8×20 ml), and the aqueous layer reduced to dryness. The resulting solid was solubilised in isopropanol and purified by flash column chromatography, gradient eluting with i-PrOH:H₂O: NH₃ (11:1:1 to 9:1:2). The appropriate fractions were reduced to dryness and freeze dried to give the pure product as a white foamy solid (106 mg, 95%).

[0203]³¹P NMR (D₂O): δ8.62 (s).

[0204]¹H N D₂O):-δ7.79 (1H,s,H8), 6.08 (1H,d,H12′), 5.77 (1H,dH3′), 5.35 (1H,t,HI′), 3.71-3.58 (2H,m,H5′), 3.41-3.32 (1H,m,CHa.a), 3.02-2.94 (1H,m,NHCH), 2.70-2.59 (2H,m,H4′+1 of CH₂), 1.57-1.49 (1H,dt,l of CH₂), 1.10 (3H,d,CH₃), 0.83-0.76 (2H,q,1 of CH₂cyclo.), 0.61-0.56 (2H,q, 1 of CH₂cyclo.).

[0205] MS ES⁺: m/z 437.9 (100%, M⁺).

[0206] MS FAB: calculated m/z 438.165481, found m/z 438.163790.

[0207] (1S,4R)-4-(2-amiDuo6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-(D-alaninyl)-phosphate diammonium salt.

[0208] (1S,4R)-4-(2-aniino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-[phenyl-(methoxy-D-alaninyl)]-phosphate (100 mg, 0.19 mmol) was stirred in H₂O: NEt₃ (8 ml, 1:1 v/v), for l 6 hrs. The reaction mixture was extracted with DCM (5×20 ml), and the aqueous layer reduced to dryness. The resulting solid was solubilised in isopropanol and purified by flash column chromatography, gradient eluting with i-PrOH:H₂O:NH₃ (11:1:1 to 9:1:2). The appropriate fractions were reduced to dryness and freeze dried to give the pure product as a white foamy solid (88%).

[0209]³¹p NMR (MeOH):-δ7.81 (s).

[0210]¹H NMR:-δ7.74 (1H,s,H8), 6.12 (1H,d,J=5.53 Hz,H2′), 5.78 (1H,t,H3′), 5.44 (1H,d,J=6.21 Hz,H1′), 3.74 (2H,t,J=5.42 Hz,H5′), 3.70-3.60 (1H,m,CHala), 3.01 (1H,bs,H4′), 2.84 (1H,d,J=3.28 Hz,CHcPr), 2.73-2.63 (1H,dt,J=8.66 Hz+5.17 Hz,1of H6′), 1.67-1.58 (1H,m,l of CH₂), 1.21 (3H,d,J=7.01 Hz,CH₃ala), 0.79-0.73 (2H,q,J=6.68 Hz,2H of CH₂cPr), 0.53 (2H,t,2H of CH₂cPr).

[0211]¹³C NMR: δ179.8 (CO), 161.2 (C2), 157.1 (C4), 151.1 (C6), 139.5 (C2′), 137.8 (C8), 130.7 (C3′), 114.6 (CS), 68.0 (C5′), 60.5 (Cl′), 51.9 (CHala), 47.6 (C4′), 35.9 (C6′), 24.4 (CHcPr), 21.7 (CH₃ala), 7.6 (CH₂cPr).

[0212] MS ES⁺: m/z 437.9 (100%, M⁺).

[0213] MS FAB: calculated m/z 438.165481, found m/z 438.167842.

[0214] Phenyl-(ethoxy-L-aianinyl)-phosphorochloridate.

[0215] C₁₁H₁₅O₄N₁Cl₁P₁, MW=291.67.

[0216] This was synthesised according to Standard Procedure 3, using L-Alanine ethyl ester hydrochloride (l.Og, 6.51 mmol), PhOP(O)Cl₂ (1.37 g, 0.97 ml, 6.51 mmol) and NEt₃ (1.32 g, 1.81 ml, 13.0 mmol) to yield 1.85 g (97.4%) of crude product as an oil that was stored in anhydrous THF (10 ml), to give a 0.63 mmol/ml solution that was used without ither purification.

[0217]³¹P NMR: δ9.41, 9.16 (1:1).

[0218]¹H NMR: δ7.42-7.35 (2H,dd, ‘o’-Ph), 7.31-7.25 (3H,m, ‘m’+‘p’-Ph), 4.71 (1H,d,NHala), 4.314.13 (3H,m,OCH₂+CHala), 1.55-1.52 (3H,dd,OCH CH₃), 1.33-1.30 (3H,dd,CH₃ala).

[0219]¹³C NMR: δ173.1 (CO), 150.2 (‘ipso’-Ph), 130.3 (‘m’-Ph), 126.4 (‘p’-Ph), 120.9 (‘o’-Ph), 62.3 (OCH₂), 51.0 (CHala), 20.9 (CH₂CH3), 14.5 (CH₃ala).

[0220] (1S,4R)-4-(2-amino-6cyclopropyla min o-⁹H-purin-9-yl)-2-cyclopentene1-methaanol O-[phenyl-(ethoxy-L-alaninyl)]-phosphate. Cf1587.

[0221] C₂₄H₃₀ O₅N₇P₁, MW=527.53.

[0222] This was synthesised according to Standard Procedure 4, using (1S,4R)-42-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (300 mg, 1.4 mmol), tBuMgCl (1.0M solution in THF) (1.57 ml, 1.57 mmol), and phenyl-(ethoxy-L-alaninyl) phosphorochloridate (0.49M solution in THF) (6.45 ml, 3.14mmol) in anhydrous THF (20 ml), and stirring at room temperature for 24 hrs. The crude product was purified by colunm chromatography eluting with 2.5% MeOH in CHCl₃ to give the product as a pale yellow foam (290 mg, 51.1%).

[0223]³¹p NMR: δ4.04, 3.96 (1:1).

[0224]¹H N: δ7.39 (1H,d,J=7.56 Hz,H8), 7.23-7.18 (2H,t,J=7.90 Hz,‘o’-Ph), 7.12-7.10 (2H,t,‘m’-Ph), 7.06-7.01 (1H,t,J=7.13 Hz,‘p’-Ph), 6.18 (1H,bs,NHcPr), 5.97-5.95 (1H,tH2′), 5.79-5.75 (1H,t,J=5.55 Hz,H3′), 5.43 (1H,s,H1′), 5.13 (2H,bs,NH₂), 4.30-4.14 (1H,m,NHala), 4.064.00 (4H,m,H5′+OCH₂), 3.96-3.84 (1H,m,CHala), 3.03 (1H,d,J=5.74 Hz,H4′), 2.92 (1H,bs,CHcPr), 2.71-2.61 (1H,m,1of H6′), 1.60-1.51 (1H,m, 1of H6′), 1.29-1.24 (3H,tJ=6.64 Hz,CH₃ala), 1.18-1.11 (3H,m,CH₂CH₃), 0.75-0.71 (2H,q,J=6.76 Hz,2H of CH₂cPr), 0.50 (2H,bs,2H of CH₂cPr).

[0225]¹³C NMR: δ173.35 (CO), 159.8 (C2), 156.0 (C4), 150.6 (C6) 150.4(‘ipso’-Ph), 136.1 (C2′), 135.1 (C8), 130.8 (C3′), 129.3 (‘m’-Ph), 124.5 (‘p’-Ph), 119.8 (‘o’-Ph), 114.4 (C5), 68.6 (C5′), 61.2 (OCH₂), 58.5 (Cl′), 50.0 (CHala), 45.3 (C4′), 34.3 (C6′), 23.4 (CcPr), 20.6 (CH₃ala), 13.8 (CH2CH₃), 7.0 (CH₂cPr).

[0226] MS ES⁺: m/z 541.9 (100%, M⁺), 546.84 (28%, M+H⁺), 563.8 (25%, M+Na⁺).

[0227] MS FAB: For C₂₅H₃₃O₅N₇P, requires 542.228081, found 542.228131.

[0228] HPLC: t_(R) 31.76, 32.03 (100%)-(100% water (0 mins), 20% water (35 mins), 20% water (45 mins), 100% water (55 mins)).

[0229] IR: 3334.1 (N-Hstr.), 1734.5 (C═Ostr.), 1595.9, 1488.0 (aromatic C-Cstr.), 1450.3 (C-Hdef.), 1394.2 (-CH₃sym.def.), 1252.8 (P═O), 1210.4 (P-O-aryl), 1153.3 (C-Ostr.), 1026.0 (P-O-alkyl), 934.8 (olefinic C-Hdef.), 759.0 (monosub.aromatic C-Hdef.).

[0230] Phenyl-(benzoxy-L-alaninyl)-phosphorochlioridate.

[0231] C₁₆H₁₇O₄N₁Cl₁P₁, MW=353.74.

[0232] This was synthesised according to Standard Procedure 3,using L-alanine benzyl ester hydrochloride (1.0 g, 4.64 mmol), PhOP(O)Cl₂ (0.98 g, 0.69 ml, 4.64 mmol) and NEt₃ (0.94 g, 1.29 ml, 9.27 mmol) to yield 1.61 g (98.2%) of crude product that was stored in anhydrous THF (10ml), to give a 0.46 mool/ml solution that was used without finrther purification.

[0233]³¹p NMR: δ9.41, 9.23 (1:1).

[0234]¹H NMR: δ7.41-7.21 (10H,m,2xPh), 5.24 (2H,d,CH2Ph), 4.95-4.88 (1H,t,NHala), 4.36-4.15 (1H,m,CHala), 1.56 (3H,t,CH₃ala).

[0235]¹³C NMR: δ172.9 (CO), 150.2 (‘ipso’-OPh), 135.5 (‘ipso’-CH₂Ph), 130.3 (‘m’-OPh), 129.0 (‘o’-CH₂Ph), 128.7 (‘m’+‘p’-CH₂Ph), 126.4 (‘p’-OPh), 121.0 (‘o’-OPh), 68.0 (OCH₂), 51.1 (CHala), 20.8 (CH₃ala).

[0236] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-[phenyl-(enzoxy-L-alaninyl)]-phosphate. Cf1582.

[0237] C₃₀H₃₅O₅N₇P₁, MW=603.6.

[0238] This was synthesised according to Standard Procedure 4, using (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (400 mg, 1.44 mmol), tBuMgCl (1.0M solution in THF) (2.1 ml, 2.1 mmol), and phenyl-(benzoxy-L-alaninyl)-phosphorochloridate (0.46M solution in THF) (9.2 ml, 4.19 mmol) in anhydrous THF (20 m1), and stirring at room temperature for 64 hrs. The crude product was purified by column chromatography eluting with 3% MeOH in CHCl₃, and then 2.5% MeOH in CHCl₃ to give the product as a white foam (82.2 mg, 9.75%).

[0239] A second synthesis was undertaken with (1S,⁴R)-⁴-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (200 mg, 0.7mmol), tBuMgCl (2.43 ml of a 1.0M soln in THF, 2.43 mmol), and phenyl-(benzoxy-L-alaninyl)-phosphorochloridate (2.2 ml of a 0.46M soln in THF, 2.Immol) in THF (2.5 ml). Purification by column chromatography eluting with 3% MeOH in CHCl₃ gave the pure product as a white foamy solid (90 mg, 21.3%).

[0240]³¹P NMR: 8 3.82, 3.72 (1:1). ¹H NMR: δ7.51 (1H,d,H8), 7.37-7.15 (IOH,m,OPh+CH₂Eh), 6.10-6.04 (1H,m,H2′), 5.96 *(H,bs,NHcPr), 5.89 (1H,dd,J=5.36 HzH3′), 5.54 (1H,t,H1′), 5.16 (2H,bs,NH₂), 4.96 (2H,bs,CH Ph), 4.234.05 (3H,m,NHala+H5′), 3.89-3.70 (1H,dt,CHala), 3.16-3.12 (1H,t,H4′), 3.03 (1H,bs,CHcPr), 2.85-2.71 (1H,m,1of H6′), 1.74-1.64 (1H,m,1of H6′), 1.44-1.39 (3H,t,J=7.84 Hz,CH₃ala), 0.88 (2H,q,J=6.75 Hz,2H of CH₂cPr), 0.64 (2H,m,2H of CH₂cPr).

[0241] 13C NMR: δ173.3 (CO), 159.7 (C2), 156.0 (C4), 150.9 (C6), 150.7 (‘ipso’-OPh), 136.4 (C2′), 135.7 (‘ipso’-Bn), 135.2 (CS), 131.0 (C3′), 129.6 (‘o’-Bn), 128.6 (‘m’-Bn), 128.5 (‘p’-Bn), 128.2 (‘m’-OPh), 124.9 (‘p’-OPh), 120.1 (‘o’-OPh), 114.8 (C5), 68.8 (C5′), 67.2 CH₂Ph), 58.9 (Cl′), 50.3 (CHala), 45.6 (C4′), 34.4 (C6′), 23.7 (CHcPr), 21.0 (CH₃ala), 7.4 (CH₂cPr).

[0242] MS ED⁺: m/z 603.8 (100%, M⁺), 604.8 (30%, M+H⁺), 625.7 (20%, M+Na⁺).

[0243] MS FAB: For C₃₀H₃₅O₅N₇P requires 604.243731, found 604.241775.

[0244] HPLC: tR 33.39 (99.7%)-(100% water (0 mins), 20% water (35 mins), 20% water (45 mins), 100% water (55 mins)).

[0245] IR: 3355.9 (N-Hstr.), 2923.3, 2853.7 (C-Hstr.), 1734.1 (C═Ostr.), 1595.6 (aromatic C-Cstr.), 1458.4 (C-Hdef.), 1376.5 (-CH₃sym.def.), 1154.4 (C-Ostr.), 1028.2 (P-O-alkyl), 935.8 (olefinic C-Hdef.), 721.7 (monosub.aromatic C-Hdef).

[0246] L-Alanine n-propyl ester hydrocbioride salt.

[0247] C₆H₁₄N₁O₂Cl₁, MW=167.634

[0248] This was synthesised according to Standard Procedure 1, using anhydrous propan-1-ol (42.0 ml, 0.56 mol), thionyl chloride (8.2 ml, 0.112 mol) and L-alanine (5.0 g, 0.056 mol). The product was isolated as a white solid (8.88 g, 94.3%).

[0249]¹H NMR (MeOH-d₄): δ4.344.26 (2H,m,OCH₂), 4.244.17 (1H,q,CHala), 1.88-1.78 (2H,m,CH₂), 1.65 (3H,d,J=7.24 Hz,CH₃ala), 1.10-1.05 (3H,t,CH₂CH₃). ¹³C NMR: δ170.1 (CO), 68.0 (OCH₂), 48.9 (CHala), 21.9 (CH₂), 15.3 (CH₃ala), 9.5 (CH2CH₃)

[0250] Phenyl-(n-propoxy-L-alaninyl)-phosphorochloridate

[0251] C₁₂H₁₇N₁O₄P₁Cl₁, MW=305.79

[0252] This was synthesised according to Standard Procedure 3, using L-Alanine n-propyl ester hydrochloride salt (0.5 g, 2.98 mmol), PhOP(O)Cl₂ (0.45 ml, 2.98 mmol), triethylamine (0.83 ml. 5.97 mmol) in DCM (70 ml). The usual workcup yielded the crude product as a yellow oil (0.84 g, 92.1%), which was stored in THF (5 ml) to give a 0.55M solution.

[0253]³¹P NMR: δ9.41, 9.17 (1:1).

[0254]¹³C NMR: δ173.1 (CO), 150.1 (‘ipso’-Ph), 130.0 (‘m’-Ph), 126.4 (‘p’-Ph), 121.0 (‘o’-Ph), 67.9 (OCH₂), 51.0 (CHala), 22.3 (CH₂CH₃), 21.0 (CH₃ala), 10.7 (CH,CH₃).

[0255] (1S,4R)-4-(2-amino6-cyclopropylamino-9H-purin-9-Sl)-2-cyclopentene-1-methanol O-Phenyl-(n-propoxy-L-alaninyl)-phosphate. Cf1646.

[0256] C₂₆H₃₄N₇O₅P, MW=555.57

[0257] This was synthesised according to Standard Procedure 4, using (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (100 mg, 0.35 mmol), tBuMgCl (0.7 ml, 0.7 mmol, of a 1.0M solution in THF), in THF (3 ml) and phenyl-(n-propyl-L-alaninyl)-phosphorochloridate (1.9 ml, 1.05 mmol, of a 0.55M solution in THF), at room temperature for 24 hrs. The crude product was purified by eluting with 3% MeOH in CHCl₃ to give the pure product as a pale yellow foamy solid (123 mg, 63.4%).

[0258]³¹P NMR: δ4.06, 3.98 (1:1).

[0259]¹H NMR: δ7.40 (1H,d,J=7.99 HzH8), 7.23-7.18 (2H,dd,‘o’-Ph), 7.12-7.02 (3H,m,‘m’+‘p’-Ph), 6.16 (1H,bs,H3′), 5.96 (1H,tH2′), 5.78 (1H,d,J-5.83 Hz,NHcycl), 5.44 (1H,bs,H1′), 5.15 (2H,bs,NH₂), 4.33-4.18 (1H,m,CHala), 4.15-4.04 (2H,m,OCH₂), 4.01-3.88 (2H,m,H5′), 3.65 (1H,bs,NHala), 3.03 (1H,d,H4′), 2.92 (1H,bs,CHcycl), 2.72-2.62 (1H,m,1of H6′), 1.60-1.47 (3H,m,1of H6′+CH₂CH₃), 1.30-1.26 (3H,t,CH₃ala), 0.84-0.80 (3H,m,CHCH:), 0.73 (2H,d,J=6.8 Hz,1of CH₂cycl), 0.51 (2H,bs,1 of CH₂cycl).

[0260]¹³C NMR: δ174.ICO 160.4 (C2), 156.6 (C4), 151.1 (C6+‘ipso’-Ph), 136.8 (C2′), 135.9 (C8), 131.5 (C3′), 130.0 (‘m’-Ph), 125.2 (‘p’-Ph), 120.5 (‘o’-Ph), 115.0 (C5), 69.2 (C5′), 67.4 (OCH₂), 59.2 (Cl′), 50.6 (CHala), 46.0 (C4′), 35.0 (C6′), 24.2 (CHcPr), 22.3 (CH₂CH₃), 21.5 (CH₃ala), 10.7 (CH7CHI), 7.7 (CH₂cycI).

[0261] MS ED⁺: m/z 555.8 (100%, M⁺), 557.0 (30%, M+H⁺).

[0262] MS FAB: For C₂₆H₃₅O₅N₇P requires 556.2437, found 556.2438.

[0263] HBLC: t_(R) 34.708 (100%)-(100% water (0 mins), 20% water (35 mins), 20% water (45 mins), 100% water (55 mins)).

[0264] L-Alanine n-butyl ester hydrochloride salt.

[0265] C₇H₁₆N₁O₂Cl₁, MW=181.661

[0266] This was synthesised according to Standard Procedure 1, using anhydrous butan-1-ol (51.4 ml, 0.56 mol), thionyl chloride (8.2 ml, 0.l 12 mol) and L-alanine (5.0 g, 0.056 mol). The product was isolated as a white solid (8.86 g, 86.9%).

[0267]¹H NMR (MeOH-d₄): δ4.29-4.17 (2H,m,OCH₂), 4.13-4.06 (1H,q,CHala), 1.71-1.62 (2H,m,OCH CH ), 1.53 (3H,d,J=7.25 Hz,CH₃ala), 1.47-1.34 (2H,m,CH₂CH₃), 0.96-0.91 (3H,t,CH CH).

[0268]¹³C NMR: δ170.1 (CO), 66.2 (OCH₂), 48.9 (CHala), 30.6 (OCH₂CH₂), 19.0 (CH₂CH₃), 15.3 (CH₃ala), 13.0 (CH₂CH₂).

[0269] Phbenyl-(n-butoxy-L-alaninyl)-phosphorochloridate

[0270] C₁₃H₁₉N₁O₄P₁Cl₁, MW=337.82

[0271] This was synthesised according to Standard Procedure 3, using L-Alanine n-butyl ester 15 hydrochloride salt (0.5 g, 2.75 mmol), PhOP(O)Cl₂ (0.41 ml, 2.75 mmol), triethylamine (0.77 m1. 5.5 mmol) in DCM (80 ml). The usual workup yielded the crude product as a yellow oil (0.84 g, 94.5%), which was stored in THF (5 ml) to give a 0.525M solution.

[0272]³¹P NMR: δ9.39, 9.10 (1:1).

[0273]¹H NMR: δ7.43-7.15 (5H,m,Ph), 4.68-4.59 (1H,q,CHala), 4.27-4.05 (3H,m,OCH₂+NHala), 1.73-1.59 (2H,m,OCH₂CH₂), 1.56-1.53 (2H,dd,CH₂CH₃), 1.46-1.37 (3H,m,CH3ala), 1.00-0.92 (3H,m,CH₂CH₃).

[0274]¹³C NMR: δ173.2 (CO), 150.1 (‘ipso’-Ph), 130.3 (‘m’-Ph), 126.4 (‘p’-Ph), 121.0 (‘o’-Ph), 66.2 (OCH₂), 51.0 (CHala), 30.9 (OCH₂CH7), 21.0 (CH₃ala), 19.4 (CH₂CH₃), 14.1 (CH₂CH₃).

[0275] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-pu rin-9-yl)-2-cyclopentene-1-methanol O-Phenyl-(n-butoxy-L-alaninyl)-phosphate. Cf1647.

[0276] C₂₇H₃₆N₇O₅P₁, MW=569.597

[0277] This was synthesised according to Standard Procedure 4, using (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (100 mg, 0.35 mmol), tBuMgCl (0.7 ml, 0.7 mmol, of a 1.0M solution in THF), in THF (3 ml) and phenyl-(n-butyl-L-alaninyl)-phosphorochloridate (2.0 ml, 1 .05 mmol, of a 0.525M solution in THF), at room temperature for 24 hrs. The crude product was pified by eluting with 3% MeOH in CHCl₃ to give the pure product as a pale yellow foamy solid (157 mg, 78.9%).

[0278]³¹P NMR: δ4.01, 3.95 (1:1).

[0279]¹H NMR: δ7.40 (1H,d,J=7.32 Hz,H8), 7.23-7.18 (2H,t,‘o’-Ph), 7.11 (2H,t,‘m’-Ph), 7.04 (1H,t,‘p’-Ph), 6.02 (1H,bs,H3′), 5.97 (1H,t,H2′), 5.78 (1H,bs,NHcycl), 5.44 (1H,bs,H1′), 5.06 (2H,bS,NH2), 4.22-3.88 (6H,m,CHala,OCH₂,H5′+NHala), 3.05 (1H,d,H4′), 2.93 (1H,bs,CHcycl), 2.72-2.62 (1H,m,1of H6′), 1.61-1.47 (3H,m,1of H6′+OCH₇CH ), 1.30-1.26 (5H,t,CH₃ala+CH₂CH₃), 0.85-0.80 (3H,t,CH CH), 0.74 (2H,d,J=6.45 Hz,1of CH₂cycl), 0.51 (2H,bs,1of CH₂cycl).

[0280]¹³C NMR: δ174.1(CO), 160.4 (C2), 156.7 (C4), 151.2 (C6), 151.1 (‘ipso’-Ph), 136.7 (C2′), 135.8 (C8), 131.5 (C3′), 130.0 (‘m’-Ph), 125.2 (‘p’-Ph), 120.5 (‘o’-Ph), 115.0 (C5), 69.3 (C5′), 65.8 (OCH₂), 59.2 (Cl′), 50.6 (CHala), 46.0 (C4′), 35.0 (C6′), 30.9 (OCH₂CH₂), 24.1 (CHcPr), 21.5 (CH₃ala), 19.4 (CHCH3), 14.1 (CH₂CH₃), 7.8 (CH₂Cycl).

[0281] MS ES⁺: m/z 569.9 (70%, M⁺), 570.9 (20%, M+H⁺), 591.8 (100%, M+Na⁺), 607.8 (20%, M+K⁺).

[0282] HPLC: tR 388.27 (100%)-(100% water (0 mins), 20% water (35 mins), 20% water (45 mins), 100% water (55 mins)).

[0283] L-Alanine i-propyl ester bydrochloride salt.

[0284] C₆H₁₄N₁O₂Cl₁, MW=167.634

[0285] This was synthesised according to Standard Procedure 1, using anhydrous propan-2-ol (43.0 ml, 0.56 mol), thionyl chloride (8.2 ml, 0.1 12 mol) and L-alanine (5.0 g, 0.056 mol). The product was isolated as a semicrystalline solid (8.86 g, 86.9).

[0286]¹H NMR (MeOH-d₄): δ5.16-5.08 (1H,m,CHala), 4.11-4.04 (1H,q,OCH(Me)₂), 1.55 (3H,d,J-7.2 1 Hz,CH₃ala), 1.34-1.31 (6H,dd,CH(Me)₂). 1³C NMR: 6 169.5 (CO), 70.8 (COCH(Me)₂), 48.9 (CHala), 20.8 (CH₃ala), 15.3 (CH(Me)₂).

[0287] Phenyl-(i-propoxy-L-alaninyl)-phosphorochloridate

[0288] C₁₂H₁₇N₁O₄P₁Cl₁, Mw=305.79

[0289] This was synthesised according to Standard Procedure 3, using L-Alanine i-propyl estr hydrochloride salt (0.5 g, 2.98 mmol), PhOP(O)Cl₂ (0.45 ml, 2.98mmol), triethylaniine (0.83 ml. 5.97 mmol) in DCM (70 ml). The usual workup yielded the crude product as a yellow oil (1.12 g, >100%), which was stored in THF (5 ml) to give a 0.597M solution.

[0290]³¹P NMR: δ9.45, 9.17 (1:1).

[0291]¹³C NMR: δ172.6 (CO), 150.2 (‘ipso’-Ph), 130.3 (‘m’-Ph), 126.4 (‘p’-Ph), 121.0 (‘o’-Ph), 70.1 (OCH), 51.1 (CHala), 22.1 (CH(CH₃)₂), 20.9 (CH₃ala).

[0292] (1S,4R)-4-(2-amino-6cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-peloyl-(i-propoxy-L-alaninyl)-p bosphate Cf1661.

[0293] C₂₆H₃₄N₇O₅P₁, MW=555.57

[0294] This was synthesised according to Standard Procedure 4, using (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (100 mg, 0.35 mmol), tBuMgCl (0.7 ml, 0.7 mmol, of a 1.0M solution in THF), in THF (3 ml) and phenyl-(i-propyl-L-alanlinyl)-phosphorochloridate (1.76 ml, 1.05mmol, of a 0.597M solution in THF), at room temperature for 72 hrs. The crude product was purified by eluting with 3% MeOH in CHCl₃ (x2) to give the pure product as a pale yellow foamy solid (106.8 mg, 54.8%).

[0295]³¹P NMR: δ4.02, 3.98 (1:1).

[0296]¹H NMR: δ7.41 (1H,d,J=8.12 Hz,H8), 7.24-7.19 (2H,m,‘o’-Ph), 7.13-7.03 (3H,m,‘m’+‘p’-Ph), 6.37 (1H,bs,,NHcPr), 5.98 (1H,t,H3′), 5.80-5.76 (1H,m,H2′), 5.43 (H,bs,H1′), 5.21 (2H,bs,NH2), 4.944.86 (1H,m,OCH), 4.15-3.98 (2H,m,H5′), 3.92-3.83 (1H,m,CHala), 3.59 (1H,bs,NHala), 3.06-2.98 (1H,m,H4′), 2.93 (1H,bs,CHCPr), 2.74-2.63 (1H,m,1of H6′), 1.62-1.53 (1H,m,1of H6′), 1.34-1.18 (3H,m,CH₃ala), 1.15-1.11 (6H,m,CH(CH₃)₂), 0.79-0.73 (2H,q,2Hof CH₂cPr), 0.53 (2H,bs,2Hof CH₂cPr).

[0297]¹³C NMR: δ173.5(CO) 159.8 (C2), 156.2 (C4), 151.1 (C6), 151.0 (‘ipso’-Ph), 136.9 (C2′), 136.1 (C8), 131.3 (C3′), 130.0 (‘m’-Ph), 125.3 (‘p’-Ph), 120.5 (‘o’-Ph), 115.0 (C5), 69.6 (C5′), 69.2 (OCH), 59.3 (Cl′), 50.7 (CHala), 46.0 (C4′), 34.9 (C6′), 24.2 (CHcPr), 22.0 (CH(CH₃)₂)2), 21.4 (CH₃ala), 7.8 (CH2cycl).

[0298] □S ES⁺: m/z 555.9 (100%, M⁺), 556.9 (30%, M+H⁺).

[0299] MS MALD/I TOF: For C₂₆H₃₅O₅N₇P found 555.575.

[0300] HPLC: t_(R) 35-85 (100%)-(100% water (0 mins), 20% water (35 mins), 20% water (45 mins), 100% water (55 mins)).

[0301] Phenyl-tertbutyloxy-L-alaninyl phosphorochloridate.

[0302] C₁₆H₁₇O₄N₁Cl₁P₁, MW=353.74.

[0303] This was synthesised according to Standard Procedure 3, using L-alanine zert-butyl ester hydrochloride (0.5 g, 2.75 mmol), PhOP(O)Cl₂ (0.41 ml, 2.75 mmol) and NEt₃ (0.77 ml, 5.5 mmol) to yield 0.77 g (87.5%) of crude product that was stored in anhydrous THF (5 ml), to give a 0.48 mmol/ml solution that was used without further purification.

[0304]³¹P NMR: δ9.53, 9.20 (1:1).

[0305]¹H NMR: δ7.44-7.39 (2H,t,‘o’-Ph), 7.32-7.26 (3H,m,‘m’+‘p’-Ph), 4.4714.34 (1H,m,NHala), 4.17-4.04 (1H,m,CHala), 1.53 (9H,3s,3xCH₃).

[0306]¹³C NMR: δ170.7 (CO), 148.7 (‘ipso’-Ph), 128.9 (‘o’-Ph), 124.9 (‘p’-Ph), 119.5 (‘m’-Ph), 81.65 (CMe₃), 50.0 (CHala), 26.9 (3xCH₃).

[0307] (1S,4R)-4-(2-amino-6-cyclopropylamino9H-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl-tertbutyloxy-L-alaninyl)-phosphate. Cf1645.

[0308] C₂₄H₃₀ O₅N₇P₁, MW=603.6.

[0309] This was synthesised according to Standard Procedure 4, using (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (140 mg, 0.52 mmol), tBuMgCl (1.05 ml, 1.05mmol of a 1.0M solution in THF), and phenyl-(tertbutyloxy-L-alaninyl)-phosphorochloridate (3.3 ml, 1 .57 mmol, of a 0.48M solution in THF), in anhydrous THF (4 ml) stimring at room temperature for 48 hrs. The crude product was purified by eluting with 3% MeOH in CHCl₃ to give the pure product as white foamy solid (192.3 mg, 69.0%).

[0310]³¹P NMR: δ4.15 (s).

[0311]¹H NMR: δ7.40 (1H,d,J=8.35 Hz,H8), 7.23-7.18 (2H,t,‘m’-Ph), 7.12 (2H,d,‘o’-Ph), 7.06-7.02 (1H,t,‘p’-Ph), 6.09 (1H,bs,H2′), 5.97 (1H,bs,H3′), 5.77 (1H,d,NHcPr), 5.44 (1H,bs,HI′), 5.10 (2H,bs,NH₂), 4.144.05 (3H,m,H5′+NHala), 3.85-3.77 (1H,q,CHala), 3.04 (1H,bs,H4′), 2.93 (1H,bs,CHcPr), 2.72-2.62 (1H,m,1of H6′), 1.58-1.53 (1H,t,1of H6′), 1.34 (9H,d,CMe₃), 1.27-1.23 (3H,t,CH₃ala), 0.73 (2H,d,2Hof CH₂cPr), 0.51 (2H,bs,2Hof CH₂cPr).

[0312]¹³C NMR: δ173.2 (CO), 160.4 (C2), 156.7 (C4), 151.2 (C6+‘ipso’-Ph), 136.8 (C2′), 135.9 (C8), 131.5 (C3′), 130.0 (‘m’-Ph), 125.2 (‘p’-Ph), 120.6 (‘o’-Ph), 115.2 (C5), 82.3 (C[H₃]₃), 69.3 (C5′), 59.1 (Cl′), 46.0 (C4′), 35.0 (C6′), 28.3 (3xCH₃), 24.2 (CHCPr), 1.5 (CH₃ala), 7.8 (CH₂cPr).

[0313] S ES⁺: m/z 570.0 (100%, M⁺), 570.9 (32%, M+H⁺).

[0314] MS FAB: For C₂₇H₃₇O₅N₇P requires 570.2594, found 570.2598.

[0315] HPLC: t_(R) 36.158 (100%)-(100% water (0 mins), 20% water (35 mins), 20% water (45 mins), 100% water (55 mins)).

[0316] L-Alanine n-pentyl ester hydrochloride salt

[0317] C₈H₁₆N₁O₂Cl₁, MW=195.69

[0318] This was synthesised according to Standard Procedure 1, using pentanol (36.3 ml, 0.337 mol), thionyl chloride (4.92 ml, 67.4 mmol) and L-Alanine (3.0 g, 33.7 mmol). The product was isolated as a white solid pure product (4.86 g, 73.7%).

[0319]¹H NMR (MeOH-d₄): δ4.324.20 (2H,m,OCH₂), 4.16-4.08 (1H,m,CHala), 1.77-1.68 (2H,m,OCH₂CH₂), 1.56 (3H,d,J=7.22 Hz,CH₃ala), 1.42-1.36 (4H,m,CH₂CH₂CH₃), 0.97-0.93 (3H,m,CH₂CH₃).

[0320]¹³C NMR: δ170.1 (CO), 66.5 (OCH₂), 48.8 (CHala), 28.2 (OCH₂CH₂), 28.0 (CH₂CH₂CH₃), 22.3 (CH₂CH₃), 15.2 (CH₃ala), 13.3 (CH₂CH₃).

[0321] Phenyl-(n-pentoxy-L-alaninyl)-phosphorochloridate

[0322] C₁₄H₂₁N₁O₄P₁Cl₁, MW=333.78

[0323] This was synthesised according to Standard Procedure 3, using L-Alanine n-pentyl ester hydrochloride salt (0.5 g, 2.56 mmol), PhOP(O)Cl₂ (0.38 ml, 2.56 mmol), triethylamine (0.71 ml. 5.11 mmol) in DCM (60 ml). The usual workup yielded the crude product as a yellow oil (0.79 g, 92.6%), which was stored in THF (5 ml) to give a 0.47M solution.

[0324]³¹P NMR: δ9.39, 9.12 (1:1).

[0325]¹H NMR: δ7.43-7.38 (2H,m,‘o’-Ph), 7.32-7.25 (3H,m,‘m’+‘p’-Ph), 4.63 (1H,bd,NHala), 4.244.11 (3H,m,OCH₂+CHala), 1.73-1.65 (2H,m,OCH2CH,), 1.57-1.53 (3H,dd,CH₃ala), 1.42-1.35 (4H,m,2xCH₂), 0.97-0.91 (3H,m,CH₂CH₃).

[0326] 1³C NMR: δ173.1 (CO), 150.1 (‘ipso’-Ph), 130.3 (‘m’-Ph), 126.4 (‘p’-Ph), 121.0 (‘o’-Ph), 66.5 (OCH₂), 51.0 (CHala), 28.6 (CH₂-C2), 28.3 (CH₂-C3), 22.7 (CH₂-C4), 21.0 (CH₃ala), 14.1 (CH₃-C5).

[0327] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol 0-Phenyl-(n-pentyloxy-L-alaninyl)-phosphate. Cf1706.

[0328] C₂₈H₃₈N₇O₅P₁, MW=583.7

[0329] This was synthesised according to Standard Procedure 4, using (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (10 mg, 0.35 mmol), tBuMgCl (0.7 ml, 0.7 mmol, of a 10M solution in THF), in THF (3 ml) and phenyl-n-pentyl-L-alaninyl)-phosphorochloridate (2.22 ml, 1.05 mmol, of a 0.47M solution in THF), at room temperature for 24 hrs. The crude product was purified by eluting with 2.5-3.0% MeOH in CHCl₃ (x2) to give the pure product as a pale yellow foamy solid (143.2 mg, 70.2%).

[0330]³¹P NMR: δ3.99, 3.95 (1:1).

[0331]¹H NMR: δ7.41 (1H,d,J=7.18 Hz,H8), 7.24-7.19 (2H,m,‘o’-Ph), 7.12-7.02 (3H,m,‘m’+‘p’-Ph), 6.09 (1H,bs,NHcPr), 5.98 (1H,d,H2′), 5.79 (1H,bs,H3′), 5.44 (1H,bs,H1′), 5.09 (2H,bs,NH2), 4.16-3.88 (6H,m,CHala,OCH₂,H5′+NHala), 3.05 (1H,bs,H4′), 2.94 (1H,bs,CHcPr), 2.73-2.63 (1H,m,1of H6′), 1.62-1.51 (3H,m,1of H6′+OCH₂CH₂), 1.31-1.21 (7H,t,CH₃ala+2xCH₂), 0.81-0.74 (5H,m,CH₃₊₂Hof CH₂cPr), 0.52 (2H,bs,2Hof CH₂cPr).

[0332]¹³C NMR: δ174.1(CO), 160.1 (C2), 156.5 (C4), 151.2 (C6), 151.1 (‘ipso’-Ph), 136.8 (C2′), 136.1 (C8), 131.5 (C3′), 130.0 (‘m’-Ph), 125.2 (5‘p’-Ph), 120.5 (‘o’-Ph), 115.1 (C5), 69.3 (C5′), 66.1 (OCH₂), 59.3 (Cl′), 50.7 (CHala), 46.0 (C4′), 34.9 (C6′), 28.6 (CH₂-C2), 28.3 (CH₂-C3), 24.2 (CHcPr), 22.6 (CH₂-C4), 21.5 (CH₃ala), 14.3 (CH₃-C5), 7.8 (CH₂cPr).

[0333] MS ES⁺: m/z 584.2 (100%, M⁺), 585.2 (25%, M+H⁺).

[0334] MS FAB: For C₂₈H₃₉O₅N₇P requires 584.2750, found 584.2757.

[0335] BPLC: t_(R) 40.294 (99.3%)-(100% water (0 mins), 20% water (35 mins), 20% water (45 mins), 100% water (55 mins)).

[0336] L-Alanine in-bexyl ester bydrochloride salt

[0337] C₉H₂₀ _(N) ₁O₂Cl₁, MW=209.75

[0338] This was synthesised according to Standard Procedure 2, using L-Alanine (2.0 g, 22.5mmol), hexan-1-ol (2.82 ml, 22.5 mmol), p-toluene sulfonic acid monohydrate (4.7 g, 24.7 mmol), and toluene (100 ml). L-alanine n-hexyl ester hydrochloride was isolated as a white powdery solid (3.32 g, 70.5%).

[0339]¹H NMR (MeOH-d₄): 5 4.31-4.18 (2H,m,OCH₂), 4.17-4.09 (1H,q,CHala), 1.75-1.66 (2H,m,OCH₂CH₂), 1.57 (3H,d,J=7.20 Hz,CH₃ala), 1.45-1.35 (6H,m,[CH+EE₂]₃CH₃), 0.94-0.89 (3H,t,CH₂CH₃).

[0340]¹³C NMR: δ170.1 (CO), 66.5 (OCH₂), 48.9 (CHala), 31.6 (OCH₂CH₂), 28.6 (O[CH₂]CH₂), 25.6 (CH₂CH₂CH₃), 22.6 (CH₂CH₃), 15.4 (CH₃ala), 13.4 (CH₂CH+EE₃)

[0341] Phenyl-(n-b exyloxy-L-alaninyl)-phosphorochloridate

[0342] C₁₅H₂₃N₁O₄P₁Cl₁, MW=347.81

[0343] This was synthesised according to Standard Procedure 3, using L-Alanine n-hexyl ester hydrochloride salt (0.5 g, 2.38 mmol), PhOP(O)Cl₂ (0.36 ml, 2.38 minol), triethylanine (0.66 ml. 4.77mmol) in DCM (60 m1). The usual workup yielded the crude product as a yellow oil (0.69 g, 83.2%), which was stored in THF (4 ml) to give a 0.496M solution.

[0344]³¹NMR: δ9.40, 9.1 0(1:1).

[0345]¹H NMR: δ7.44-7.14 (5H,m,OPh), 4.25 (1H,bs,NHala), 4.23-4.03 (3H,m,OCH₂+CHala), 1.70-1.63 (2H,m,CH₂-2), 1.57-1.54 (2H,m,CH₂-3), 1.47-1.32 (7H,m,CH₃ala+2CH₂-4,5), 0.93-0.91 (3H,dd,CH₃-6).

[0346]¹³C NMR: δ173.2 (CO), 150.1 (‘ipso’-Ph), 130.3 (‘m’-Ph), 126.4 (‘p’-Ph), 120.9 (‘o’-Ph), 66.4 (OCH₂), 51.0 (CHala), 31.7 (CH₂-C2), 28.9 (CH₂-C3), 25.8 (CH₂-C4), 22.9 (CH₂-C5), 21.0 (CH₃ala), 14.4 (CH₃-C6).

[0347] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-Phenyl-(n-hexyloxy-L-alaninyl)-phosphate.

[0348] C₂₉H₄₀N₇O₅P₁, MW=597.651

[0349] This was synthesised according to Standard Procedure 4, using (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (100 mg, 0.35 mmol), tBuMgCl (0.7 ml, 0.7mmol, of a 1.0M solution in THF), in THF (3 ml) and phenyl-(n-hexoxy-L-alaninyl)-phosphorochloridate (2.11 ml, 1.05 mmol, of a 0.496M solution in THF), at room temperature for 24 hrs. Additional phenyl-(n-hexoxy-L-alaninyl)- phosphorochloridate (1.5 ml, 0.68 mmol, of a 0.496M solution in THF), was added and the reaction stirred for a fuirther 24 hrs. The crude product was purified by eluting with 3.0% MeOH in CHCl₃ (x2) to give the pure product as a pale yellow foamy solid

[0350]³¹P NMR: δ3.94, 3.91 (1:1).

[0351]¹H NMR: δ7.52 (1H,d,J=8.00 Hz,H8), 7.36-7.31 (2H,m,‘o’-Ph), 7.25-7.15 (3H,m,‘m’+‘p’-Ph), 6.26 (1H,bs,NHcPr), 6.13-6.08 (1H,m,H2′), 5.93-5.88 (1H,m,H3′), 5.58-5.53 (1H,m,H1′), 5.14 (2H,bs,NH₂), 4.28-3.89 (6H,m,CHala,OCH₂,H5′+NHala), 3.17 (1H,t,H4′), 3.04 (1H,bs,CHcPr), 2.87-2.75 (1H,m,1of H6′), 1.74-1.61 (3H,m,1of H6′+OCH₂CH₂), 1.43-1.31 (9H,t,CH₃ala+3xCH₂), 0.92-0.85 (5H,m,CH₃+2Hof CH₂cPr), 0.68-0.63 (2H,q,2Hof CH₂cPr).

[0352]¹³C NMR: δ174.1C0, 160.1 (C2), 156.5 (C4), 151.2 (C6), 151.1 (‘ipso’-Ph), 136.9 (C2′), 136.0 (C8), 131.4 (C3′), 130.0 (‘m’-Ph), 125.3 (‘p’-Ph), 120.5 (‘o’-Ph), 115.0 (C5), 69.2 (C5′), 66.1 (OCH₂), 59.3 (Cl′), 50.7 (CHala), 46.0 (C4′), 34.9 (C6′), 31.7 (OCH₂CH₂), 28.8 (CH₂-ester), 25.8 (CH₂-ester), 24.2 (CHcPr), 21.9 (CH₂-ester), 21.5 (CH₃ala), 14.4 (CH₃-ester), 7.8 (CH₂cPr).

[0353] L-Alanine cyclo-hexyl ester hydrochloride salt

[0354] C₉H₁₆N₁O₂Cl₁J, MW=205.71

[0355] This was synthesised according to Standard Procedure 2, using L-Alanine (2.0 g, 22.5 mmol), cyclohexanol (2.34 ml, 22.5 mmol), p-toluene sulfonic acid monohydrate (4.7 g, 24.7 mmol), and toluene (100 ml). The p-toluene sulfonate salt was isolated as a pale orange solid (1.45 g).

[0356] The reaction was repeated using L-Alanine (3.0 g, 33.7 mmol), cyclohexanol (5.26 ml, 50.6 mmol),p-toluene sulfonic acid monohydrate (9.62 g, 50.6nmmol), and toluene (100 ml). L-alanine cyclohexyl ester hydrochloride salt was isolated as a white solid (3.15 g, 45.45%).

[0357]¹H NMR (MeOH-d₄): δ4.90 (1Hm,OCH), 4.12-4.04 (1H,q,CHala), 1.92-1.81 (2H,m,OCHCH₂), 1.80-1.63 (2H,m,OCHCH₂), 1.55 (3H,d,J=7.23 Hz,CH₃ala), 1.49-1.33 (6H,m,[CH₂]₃).

[0358]¹³C NMR: δ169.5 (CO), 75.4 (OCH), 48.9 (CHala), 31.3 (2xCH₂-o), 25.2 (2xCH₂-M), 23.5 (p-CH₂), 15.3 (CH₃ala).

[0359] Phenyl-(c-hexyloxy-L-alaninyl)-phosphorochloridate

[0360] C₁₅H₂₁N₁O₄P₁Cl₁, MW=345.79

[0361] This was synthesised according to Standard Procedure 3, using L-Alanine c-hexyl ester hydrochloride salt (0.7 g, 3.4 mmol), PhOP(O)Cl₂ (0.51 ml, 3.4 mmol), triethylamine (0.95 ml 6.8 mmol) in DCM (60 ml). The usual workup yielded the crude product as a yellow oil (1.12 g, 95.2%), which was stored in THF (7 ml) to give a 0.46M solution.

[0362] 31P NMR: δ9.43, 9.07 (1:1).

[0363]¹H NMR: δ7.44-7.33(2H,m,‘o’-Ph), 7.32-7.20 (3Hm,‘m’+‘p’-Ph), 4.924.83 (1H,m,OCH), 4.55-4.42 (1H,m,NHala), 4.28-4.15 (1H,m,CHala), 1.89 (2H,bd,CH₂-‘o’), 1.76 ( 1H,bd,CH₂-‘o’), 1.54 (3H,d,CH₃ala), 1.49-1.32 (6H,m,CH₃3CH₂-‘m’+‘p’).

[0364]¹³C NMR: δ172.5 (CO), 150.1 (‘ipso’-Ph), 130.3 (‘m’-Ph), 126.4 (‘p’-Ph), 121.0 (‘o’-Ph), 74.9 (OCH), 51.1 (CHala), 31.8 (CH₂-‘o’), 25.6 (CH₂-‘p’), 21.0 (CH₃ala).

[0365] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopeniene-1-methanol O-Phenyl-(c-hexyloxy-L-alaninyl)-phosphate. Cf 1707.

[0366] C₂₉H₃₈N₇O₅P₁, MW=595.635

[0367] This was synthesised according to Standard Procedure 4, using (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (100 mg, 0.35 mmol), tBuMgCl (0.7 ml, 0.7 mmol, of a 1.0M solution in THF), in THF (3 ml) and phenyl-(c-hexoxy-L-alaninyl)-phosphorochloridate (2.28 ml, 1.05 mmol, of a 0.46M solution in THF), at room temperature for 24 hrs. The crude product was purified by eluting with 3-4% MeOH in CHCl₃, and then 2.5-3.0% MeOH in CHCl₃ to give the pure product as a pale yellow foamy solid (199 mg, 95.7%).

[0368]³¹P NMR: δ4.06, 3.99 (1:1).

[0369]¹H NMR: δ7.42 (1H,d,J=8.15 Hz,H8), 7.23-7.18 (2H,n,‘o’-Ph), 7.12-7.02 (3H,m,‘m’+‘p’-Ph), 6.31 (1H,bs,NHcPr), 5.98 (1H,bs,H2′), 5.78 (1H,bs,H3′), 5.43 (1H,bs,H1′), 5.21 (2H,bs,NH2), 4.66 (1H,bs,OCH), 4.17-4.02 (3H,m,H5′+NHala), 3.95-3.85 (1H,m,CHala), 3.05-2.94 (2H,m,H4′+CHcPr), 2.73-2-63 (1H,m,1of H6′), 1.69 (2H,bs,CH₂-‘o’), 1.62-1.53 (2H,m,CH2-‘o’), 1.45-1.18 (9H,m,CH₃ala+3xCH₂-‘m’+‘p’′), 0.76 (2H,d,2Hof CH2cPr), 0.53 (2H,bs,2Hof CH₂cPr).

[0370]¹³C NMR: δ172.OCO, 158.4 (C2), 154.8 (C4), 149.7 (C6), 149.6 (‘ipso’-Ph), 135.5 (C2′), 134.7 (C8), 130.0 (C3′), 128.6 (‘m’-Ph), 123.8 (‘p’-Ph), 119.1 (‘o’-Ph), 113.1 (CS), 72.9 (OCH), 67.8 (C5′), 57.9 (Cl′), 59.4 (CHala), 44.7 (C4′), 34.5 (C6′), 30.3 (CH₂-‘o’), 24.2 (CH₂-‘m’), 22.8 (CHcPr), 22.5 (CH₂-‘p’), 20.1 (CH₃ala), 6.4 (CH₂cPr).

[0371] MS ES⁺: m/z 596.2 (100%, M⁺), 597.3 (20%, M+H⁺).

[0372] MS FAB: For C₂₉H₃₉O₅N₇P requires 596.2750, found 596.2750.

[0373] HPLC: t_(R) 40.502 (99.8%)-(100% water (0 mins), 20% water (35 mins), 20% water (45 mins), 100% water (55 mins)).

[0374] L-alanine cyclobexane-methyl ester hydrochloride

[0375] C₁₀H₂₀N₁O₂Cl₁, MW=221.75

[0376] This was synthesised according to Standard Procedure 2, using L-Aianine (3.0 g, 33.7 mmol), cyclohexane methanol (4.15 ml, 33.7 mmol), p-toluene sulfonic acid monohydrate (7.05 g, 37.1 mmol), and toluene (100 ml). 9.2 g of the the PTSA salt was solubilised in DCM (50 ml), and washed with 10% K₂CO₃ (50 ml), and water (2×50 ml), dried over MgSO₄, filtered and the filtrate reduced to dryness to give a yellow oil. This was neutralised with 2M HCl, stirred for 2 hrs, and then freeze-dried to give the hydrochloride salt as a white solid (4.32 g, 75.8%).

[0377]¹H NMR (MeOH-d₄): δ4.194.01 (3H,m,OCH+CHala), 1.79-1.69 (5H,m,CH+o-CH₂), 1.58 (3H,d,J=7.21 Hz,CH₃ala), 1.37-1.20 (4H,m,m-CH₂), 1.09-0.98 (2H,q,p-CH₂).

[0378]¹³C NMR: δ170.1 (CO), 71.3 (OCH₂), 48.9 (CHala), 37.3 (CH), 29.5 (2xCH₂-o), 26.4 (p-CH₂), 25.7 (2xCH₂-m), 15.4 (CH₃ala).

[0379] Phenyl-(cyclohexane-methoxy-L-alaninyl)phosphorochloridate

[0380] C₁₆H₂₃N₁O₄P₁Cl₁, MW=359.82

[0381] This was synthesised according to Standard Procedure 3, using L-Alanine cyclohexane-methyl ester hydrochloride salt (0.7 g, 3.16 mmol), PhOP(O)Cl₂ (0.47 ml, 3.16mmol), triethylamine (0.88 ml. 6.31mmol) in DCM (70 ml). The usual workup yielded the crude product as a yellow oil (I.lOg, 96.8%), which was stored in THF (6 ml) to give a 0.51M solution.

[0382]³¹P NMR: δ9.35, 9.05 (1:1).

[0383]¹H NMR: δ4.614.50 (1H,q,NHala), 4.284.13 (1H,m,CHala), 4.044.00 (2H,q,OCH₂), 1.78-1.74 (7H,t,CH₂Hx+‘o’-CH₂), 1.57-1.54 (3H,dd,CH₃ala), 1.06-0.96 (2H,q,‘p’-CH₂).

[0384]¹³C NMR: δ173.1 (CO), 150.1 (‘ipso’-Ph), 130.3 (‘m’-Ph), 126.4 (‘p’-Ph), 121.0 (‘o’-Ph), 71.4 (OCH₂), 51.0 (CHala), 37.4 (CHcHx), 29.9 (CH₂-‘o’), 26.7 (CH₂-‘m’), 25.9 (CH₂-‘p’), 21.1 (CH₃ala).

[0385] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2cyclopentene-1-methanol O-Phenyl-(cyclobexane-methoxy-L-alaninyl)-phosphate. Cf1708.

[0386] C₃₀H₄₀N₇O₅P₁, MW=609.66

[0387] This was synthesised according to Standard Procedure 4, using (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyolopentene-1-methanol (100 mg, 0.35mmol), tBuMgCl (0.7mn, 0.7 mmol, of a 1.0M solution in THF), in THF (5 ml) and phenyl-(cyclohexane-methoxy-L-alaninyl)-phosphorochloridate (2.06 ml, 1.05 mmol, of a 0.51M solution in THF), at room temperature for 48 hrs. The crude product was purified by eluting with 4-6% MeOH in DCM, and then 3% MeOH in CHCl₃ to give the pure product as a pale yellow foany solid (161.1 mg, 75.6%).

[0388] 31p NMR: δ3.99,3.92 (1:1).

[0389]¹H NMR: δ7.40 (1H,d,J=7.07 Hz,H8), 7.24-7.19 (2H,t,‘o’-Ph), 7.13-7.03 (3H,m,‘m’+‘p’-Ph), 6.00-5.96 (2H,m,H2′+NHcPr), 5.79 (1H,qJH3′), 5.45 (1H,d,H1′), 5.05 (2H,bs,NH₂), 4.16-4.01 (3H,m,OCH₂+NHala), 3.98-3.88 (1H,m,CHala), 3.86-3.74 (2Hm,H5′), 3.07-3.00 (1H,t,H4′), 2.94 (1H,bs,CHcPr), 2.74-2.63 (1H,m,1of H6′), 1.88-1.50. (7H,m,CHcHx+2CH₂-‘o’), 1.31-1.27 (3H,t,CH₃ala), 1.21-0.99 (4H,m,2CH₂-‘m’), 0.89-0.79 (2H,q,CH₂-‘p’), 0.75 (2H,d,2Hof CH₂cPr), 0.54-0.50 (2H,t,2Hof CH₂cPr).

[0390]¹³C NMR: δ174.1(CO), 160.2 (C2), 156.4 (C4), 151.2 (C6), 151.1 (‘ipso’-Ph), 136.7 (C₂′), 136.0 (C8),131.5 (C3′), 130.0 (‘m’-Ph), 125.2 (‘p’-Ph), 120.5 (‘o’-Ph), 115.1 (C5), 71.0 (OCH₂), 69.3 (C5′), 59.3 (Cl′), 50.7 (CHala), 46.1 (C4′), 37.4 (CHcHx), 34.9 (C6′), 29.9 (CH₂-‘o’), 26.6 (CH₂-‘m’), 25.9 (CH₂-‘p’), 24.2 (CHcPr), 21.5 (CH₃ala), 7.8 (CH₂cPr).

[0391] MS ES⁺: miz 610.3 (50%, M+l⁺), 632.3 (100%, M+Na⁺), 633.3 (M+H+Na⁺).

[0392] MS FAD: For C₃₀H₄₀O₅N₇NaP requires 632.2726, found 632.2710.

[0393] HPLC: t_(R) 42.859 (100%)-(100% water (0 mins), 20% water (35 mins), 20% water (45 mins), 100% water (55 mins)).

[0394] 4-Chlorophenyl-phosphorodichloridate

[0395] C₆H₄O₂P₁Cl₃, MW=246.43

[0396] Phosphorus oxychloride (2 ml, 21.5mmol) was stirred with anhydrous diethylether (70 ml) in a 250 ml RBF. To this was added, dropwise, a solution of 4-chlorophanol (2.1 ml, 21.5mmol), and anhydrous triethylamine (3.0 ml, 21.5mmo) in anhydrous diethylether (30 ml) at −80° C. This was stirred vigorously at −80° C. for 1 hr and left to rise to room temperature over 16 hrs. The triethylamine hydrochloride salt was filtered off, and the filtrate reduced to dryness to give the crude product as a yellow oil (4.61 g, 87.2%).

[0397]³P NMR: δ4.99 (s).

[0398]^(s3)C NMR: δ148.4 (‘ipso’-PhX, 133.2 (‘p’-Ph), 130.7 (‘m’-Ph), 122.4 (‘o’-Ph).

[0399] 4-Chlorophenyl-(methoxy-L-alaninyl)-phosphorochloridate

[0400] C₁₀ H₁₂N₁O₄P₁Cl₂, MW=246.43

[0401] This was synthesised according to Standard Procedure 3, using L-Alanine methyl ester hydrochloride (2.61 g, 18.7 mmol) and p-chlorophenyl phosphorodichloridate (4.61 g, 18.7 mmol) and tniethylamine (5.21 ml, 37.4 mmol) in anhydrous DCM (100 ml). The usual workup yielded the crude product as a colourless crude oil (3.76 g, 64.4%) which was stored in anhydrous THF (20 ml) to give a 0.6M solution that was used without flurther purification.

[0402]³¹ P pNMR: δ9.48, 9.25 (1:1).

[0403]¹H NMR: δ7.36 (2H,d,J=8.20 Hz,‘o’-Ph), 7.32-7.22 (2H,m,‘m’-Ph), 4.69 (1H,d,NHala), 4.274.15 (1H,m,CHala), 3.82 (3H,d,OCH₃), 1.56-1.53 (3H,dd,J=7.04 Hz,CH₃ala).

[0404]¹³C NMR: δ173.4 (CO), 148.6 (‘ipso’-Ph), 131.9 (‘p’-Ph), 130.3 (‘m’-Ph), 122.3 (‘o’-Ph), 53.2 (OCH₃), 50.9 (CHala), 20.9 (CH₃ala).

[0405] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-⁹-yl)-2-cyclopentene-1-methanol O-[4-chlorophenyl-(methoxy-L-alaninyl)]-phosphate. Cf 1620.

[0406] C₂₄H₂₉N₇O₅P₁Cl₁, MW=562.02

[0407] This was synthesised according to Standard Procedure 4, using (1S,4R)-4-(2-amino6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (250 mg, 0.87 mmol), tBuMgCl (1.75 ml, 1.75mmol of a 1.0M solution in THF), and 4-chlorophenyl-(methoxy-L-alaninyl)-phosphorochloridate (4.37 ml, 2.62 mmol, of a 0.6M solution in THF), in anhydrous THF (13 ml) stirring at room temperature for 24 hrs. The crude product was purified by eluting with 3% MeOH in CHCl₃ to give the pure product as white foamy solid (364.5 mg, 74.50/%).

[0408]³¹P NMR: δ4.01 (s).

[0409]¹H NMR: δ7.42 (1H,d,HS), 7.22-7.17 (2H,m,‘m’-Ph), 7.09-7.03 (2H,t,‘o’-Ph), 5.99 (1H,d,H2′), 5.93 (1H,s,H3′), 5.83 (1H,bs,NHcPr), 5.45 (1H,bs,H1′), 4.96 (2H,bs,NH₂), 4.11 (2H,bs,H5′), 4.03-3.86 (1H,m,CHala), 3.62 (3H,s,OCH₃), 3.07 (1H,d,J=5.9 Hz,H4′), 25 2.92 (1H,bs,CHcPr), 2.76-2.64 (1H,m,1of H6′), 1.64-1.59 (1H,t,1of H6′), 1.32-1.26 (3H,q,CH3ala), 0.76 (2H,d,J=6.4OHz,2Hof CH₂cPr), 0.53 (2H,bs,2Hof CH₂cPr).

[0410]¹³C NMR: δ174.4 (CO), 160.4 (C2), 156.7 (C4), 151.3 (C6), 149.7 (‘ipso’-Ph), 136.7 (C2′), 135.9 (C8), 131.6 (C3′), 130.5 (‘p’-Ph), 130.0 (‘m’-Ph), 121.9 (‘o’-Ph), 115.2 (C5), 69.4 (C5′), 59.25 (Cl′), 52.9(OCH₃), 50.6 (CHala), 46.0 (C4′), 34.9 (C6′), 24.1 (CHCPr), 30 21.4 (CH3ala), 7.8 (CH₂cPr).

[0411] HPLC: t_(R) 32.693, 33.012 (100%)-(100% water (0 mins), 20% water (35rains), 20% water (45 mins), 100% water (55 mins)).

[0412] 4-Bromophenyl-phosphorodichloridate

[0413] C₆H4O₂Cl₂Br₁, MW=289.87

[0414] This was synthesised by a method analogous to that of 4-chlorophenyl-phosphorodichloridate, except using: Phosphorus oxychloride (3.29 g, 2 ml, 21.5nimol), and 4-bromophenol (3.71 g, 21.5mmol) in anhydrous diethylether (70 ml), and anhydrous tfiethylamine (2.71 g, 3 ml, 21.5 mmol) in anhydrous diethylether (30 ml). The reaction was stirred at −80° C. to room temperature for 1 6 hrs. After filtration, and removal of the solvent, the product was obtained as a clear liquid (5.14 g, 82.6%).

[0415]³¹P NMR: δ4.88 (s).

[0416] 1H NMR: δ7.63 (2H,d,J=8.14 Hz,‘o’-Ph), 7.28 (2H,t,‘m’-Ph),

[0417]¹³C NMR: δ149.0(‘ipso’-Ph), 133.7 (‘m’-Ph), 122.6 (‘o’-Ph), 120.9 (‘p’-Ph).

[0418] 4-Bromophienyl-(methoxy-L-alaninyl)-phosphorochloridate

[0419] C₁₀H₁₂N₁O₄P₁Cl₁Br₁, MW=356.55

[0420] This was synthesised according to Standard Procedure 3, using L-alanine methyl ester hydrochloride salt (10 g, 7.1 6mmol), 4-bromophenyl-phoshorodichloridate ( .82 g, 7.16 mmol), triethylamine (2 ml. 14.3 mmol) in DCM (70 ml). The usual workup yielded the crude product as a yellow oil (2.24 g, 87.7%), which was stored in THF (12 ml) to give a 0.524M solution.

[0421] 31P NMR: δ9.16, 9.10 (1:1).

[0422]¹³C NMR: δ173.4(CO), 150.1 (‘ipso’-Ph), 133.3 (‘m’-Ph), 122.7 (‘o’-Ph), 119.6 (‘p’-Ph), 53.3 (OCH₃), 51.0 (CHala), 20.9 (CH₃ala).

[0423] (1S,4R)-4-(2-amin o-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-[4-bromophenyl-(methoxy-L-alaninyl)]-phosphate. Cf1710.

[0424] C₂₄H₂₉N₇O₅P,Br₁, MW=606.42

[0425] This was synthesised according to Standard Procedure 4, using (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (100 mg, 0.35 mmol), tBuMgCl (0.7 ml, 0.7 mmol, of a 1.0M solution in THF), in THF (5 ml) and 4-bromophenyl-(methoxy-L-alaninyl)-phosphorochloridate (2.0 ml, 1.05 mmol, of a 0.524M solution in THF), at room temperature for 24 hrs. The crude product was purified by eluting with 4-6% MeOH in DCM, and then in 4% MeOH in DCM, to give the pure product as a white foamy solid (115.2 mg, 54.4%).

[0426]³¹ p NMR: δ3.96 (s).

[0427]¹H NMR: δ7.42 (1H,d,H8), 7.34-7.30 (2H,dd,J=8.73 Hz,‘o’-Ph), 7.03-6.97 (2H,t,J=8.68 Hz,‘m’-Ph), 6.02-5.97 (2H,m,H2′+NHcPr), 5.83-5.79 (1H,m,H3′), 5.43 (1H,t,H1′), 5.06 (2H,bs,NH₂), 4.28-4.04 (3H,m,H5′+NHala), 4.02-3.85 (1H,m,CHala), 3.61 (3H,d,OCH₂), 3.05 (1H,d,J=6.09 Hz,H4′), 2.94 (1H,d,CHcPr), 2.75-2.66 (1H,m,1of H6′), 1.66-1.56 (1Hm,1of H6′), 1.31-1.25 (3H,dd,CH₃ala), 0.79-0.72 (2H,q,2Hof CH₂cPr), 0.54-0.49 (2H,t,2Hof CH₂cPr).

[0428]¹³C NMR: δ174.4(CO), 160.3 (C2), 156.6 (C4), 151.3 (C6) 150.2 (‘ipso’-Ph), 136.7 (C2′), 136.0 (C8), 133.0 (‘m’-Ph), 131.6 (C3′), 122.4 (‘o’-Ph), 118.1 (‘p’-Ph), 115.2 (C5), 69.4 (C5′), 59.3 (Cl′), 52.9 (OCH₃), 50.6 (CHala), 46.0 (C4′), 34.8 (C6′), 24.2 (CHcPr), 21.3 (CH₃ala), 7.8 (CH₂cPr).

[0429] MS ES⁺: m/z 606.13 (40%, M⁺), 628.1065 (100%, 79-M+Na⁺), 630.0967 (95%, 81-M+Na⁺).

[0430] MS FAB: For C₂₄H₂₉O₅N₇NaPBr requires 628.1049, found 628.1058, and C₂₄H₂₉O₅N₇NaP

[0431]⁸1Br requires 630.1028, found 630.1042.

[0432] HPLC: t_(R) 35.882 (100%)-(100% water (0 mins), 20% water (35 mins), 20% water (45 mins), 100% water (55 mins)).

[0433] 4-Fluorophenyl-phosphorodichlondate

[0434] C₆H₄O₂P₁Cl₂F₁, MW=228.97

[0435] This was synthesised by a method analogous to that of 4-chlorophenyl-phosphorodichloridate, except using: Phosphorus oxychloride (3.29 g, 2 ml, 21.5 mmol), and 4-fluorophenol (2.41 g, 21.5 mmol) in anhydrous diethylether (70 ml), and anhydrous triethylamine (2.71 g, 3 ml, 21.5 mmol) in anhydrous diethylether (30 ml). The reaction was stirred at −80° C. for 4 hrs, and then at room temperature for 2 hrs. After filtration, and emoval of the solvent, the product was obtained as a clear liquid (4.08 g, 83.0%).

[0436]³¹P NMR: δ5.50 (s).

[0437]¹H NMR: δ7.29-7.24 (2H,m,‘o’-Ph), 7.09 (2H,t,J=8.29 Hz,‘m’-Ph), ³C NMR: δ159.7(‘ipso’-Ph), 145.8 (‘m’-Ph), 122.6 (‘o’-Ph), 117.5 (‘p’-Ph).

[0438] 4-Fluorophenyl-(methoxy-L-alaninyl)-phosphorochloridate

[0439] C₁₀H₁₂N₁O₄P₁Cl₁F₁, MW=295.65

[0440] This was synthesised according to Standard Procedure 3, using L-alarine methyl ester hydrochloride salt (1.Og, 7.16 mmol), 4-fluorophenyl-phoshorodichloridate (1.64 g, 7.6 mmol), triethylamine (2 ml. 14.3 mmol) in DCM (70 ml). The usual workup yielded the crude product as a yellow oil (1.97 g, 93.0%), which was stored in THF (12 ml) to give a 0.56M solution.

[0441] 31P NMR: δ9.84, 9.60 (1:1).

[0442]¹H NMR: δ7.32-7.23(2H,m,‘o’-Ph), 7.12-7.06 (2H,m,‘m’-Ph), 4.69 (1H,bs,NHala), 4.22 (1H,bs,CHala), 3.82 (3H,d,OCH₃), 1.57-1.53 (3H,m,CH₃ala).

[0443]¹³C NMR: δ173.5(CO), 161.6 (‘ipso’-Ph), 145.9 (‘m’-Ph), 122.5 (‘o’-Ph), 117.0 (‘p’-Ph), 53.2 (OCH₃), 50.9 ((Hala), 20.9 (CH₃ala).

[0444] (1S,4R4-(2-amino-6-cyclopropylamino9H-purin-9-yl)-2-cyclopentene-1-methanol O-[(4-fluoropheny]-(methoxy-L-alaninyl)]-phosphate. Cf1737.

[0445] C₂₄H₂₉N₇O₅P₁F₁, MW=545.57

[0446] This was synthesised according to Standard Procedure 4, using (lS,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (100 mg, 0.35 mmol), tuMgCl (0.7 ml, 0.7 mmol, of a 1.0M solution in THF), in THF (5 ml) and 4-fluorophenyl-(methoxy-L-alaiinyl)-phosphorochloridate (1.89 ml, 1.05 mmol, of a 0.56M solution in THF), at room temperature for 24 hrs. The solvent was removed under reduced pressure and the residue columned in 2.5-5% methanol in chloroform, and then in 3% methanol in chloroform, to give the pure product as a pale yellow foamy solid (62.0 mg, 32.5%).

[0447]³¹ P NMR: δ4.24, 4.23, 4.20, 4.19.

[0448]¹H NMR: δ7.52 (1H,d,H8), 7.21-7.14 (2H,m,‘o’-Ph), 7.03-6.97 (2H,m,‘m’-Ph), 6.16 (1H,bs,NHcPr), 6.10-6.07 (1H,q,H2′), 5.93-5.89 (1H,q,H3′), 5.44 (1H,d,H1′), 5.14 (2H,bs,NH₂), 4.23-3.98 (4H,mH5′,NHala+CHala), 3.72 (3H,d,OCH₂), 3.16 (1H,d,J=6.03 Hz,H4′), 3.03 (1H,d,CHcPr), 2.86-2.74 (1H,m,1of H6′), 1.76-1.66 (1H,m,1of H6′), 1.42-1.35 (3H,dd,CH₃ala), 0.89-0.83 (2H,q,2Hof CH₂cPr), 0.65-0.60 (2H,t,2Hof CH₂cPr).

[0449]¹³C NMR: δ174.4(CO), 161.5 (C2), 160.3+156.6 (‘p’-Ph), 156.6 (C4), 151.3 (C6) 150.2 (‘ipso’-Ph), 136.8 (C2′), 136.0 (C8), 131.6 (C3′), 121.9 (‘o’-Ph), 115.1 (C5), 69.3 (C5′), 59.3 (Cl′), 52.9 (OCH₃), 50.6 (CHala), 46.0 (C4′), 34.9 (C6′), 24.2 (CHcPr), 21.3 (CH₃ala), 7.8 (CH₂cPr).

[0450] HPLC: t_(R) 31.536 (100%)-(100% water (0 mins), 20% water (35 mins), 20% water (45 mins), 100% water (55 mins)).

[0451] 4-Iodophenyl-phosphorodichloridate

[0452] C₆H₄O₂P₁Cl₂I₁, MW=336.07

[0453] This was synthesised by a method analogous to that of 4-chlorophenyl-phosphorodichloridate, except using: Phosphorus oxychloride (3.29 g, 2 ml, 21.5 mmol), and 4-iodophenol (4.72 g, 21.5 mmol) in anhydrous diethylether (60 ml), and anhydrous triethylamine (2.71 g, 3 ml, 21.5nmmol) in anhydrous diethylether (20 ml). The reaction was stirred at −80° C. for 4 hrs, and then at room temperature for 2 hrs. After filtration, and removal of the solvent, the product was obtained as a clear liquid (6.2 g, 85.8%).

[0454]³¹P NMR: δ4.72 (s).

[0455]¹H NMR: δ7.71 (2H,d,J=8.59 Hz,‘o’-Ph), 7.06-7.02 (2H,dd,J=8.80 Hz,‘m’-Ph),

[0456]¹C NMR: δ149.9(‘ipso’-Ph), 139.8 (‘m’-Ph), 122.9 (‘o’-Ph), 91.9 (‘p’-Ph).

[0457] 4-Iodophenyl-(methoxy-L21aninyl)-phosphorochloridate

[0458] C₁₀H₁₂N₁O₄P₁Cl₁,I₁, MW=403.55

[0459] This was synthesised according to Standard Procedure 3, using L-alanine methyl ester hydrochloride salt (1.0 g, 7.16 mmol), 4-iodophenyl-phoshorodichloridate (2.41 g, 7.16 mmol), triethylamine (2 ml. 14.3 mmol) in DCM (70 ml). The usual workup yielded the crude product as a yellow oil (3.59 g, >100%), which was stored in THF (14 ml) to give a 0.51M solution.

[0460]³¹P NMR. δ9.31, 9.08 (1:1).

[0461]¹H NMR: 7.74-7.69(2H,m,‘o’-Ph), 7.32-7.05 (2H,m,‘m’-Ph), 4.73 (1H,bs,NHala), 4.20 (1H,bs,CHala), 3.81 (3H,d,0CH₃), 1.56-1.53 (3H,dd,J=7.06 Hz,CH₃ala).

[0462]¹³C NMR: δ173.4(CO), 149.9 (‘ipso’-Ph), 139.5 (‘m’-Ph), 123.0 (‘o’-Ph), 90.4 (‘p’-Ph), 53.3 (OCH₃), 50.9 (CHala), 20.9 (CH₃ala).

[0463] (1S,4R)-4-(2-amino6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-[4-iodophenyl-(methoxy-L-alaninyl)]-phosphate. Cf1738.

[0464] C₂₄H₂₉N₇O₅P₁I₁, MW=653.48

[0465] This was synthesised according to Standard Procedure 4, using (1S,4R)-4-(2-amino-6-cyclopropylaniino-9H-purin-9-yl)-2-cyclopentene-1-methanol (100 mg, 0.35 mmol), tBuMgCl (0.7 ml, 0.7mmol, of a 1.0M solution in THF), in THF (Smil) and 4-iodophenyl-(metfoxy-L-alaninyl)-phosphorochloridate (2.05 ml, 1.05mmol, of a 0.51M solution in THF), at room temperature for 48 hrs. The solvent was removed under reduced pressure and the residue colurired in 3-6% methanol in chloroform, and then in 3% methanol in chloroform, to give the pure product as a white foamy solid (82.0 mg, 29.9%).

[0466]³¹ P NMR: δ3.92 (s).

[0467]¹H NMR: δ7.63-7.59 (2H,dd,J=8-65 Hz,‘m’-Ph), 6.98 (2H,t,J-8.20 Hz‘o’-Ph), 6.25 (1H,bs,NHcPr), 6.09 (1H,t,H2′), 5.91 (1H,t,H3′), 5.54 (1H,d,H1′), 5.21 (2H,bs,NH₂), 4.35-4.16 (3H,m,H5′,NHala), 4.07-3.95 (1H,m,CHala), 3.71 (3H,d,OCH₃ala), 3.15 (1H,d,J=7.23 Hzl4′), 3.03 (1H,bs,CHcPr), 2.85-2.74 (1H,m,1of H6′), 1.761.65 (1H,m,1of H6′), 1.43-1.35 (3H,t,CH₃ala), 0.89-0.83 (2H,q,2Hof CH₂cPr), 0.63 (2H,bs,2Hof CH₂cPr).

[0468]¹³C NMR: δ174.4(CO) 160.2 (C2), 156.5 (C4), 151.1 (C6) 151.0 (‘ipso’-Ph), 139.0 (C2′), 136.8 (‘m’-Ph), 136.0 (C8), 131.5 (C3′), 122.8 (‘o’-Ph), 115.0 (C5), 88.9 (‘p’-Ph), 69.4 (CS′), 59.3 (C1′), 52.9 (OCH3), 50.6 (CHala), 46.0 (C4′), 34.8 (C6′), 24.2 (CHcPr), 21.3 (CH₃ala), 7.8 (CH₂cPr).

[0469] HPLC: t_(R) 33.848 (100%)-(100% water (0 mins), 20% water (35 mins), 20% water (45 mins), 100% water (55 mins)).

[0470] L-Alanine (3-pentyl) ester hydrochloride salt

[0471] Tionyl chloride (1.6 ml, 0.022 M) was added dropwise to a stirred solution of 3-pentanol (18.2 ml, 0.17 M) at 0° C. under nitrogen. The mixture was stirred for 30 minutes, then allowed to warm to room temperature. L-Alanine (pre-dried at 60 ° C. over P₂O₅ for 4 hrs: 1.0 g, 0.011 M) was added and the resulting suspension was heated at reflux overnight (the reaction mixture became a clear, colourless solution). The solvent was removed under reduced pressure to leave an oil which was repeatedly triturated and coevaporated with diethyl ether, then petrol (60/80) to remove traces of 3-pentanol. The resulting oily residue solidified on drying under high vacuum to give a peach-coloured solid (1.96 g, 10 mmol, 89%).

[0472] δ_(H) (d₄-CH₃OH, 300 MHz) 0.94 (t, 6H, O-CH(CH₂CH₃)₂, J =7), 1.57 (d, 3H, CH₃-ala, J=7), 1.67 (m, 4H, O-CH(CH₂CH₃)₂, J=7), 4.12 (q, 1H, CH-ala, J =7), 4.88 [m, 1H, O-CH(C₂H₂)₂]; δ_(c)(d₄-CH₃OH, 75 MHz) 8.87 [O-CH(CH₂CH₃)₂], 15.38 (CH₃-ala), 26.39, 26.44 [O-CH(CH₂CH₃)₂J, 48.82 (CH-ala), 79.88 [O-CH(C₂H)₂], 170.03 (C═O).

[0473] Phenyl (3-pentyloxy-L-alaninyl)phosphorochloridate

[0474] Prepared according to Standard Procedure 3, from phenyl dichlorophosphate (0.45 ml, 3.0 mmol), dry triethylamiine (0.8 ml, 6.0 mmol), L-alanine (3-pentyl) ester hydrochloride salt 1a (0.583 g, 3.0 mmol) and dry DCM (60 ml total). The crude product was obtained as a clear, pale yellow oil (1.055 g, >100%)

[0475] δ_(P) (CDCl₃, 121 Mz) 8.99, 9.37

[0476] The product was redissolved in dry THF 5 ml) and used as a 0.211 g/ml solution.

[0477] (1S,4R)-4-(2-amino-6cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-[phenyl (3-pentyloxy-L-alaninyl)phosphate [Cf 1685]

[0478] Prepared according to Standard Procedure 4, from (1S,4R)-4-(2-amino-6-cyclopropylamino9H-purin-9-yl)-2-cyclopentene-1-methanol (0.2 g, 0.7 mmol), ′BuMgCl (1.0M in THF: 1.4 ml, 1.4 nmmol), phenyl(3-pentyloxy-L-alaninyl)phosphorochloridate 1b (3.3 ml of 0.211 g/ml solution 4 2.1 mmol) and dry THF (8 ml). TLC (8% MeOH in CHCl₃) showed the reaction to be complete after 1.5 hrs. The crude residue was purified twice by column chromatography, using (i) MeOH:CHCl₃ (4:96) and (ii) MeOH:CHCl₃ (3:97) as eluent, to give the product as a clear, colourless oil, which solidified to a white foam after trituration and coevaporation with diethyl ether (0.202 g, 0.35 mmol, 50%). δ_(P) (CDCl₃, 121 MHz) 3.89; 31 (CDCl₃, 300 lvhz) 0.66 (m, 2H, CH2-CPr), 0.90 [m, 8H CH₂-cPr and CH(CH₂CH₃)₂], 1.43 (m, 3H, CH₃-ala), 1.58 [m, 4H, CH(CH₂CH₃)₂], 1.72 (m, 1H, 6¹H.), 2.82 (m, 1H, ⁶′H_(b)), 3.05 (m, 1H, C1H-cPr), 3.20 (m, 1H, 4′H), 3.77 (m, 1H, CH-ala), 4.05 (m, 1H, NH-ala), 4.22 (m, 2H, 5¹H), 4.80 (m, 1H, O-CH—), 4.89 (s, 2 M, NH₂), 5.56 (m, 1H, 1′H), 5.78 (bs, 1H, NHPr), 5.93 (m, 1H, 3¹H), 6.12 (m, 1H, 2¹H), 7.26 (m, 5H, ArH), 7.51 (d, 1H, 8H); δ_(c) (CDCl₃, 75 MHz) 6.37 (CH₂-cPr), 8.50 [CH(CH₂CH₃)₂], 20.28 (CH3-ala), 22.68 (CH-cPr), 25.28, 25.38 [CH(CH₂CH₃)₂], 33.51, 33.60 (6° C.), 44.59, 44.69 (4° C.), 49.40 (CH-ala), 57.79, 57.83 (1° C.), 67.90 (5° C.), 7729 (OCH), 113.86 (5C), 119.10-119.18 (o-Ph), 123.84 (p-Ph), 128.61 (m-Ph), 130.09, 130.16 (3′C), 134.45, 134.56 (8C), 135.27, 135.41 (2′C), 149.66-149.93 (6C and ipso-Ph), 155.26 (4C), 158.95 (2C), 172.32, 172.44 (C═O); m/z (FAB) 584.2751 (MW, C₂₈H₃₉N₇O₅P requires 584.2750).

[0479] L-Alanine (3,3-dimethyl-1-butyl) ester hydrochloride salt

[0480] Prepared according to Standard Procedure 2, from L-alanine (1.6 g, 18 mmol), PTSA monohydrate (3.8 g, 20 mmol), 3,3-dimethyl butan-1-ol (2.2 ml, 18 mmol) and toluene (100 ml). Conversion to the hydrochloride salt: the p-toluene sulfonate salt was redissolved in CHCl₃ and washed with 10% potassium carbonate solution and water. The organuc layer was dried (MgSO₄), filtered and the solvent was reroved under reduced pressure to give the crude product as an oil. Aq. HCl (1 M), was added and the solution stirred for 30 minutes at room temperature. The solution was freeze-dried to give the hydrochloride salt as awhite solid (3.31 g, 15.8 mmol, 88%).

[0481] δ_(H) (d₄-CH₃OH, 300M ) 0.93 [s, 9H, O-(CH₂)₂(CH₃)₃], 1.50 (d, 3H, CH₃-ala, J=7), 1.59 (t, 2H, O-CH₂CH₂, J=7), 4.05 (q, 1I, CH-ala, J 7), 4.25 (m, 2H, O—CH₂); 8c (d₄-CH₃OH, 75 MHz) 15.18 (CH3-ala), 28.91 [C(CH₃)₃], 29.54 [C(CH₃)₃], 41.62 (O—CH₂CH₂—), 48.85 (CH-ala), 64.11 ()—CH₂CH₂—), 170.03 (C═O).

[0482] Phenyl(3,3-dimethyl-1-butoxy-L-alaninyl)phosphorochloridate

[0483] Prepared according to Standard Procedure 3, from phenyl dichlorophosphate (0.45 ml, 3.0 mmol), dry triethylamine (0.8 ml, 6.0 mmol), L-alanine (3,3-dimethyl-1-butyl) ester hydro-chloride salt 2a (0.632 g, 3.0 mmol) and dry DCM (60 ml total). The crude product was obtained as a clear, pale yellow oil (1.038 g, 99%).

[0484] δ_(p) (CDCl₃, 121 MHz) 8.94, 9.30

[0485] The product was redissolved in dry THF (5 ml) and used as a 0.208 g/ml solution

[0486] (1S,4R)-4-(2-amino6cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-[phenyl(3,3-dimethyl-]-butoxy-L-alaninyl)phosphate [Cf 1687]

[0487] Prepared according to Standard Procedure 4, from (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (0.2 g, 0.7 mmol), BuMgcl (1.0M in THF: 1.4 ml, 1.4 minol), phenyl (3,3-dimethyl-1-butoxylalaninyl) phosphorochloridate 2b (3.5 ml of 0.208 g/ml solution, 2.1 mmol) and dry THF (8 ml). TLC (8% MeOH in CHCh3) showed thle reaction to be complete after 1.5 hrs. The crude residue was purified twice by column chromatography, using MeOH:CHCl₃ (4:96) as eluent, to give thle product as a clear, colourless oil, which solidified to a white foam after trituration and coevaporation with diethyl ether (0.287 g, 0.5 mmol, 69%). 5? (CDCl₃, 121 M) 3.83; 5H (CDCl₃, 300 M) 0.66 (m, 2H, CH₂,-cPr), 0.90 (m, 2H, CH₂cPr), 0.97 [s, 9H, C(CHl₃)₃]1.41 (m, 3H1, CH₃-ala), 1.57 (m, 2H, O—CH₂CH₂), 1.74 (m, 111, 6¹H.), 2.82 (m, 111, ⁶′H_(b)), 3.05 (m, 1ill CH-cPr), 3.20 (m, 1H, 4′H), 3.70 (m, 1H CH-ala), 4.04 (m, 1H, NH-ala), 4.22 (i, 4H, 5′H and C-CH₂CH₂), 4.88 (s, 2H, NH₂), 5.57 (m, 1H, 1′H), 5.75 (bs, 1H, NH-cPr), 5.93 (m, 1H, 3′H), 6.12 (m, 1H, 2′H), 7.27 (m, 5H, ArH), 7.52 (d, 1H, 8H); 5c (CDCl₃, 75 MHz) 6.35 (CH₂-cPr), 19.95, 20.01 (CH₃-ala), 22.69 (CH-cPr), 28.52 [C(CH₃)₃], 28.52 [C(CH₃)₃], 33.49, 33.57 (6′C), 40.59, 40.63 (OCH₂CH₂—), 44.58, 44.68 (4′C), 49.28 (CH-ala), 57.79, 57.83 (1′C), 62.28, 62.31 (OCH₂CH₂—), 67.86, 67.94 (5′C), 113.81 (5C), 119.10, 119.16 (p-Ph), 123.84 (o-Ph), 128.61 (m-Ph), 130.10, 130.16 (3′C), 134.47,134.56 (8C), 135.29, 135.40 (2′C), 149.67-149.75 (6C and ipso-Ph), 155.25 (4C), 158.96 (2C), 172.55, 172.65 (C═O); m/z (FAB) 598.2896 (MH⁺, C₂₉H₄₁ N₇O₅P requires 598.2907).

[0488] L-Alanine (4-methyl-1-pentyl) ester p-toluene sulfonate salt

[0489] Prepared according to Standard Procedure 2, from L-alanine (1.6 g, 18 mmol), p-TSA monohydrate (3.8 g, 20 mmol), 4-methyl pentan-1-ol (2.24 ml, 18 mmol) and toluene (100 ml). Thep-toluene sulfonate salt was isolated as a white solid (6.082 g, 17.6 mmol, 98%). 8H (d₄-CH30H, 300 MHz) 0.93 [d, 6H, CH(CH₃)₂], 127 (m, 21I, O-CH₂CH₂CH₂—), 1.54 (d, 3H, CH₃-ala), 1.59 (m, 1H, CH(CH₃)₂), 1.69 [m, 2H, O—(CH2)2C , 2.39 (s, 3H, CH₃, p-TSA), 4.10 (m, 1H, CH-ala), 4.24 (m, 2H, O-CHz), 7.25 (d, 2H, Arl, p-TSA), 7.72 (d, 2H, ArH, p-TSA); δ_(c) (d₄-CH₃OH, 75 MHz) 15.23 (CH₃-ala), 20.31 (CH₃-pTSA), 21.83 [CH(CH₃)₂], 26.45 (O-CH₂CH₂CH₂—), 27.87 [CH(CH₃)₂], 34.93 (O—CH₂CH₂CH₂—), 48.85 (CH-ala), 66.77 [O—CH₂(CH₂)₂], 125.93 (o-Ph, p-TSA), 128.83 (m-Ph, p-TSA), 140.75 (ipso-C-CH₃,p-TSA), 142.39 (ipso-C-S, p-TSA), 170.07 (C═O).

[0490] Phenyl(4-methyl-1-pentyioxy-L-alaninyl)phosphorochloridate

[0491] Prepared according to Standard Procedure 3, from phenyl dichlorophosphate (0.9 ml, 6.0 mmol), dry triethylarine (1.7 ml, 12.0 mmol), L-alanine (4-methyl-1-pentyl) ester p-toluene sulfonate salt 3a (2.081 g, 6.0 mmol) and dry DCM (100 ml total). The crude product was obtained as a clear, colourless oil (1.79 g, 85%).

[0492] δ_(P) (CDCl₃, 121 MHz) 8.95, 9.31

[0493] The product was redissolved in dry THF (10 ml) and used as a 0.179 g/ml solution.

[0494] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-y))-2-cyclopeDtene-1-methanol O-[phenyl (4-methyl-1-pentyloxy-L-alaninyl)phosphate [Cf 1721]

[0495] Prepared according to Standard Procedure 4, from (1S,4R)-4-(2-amino-6-cyclopropylaraino-9H-purin-9-yl)-²-cyclopentene-1-methanol (0.2 g, 0.7 mmol), ′BuMgl (1.0M in THF: 1.4 ml, 1.4 mmol), phenyl(4-methyl-lpentyloxy-L-alaninyl)phosphorochloridate 3b (4.1 ml of 0.179 g/ml solution, 2.1 mmol) and dry THF (10 ml). TLC (8% MeOH in CHCl₃) showed the reaction to be complete after 3 hrs. The crude residue was purified by column chromatography, using MeOH:CHCl₃ (4:96) as eluent, to give the product as a clear, colourless oil, which solidified to a white foam after trituration and coevaporation with diethyl ether (0.288 g, 0.5 mmol, 69%).

[0496] δ_(P) (CDCl₃, 121 M) 3.84, 3.88; δ_(H) (CDCl₃, 300 M) 0.64 (m, 2H, CH₂-CPr), 0.87 (m, 2H, CH₂CPr), 1.24 [m, 2H, CH(CH₃),₂], 1.40 (t, 3H, CH₃-ala), 1.60 [m, 3H, CH(Cl₃)CH₃], 1.73 [m, 3H, CH(CH₃)CH₃], 2.19 (m, 1H, 6′H_(b)), 2.80 (m, 1H, ⁶′H_(b)), 3.03 (m,1H, CHCPr), 3.18 (mi, 1H, 4′H), 3.88 (m, 1H, CH-ala), 4.03 (m, 3H, OCH₂— and NH—ala), 4.21 (m, 2H, 5′H), 4.99 (bs, 2H, NH2), 5.55 (m, 1′H, 1′H), 5.91 (m, 2H, NH-cPr and 3¹H), 6.10 (m, 1H, 2¹H), 7.29 (m, 5H, ArH), 7.51 (d, 1H, 8H); bc (CDCl₃, 75 MHz) 7.79 (CH₂-cPr), 21.55 (CH₃-ala), 21.61 [CH(CH₃)₂], 23.69 (CH-cPr), 25.66 (O—CH₂CH₂CH₂—), 29.63 [CH(CH₃)₂], 35.00 (6′C), 38.81 (O-CH₂CH₂CH₂—), 46.01, 46.11 (4° C.), 50.72 (CH-ala), 59.21 (1′C), 69.31 (5′C), 69.85 (O-CH₂CH₂-), 115.25 (5C), 120.52-120.62 (p-Ph), 125.25 (o-Ph), 130.04 (m-Ph), 131.59 (3′C), 135.98 (8C), 136.71, 136.79 (2′C.), 151.08, 151.17 (6C and ipso-Ph), 156.70 (4C), 160.40 (2C), 174.00, 174.10 (C═O); m/z (FAB) 598.2883 (MH⁺, C₂₉H₄₁N₇O₅P requires 598.2907).

[0497] L-Alanine (cyclopropyl methyl) ester hydrochloride salt

[0498] Thionyl chloride (1.2 ml, 0.017 M) was added dropwise to a stirred solution of cyclopropyl methanol (6.8 ml, 8.4 mmol) at 0° C. under nitrogen. The mixture was stirred for 30 minutes, then allowed to warm to room temperature. L-Alanine (pre-dried at 60° C. over P₂O₅ for 4 hrs: 0.75 g, 8.4 mmol) was added and the resulting suspension was heated at reflux overnight (the reaction mixture became a clear, colourless solution). The solvent was removed under reduced pressure to leave an orange/red oil which was repeatedly triturated and coevaporated with diethyl ether, to remove traces of cyclopropyl methanol. Diethyl ether (200 ml) was added and the mixture was stirred for 30 niin. The resulting suspension was filtered to give the product as a cream solid (1.29 g, 7.1 mmol, 85%).

[0499] δ_(H)(d₄-C:H₃OH, 300 MHz) 0.38 (m, 21, CH₂-cPr), 0.65 (m, 2H, CH₂-cPr), 1.24 (m, 1H, CH-cPr), 1.60 (d, 3H, CH₃-ala, J=7), 4.13 (m, 3H, CH-ala and O-CH₂); bc (d₄-CH₃OH, 75 MHz) 4.17 (CH₂-cPr), 10.98 (CH-cPr), 16.72 (CH₃-ala), 50.33 (CH-ala), 72.70 (O-CH₂), 171.56 (C═O).

[0500] Phenyl(cyclopropyl methoxy-L-alaninyl)phosphorochloridate

[0501] Prepared according to Standard Procedure 3, from phenyl dichlorophosphate (0.9 ml, 6.0 mmol), dry triethylamine (1.7 ml, 12.0 mmol), L-alanine (cyclopropyl methyl) ester p-toluene sulfonate salt 4a (1.082 g, 6.0 mmol) and dry DCM (100 ml total). The crude product was obtained as a clear, yellow oil (1.79 g, 94%).

[0502] δ_(P)(CDCl₃, 121 ) 9.00, 9.36

[0503] The product was redissolved in dry THF (5 ml) and used as a 0.385 g/ml solution.

[0504] (1S,4R)-4(2-amino6-cyclopropylamino-9H-purin-9-yl)-2-cyclopeutene-1-methanol O-[phenyl(cyclopropyl methoxy-L-alaninyl)lphosphate

[0505] Prepared according to Standard Procedure 4, from (lS,4R)-4-(2-amino6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (0.2 g, 0.7 mmol), ′BuMgCl (1.0M in THF: 1.4 ml, 1.4 mmol) phenyl(cyclopropyl methoxy-L-alaninyl) phosphorochloridate 4b (1.85 ml of 0.385 g/ml solution, 2.1 mmol) and dry THF (8 ml). TLC (8% MeOH in CHCl₃) showed the reaction to be complete after 3.5 hrs. The crude residue was purlifed twice by column chromatography, using MeOH:CHCl₃ (4:96) as eluent, to give the product as a clear, colourless oil which solidified to a white foam after trituration and coevaporation with diethyl ether (0.244 g, 0.4 mmol, 61%).

[0506] δ_(P) (CDCl₃, 121 MHz) 3.88, 3.94; δ_(H) (CDCl₃, 300 MHz) 0.29 (m, 2H, CH₂-cPr), 0.61 (m, 2H, CH₂-cPr), 0.87 (m, 2H, CH2-cPr), 1.17 (m, 1H, CH-cPr), 1.42 (t, 3H, CH₃-ala), 1.69 (m, 1H, 6′H_(a)), 2.81 (m, 1H, 6′H_(b)), 3.04 (m, 1H, CH-cPr), 3.18 (m, 1H, 4′H), 4.01 (m, 41, OCH₂—, CH-ala and NH-ala), 4.21 (m, 2H, 5¹H), 5.03 (bs, 2H, NH2), 5.56 (m, 1I, 1′H), 5.91 (m, 1H, 3¹H), 6.05 (bs, 1H, NH-cPr), 6.10 (m, 1H, 2¹H), 7.25 (m, 5H, ArH), 7.51 (d, 111H, 8H); ⁵c (CDCl₃, 75 MHz) 2.24 (CH2-cPr), 6.33 (CH₂-cPr), 8.66 (CH₂-cPr), 20.05, 20.11 (CH₃-ala), 22.68 (CH-cPr), 33.55 (6′C), 44.58, 44.68 (4′C), 49.24, 49.31 (CH-ala), 57.77, 57.82 (1′C), 67.76, 67.93 (0-CH2), 69.27, 69.29 (5′C), 113.74 (5C), 119.10-119.19 (p-Ph), 123.84 (o-Ph), 128.61 (m-Ph), 130.09, 130.13 (3′C), 134.42, 134.50 (8C), 135.32, 135.40 (2′C), 149.66, 149.74 (6C and ipso-Ph), 155.26 (4C), 159.00 (2C), 172.64, 172.73 (C═O).

[0507] L-Alanine (cyclobutyl methyl) ester hydrochloride salt

[0508] Prepared according to Standard Procedure 2, from L-ala,niIe (1.6 g, 18 mmol), PTSA monohydrate (3.8 g, 20 mmol), cyclobutane methanol (1.9 ml, 20 mmol) and toluene (100 ml). Thep-toluene sulfonate salt was isolated as a white solid (4.249 g, 12.9 mmol, 72%).

[0509] δ_(H) (d₄-CH30H, 300 MHz) 1.54 (d, 3H, CH₃-ala, J=7), 1.89 (m, 4H, cPu-2/4H), 2.08 (m, 2H, cBu-3H), 2.39 (s, 3H, CH₃, p-TSA), 2.69 9 m, 1H, CH-cBu), 4.11 (q, 11, CH-ala, J=7), 4.22 (m, 2H, O—CH₂), 7.26 (d, 2H, ArH, p-TSA), 7.73 (d, 2H, ArH, p-TSA); δ_(c) (d₄-CH₃OH, 75 MHz) 16.7 (CH₃-ala), 19.6 (CH₂-cBu), 21.7 (CH₃-pTSA), 25.9 (CHl₂-cBu), 35.7 (CH-cBu), 48.9 (CH-ala), 71.3 (O—CH₂), 127.4 (o-Ph, p-TSA), 130.3 (m-Ph, p-TSA), 142.2 (ipso-C-CH₃,p-TSA), 143.8 (ipso-C-S,p-TSA), 171.6 (C═O).

[0510] Phenyl(cyclobutyl methoxy-L-alaninyl)phosphorochloridate

[0511] Prepared according to Standard Procedure 3, from phenyl dichlorophosphate (0.9 ml, 6.0 1 mmol), dry triethylamine (1.7 ml, 12.0 mmol), L-alanine (cyclobutyl methyl) ester p-toluene sulfonate salt 5a (1.98 g, 6.0 mmol) and dry DCM (100 ml total). The crude product was obtained as a clear, colourless oil (2.04 g, >100%).

[0512] δ_(P) (CDCl₃, 121 ) 9.00, 9.34

[0513] The product was redissolved in dry THF (5 ml) and used as a 0.408 g/ml solution.

[0514] (1S,4R)-4-(2-amino-6-cyclopropylaminon9H-purin-9-yl)-2-cyclopentene-1-methanol O-[phenyl(cyclobutyl methoxy-L-alaninyl)]phosphate [Cf 1773]

[0515] Prepared according to Standard Procedure 4, from (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-²-cyclopentene-1-methanol (0.2 g, 0.7 mmol), ′BuMgCl (1.0M in TEF: 1.4 ml, 1.4 mmol) phenyl(cyclobutyl methoxy-L-alainyl) phosphorochloridate 5b (1.7 ml of 0.408 g/ml solution, 2.1 mmol) and dry THF (8 ml). TLC (8% MeOH in CHCl₃) showed the reaction to be complete after 3 hrs. The crude residue was purified twice by column chromatography, using MeOH:CHCl₃ (4:96) as eluent, to give the product as a clear, colourless oil, which solidified to a white foam after trituration and coevaporation with diethyl ether (0.213 g, 0.4 mmol, 52%).

[0516] δ_(P) (CDCl₃, 121M ) 3.87, 3.91; ³H (CDCl₃, 300M ) 0.65 (m, 2H, CH2cPr), 0.89 (m, 2H, CH₂-cPr), 1.41 (t, 3H, CH₃-ala), 1.74 (m, 3H, CH₂-cBu and 6¹H,), 2.06 (m, 2H, CH₂-cBu), 2.61 (m, 2H, CH₂-cBu), 2.81 (m, 1H, ⁶ ¹H_(b)), 3.04 (m, 1H, CH-cPr), 3.19 (m, 1H, 4′H), 3.90 (m, 1H, NH-ala), 4.09 (m, 3H, OCH₂—, and CH-ala), 4.22 (m, 2H, 5′H), 4.98 (bs, 2H, NH₂), 5.56 (m, 1H, 1¹H), 5.92 (m, 2H, 3¹H and NH-cPr), 6.11 (m, 1H, 2′H), 7.26 (m, 5H, ArH), 7.52 (d, 1H, 8H); δ_(c) (CDCl₃, 75 MHz) 6.37 (CH₂-cPr), 17.33 (CH₂-cBu), 20.17, 20.23 (CH₃-ala), 22.68 (CH-cPr), 23.57 (2×CH₂-cBu), 32.86 (CHBu), 33.51, 33.55 (6′C), 44.58, 44.68 (4′C), 49.23, 49.28 (CH-ala), 57.81, 57.85 (1′C), 67.78-67.94 (5′C), 68.17, 68.20 (O-CH₂), 113.83 (5C), 119.09-119.19 p-Ph), 123.87 (o-Ph), 128.62 (m-Ph), 130.11, 130.15 (3′C), 134.51, 134.61 (8C), 135.30,135.39 (2′C), 149.64149.97 (6C and ipso-Ph), 155.20 (4C), 158.87 (2C), 172.64, 172.74 (C═O).

[0517] L-Alanine (cyclopentyl methyl) ester p-toluene sulfonate salt

[0518] Prepared according to Standard Procedure 2, from L-alanine (1.6 g, 18 mmol), p-TSA monohydrate (3.8 g, 20 mmol), cyclopentane methanol (1.9 ml, 18 mmol) and toluene (100 ml). Thep-toluene sulfonate salt was isolated as a white solid (6.21 g, 18 mmol, 100%). 5H (d₄-CH₃OH, 300 MH:) 1.22 (m, 2H, cPent 2/5H.), 1.46 (d, 3H, CH₃-ala), 1.56 (m, 4H, cPent 2/3/4/5H_(b)), 1.70 (m, 2H, cPent 3/4H.), 2.19 (m, 1′H, CH-cPent), 2.31 (s, 3H, CH₃, p-TSA), 4.06 (m, 3H, O-CH₂ and CH-ala), 7.18 (d, 2H, ArH, p-TSA), 7.64 (d, 2H, ArH, p-TSA);

[0519]67 _(c) (d₄-CH₃OH, 75 MHz) 15.25 (CH₃-ala), 20.30 (CH₃,p-TSA), 25.27 (CH₂-cPent), 29.10, 29.15 (CH₂-cPent), 38.72 (CH-cPent), 48.84 (CH-ala), 70.12 (O-CH₂), 125.93 (o-Ph, p-TSA), 128.82 (m-Ph, p-TSA), 140.75 (ipso-C-CH₃, p-TSA), 142.40 (ipso-C-S, p-TSA), 170.09 (C═O).

[0520] Phenyl(cyclopentyl methoxy-L-alaninyl)phosphorochioridate

[0521] Prepared according to Standard Procedure 3, from phenyl dichlorophosphate (0.9 ml, 6.0 mmol), dry triethylaniine (1.7 ml, 12.0 mmol), L-alanne (cyclopentane methiyl) ester p-toluene sulfonate salt 6a (2.069 g, 6.0 mmol) and dry DCM (100 ml total). The crude product was obtained as a clear, yellow oil (1.97 g, 95%).

[0522] δ_(P) (CDCl₃, 121 M)8.94, 9.30

[0523] The product was redissolved in dry THF (IO ml) and used as a 0.197 g/ml solution.

[0524] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-[phenyl(cyclopentyl methoxy-L-alaninyl)phosphate [Cf 1722]

[0525] Prepared according to Standard Procedure 4, from (1S,4R)-4-(2-ainino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (0.2 g, 0.7 mmol), ′BuMgCl (1.0M in THF: 1.4 ml, 1.4 mmol), phenyl (cyclopentene methoxy-L-alaninyl) phosphorochloridate 6b (3.7 ml of 0.197 g/ml solution, 2.1 mmol) and dry THF (10 ml). TLC (8% MeOH in CHCl₃) showed the reaction to be complete after 3 hrs. The crude residue was purfied by column chromatography, using MeOH:CHCl₃ (4:96) as eluent, to give the product as a clear, colourless oil, which solidified to a white foam after trituration and coevaporation with diethyl ether (0.314 g, 0.5 mmol, 75%).

[0526] δ_(P) (CDCl₃, 121 MHz) 3.86, 3.87; 5H (CDCl₃, 300 Mfz) 0.65 (m, 2H, CH₂-cPr), 0.89 [m, 8H, CH₂-cPr and (CH₂)3-cPent], 1.24 (m, 2H, CH₂-cPent), 1.41 (m, 311, CH₃-ala), 1.65 (m, 2H, CH-cPent and 6¹H.), 2.81 (m, 1H, 6′H_(b)), 3.04 (in, 1H, CH-cPr), 3.19 (m, 1H, 4¹H), 3.80 (in, 1H, CH-ala), 4.07 (m, 3H, OCH₂ and NH-ala), 4.22 (m, 2H, 5′H), 4.92 (bs, 2H, NH₂), 5.55 (m, 1H, 1′H), 5.81 (bs, 1H, NH-cPr), 5.92 (in, 1H, 3¹H), 6.11 (m, 1H, 2′H), 7.26 (m, 5H, ArH), 7.52 (d, 1H, 8H); δ_(c) (CDCl₃, 75 MHz) 6.42 (CH2-cPr), 21.43 (CH₃-ala), 22.73 (CH-cPr), 24.59 (CH₂-cPcnt), 25.35 (CH₂-cPent), 26.64 (CH-cPent), 33.43, 33.51 (6′C), 44.58, 44.68 (4′C), 49.23 (CH-ala), 57.86, 57.91 (1′C), 64.69, 64.97 (O-CH₂—), 67.84 (5′C), 113.74 (5C), 119.09-119.18 (p-Ph), 123.88 (o-Ph), 128.62 (m-Ph), 130.05, 130.11 (3′C), 134.65,134.76 (8C), 135.33, 135.44 (2′C), 149.63, 149.72 (6C and ipso-Ph), 154.98 (4C), 158.59 (2C), 172.50, 172.60 (C═O); nil/z (FAB) 598.2745 (MH⁺, C₂₉H₃₉N₇O₅P requires 596.2750).

[0527] L-Alanine (cyclobutyl) ester p-toluene sulfonate salt

[0528] Prepared according to Standard Procedure 2, except using benzene as solvent: from L-alanine (1.0 g, 11 mmol),p-TSA monohydrate (2.35 g, 12 mmol), cyclobutanol (0.9 ml, 11 mmol) and benzene (65 ml). The p-toluene sulfonate salt was isolated as a white solid (1.73 g, 5.5 mmol, 49%). ⁶H (d₄-CH₃OH, 300 MHz) 1.51 (d, 3H, CH₃-ala, J =7), 1.75 (m, 2H, CH₂-cBu), 2.14 (m, 2H, CH₂-cBu), 2.37 (m, 5H, CH₂-c]u and CH₃, p-TSA), 4.05 (q, 1H, CH-ala, J=7), 5.08 (m, 1H, CH-cBu), 7.24 (d, 2H, ArH, p-TSA), 7.70 (d, 2H, ArH, p-TSA); bc (d₄-CH₃OH, 75 MHz) 14.57 (CH2-cBu), 16.58 (CH₃-ala), 21.73 (CH₃-pTSA), 31.38, 31.44 (CH₂-cBu), 50.16 (CH-ala), 72.47 (CH-cBu), 127-35 (o-Ph, p-TSA), 130.23 (m-Ph, p-TSA), 142.13 (ipso-C-CH₃, p-TSA), 143.89 (ipso-C-S, p-TSA), 170.71 (C═O).

[0529] Phenyl(cyclobutoxy-L-alaninyyl)phosphorochloridate

[0530] Prepared according to Standard Procedure 3, from phenyl dichlorophosphate (0.75 ml, 15.0 mmol), dry triethylamine (1.4 ml, 10.0 mmol), L-alanne (cyclopentane methyl) ester p-toluene sulforiate salt 7a (1.58 g, 5.0 mmol) and dry DCM (65 ml total). The crude product was obtained as a clear, colourless oil (1.13 g, 71%)

[0531] δ_(P) (CDCl₃, 121 M)8.96, 9.33

[0532] The product was redissolved in dry THF (5 ml) and uised as a 0.226 g/ml solution.

[0533] (1S,4R)-4-(2-amino-6-cyclopropylamino-911-purine-9-yl)-2-cyclopentene-1-methanol O[pheny](cyclobutoxy-L-alaninyl)lphosphate [Cf 1775]

[0534] Prepared according to Standard Procedure 4, from (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (0.2 g, 0.7 mmol), ′BuMgCl (1.0M in THF: 1.4 ml, 1.4 mmol) phenyl(cyclobutyl methoxy-L-alaninyl) phosphorochloridate 7b (2.95 ml of 0.226 g/ml solution, 2.1 mmol) and dry THF (8 ml). TLC (8% MeOH in CHCl₃) showed the reaction to be complete after 3.5 hrs. The crude residue was purified by column chromatography, using MeOH:CHCl₃ (4:96) as eluent, to give the product as a pale, yellow oil, which solidified to a cream solid after trituration and coevaporation with diethyl ether (0.238 g, 0.4 mmol, 60%).

[0535] δ_(P) (CDCl₃, 121 MHz) 3.89, 3.93; δ_(H) (CDCl₃, 300M ) 0.63 (m, 2H, CH₂-cPr), 0.87 (m, 2H, CH₂-cPr), 1.39 (m, 3H, CH3-ala), 1.65 (m, 2H, CH₂-cBu), 1.81 (m, 1H, 6¹H,), 2.04 (m, 2H, CH₂-cBu), 2.36 (m, 2H, CH₂-cBu), 2.80 (m, 1H, 6′H_(b)), 3.03 (m, 1H, CH-cPr), 3.17 (m, 1H, 4′H), 3.97 (m, 2H, NH-ala and CH-ala), 4.18 (m, 2H, 5′H), 4.98 (m, 3H, NH₂ 42 and OCH), 5.55 (m, 1H, 1¹H), 5.91 (m, 1H, 3¹H), 6.01 (m, 1H, NH-cPr), 6.10 (m, 1H, 2′H), 7.25 (m, 5H, ArH), 7.51 (d, 1H, 8H); δ_(c) (CDCl₃, 75 Mz) 7.80 (CH₂-cPr), 13.82 (CH₂-cBu), 21.42 (CH₃-ala), 22.06 (CH-cPr), 30.52-30.63 (CH₂-cBu), 35.01 (6′C), 46.01, 46.12 (4′C), 50.50 (CH-ala), 59.26 (1′C), 69.30 (CH-cBu), 70.19 (5′C), 115.25 (5C), 120.53, 120.59 (p-Ph), 125.28 (o-Ph), 130.05 (m-Ph), 131.53 (3′C), 135.97 (8C), 136.73, 136.85 (2′C), 151.08-151.17 (6C and ipso-Ph), 156.71 (4C), 160.44 (2C), 173.33 (C═O).

[0536] L-Alanine (cyclopentyl) ester p-toluene sulfonate salt

[0537] Prepared according to Standard Procedure 2, except using benzene as solvent: from L-alanine (1.6 g, 18 mmol), p-TSA monohydrate (3.8 g, 20 mmol), cyclopentanol (1.6 ml, 18 mmol) and benzene (100 ml). The p-toluene sulfonate salt was isolated as a beige solid (2.81 g, 8.5 mmol, 47%).

[0538] δ_(H) (d₄-CH₃OH, 300M ) 1.51 (d, 3H, CH₃-ala, J=7), 1.71 (m, 6H, CH₂-cPnt), 1.92 (m, 2H, CH₂-cPnt), 2.39 (m. 5H, CH₂-cBu and CH₃,p-TSA), 4.04 (q, 1H, CH-ala, J=7), 5.28 (m, 1H, CH-cPnt), 7.26 (d, 2H, ArH, p-TSA), 7.73 (d, 2H, ATH, p-TSA); δ_(c) (d₄-CH₃OH, 75 MHz) 16.59 (CH₃-ala), 21.72 (CH₃-pTSA), 24.97 (CH₂-cPnt), 33.81, 33.97 (CH₂-cPnt), 50.31 (CH-ala), 81.37 (CH-cPnt), 127.36 (o-Ph, p-TSA), 130.25 (m-Ph, p-TSA), 142.20 (ipso-C-CH₃, p-TSA), 143.79 (ipso-C-S, p-TSA), 171.17 (C═O).

[0539] Phenyl(cyclopentyloxy-L-alaninyl)phosphorochloridate

[0540] Prepared according to Standard Procedure 3, from phenyl dichlorophosphate (0.9 ml, 6.0 10 mmol), dry triethylamine (1.7 ml, 12.0 mmol), L-alanine (cyclopentane methyl) ester p-toluene sulfonate salt 8a (1.98 g, 6.0 mmol) and dry DCM (100 ml total). The crude product was obtained as a clear, colourless oil (1.8 g, 91%).

[0541] δ_(P) (CDCl₃, 121 MHz) 9.01, 9.37

[0542] The product was redissolved in dry THF (5 ml) and used as a 0.361 g/ml solution. (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-[phenyl(cyclopentoxy-L-alaninyl)]phosphate [Cf 1776]

[0543] Prepared according to Standard Procedure 4, from (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (0.2 g, 0.7 mmol), ′BuMgCl (1.0M in THF: 1.4 ml, 1.4 mmol) phenyl(cyclobutyl meth-oxy-L-alaninyl) phosphorochloridate 8b (1.93 ml of 0.361 g/ml solution, 2.1 mmol) and dry THF (8 ml). TLC (8% MeOH in CHCl₃) showed the reaction to be complete after 3.5 hrs. The crude residue was purified twice by column chromatography, using MeOH:CHCl₃ (4:96) as eluent, to give the product as a clear, colourless oil, which solidified to a white foam after trituration and coevaporation with diethyl ether (0.254 g, 0.4 mmol, 62%).

[0544] δ_(P) (CDCl₃, 121 MHz) 3.97, 3.98; SH (CDCl₃, 300 MHz) 0.64 (m, 2H, CH₂-cPr), 0.87 (m, 2H, CH₂-cPr), 1.38 (m, 3H, CH₃-ala), 1.67 (m, 7H, 3×CH₂-cPent and 6¹H.), 1.86 (m, 2H, CH₂-cPent), 2.81 (m, 1H, 6′H_(b)), 3.04 (m, 1H, CH-cPr), 3.18 (m, 1H, 4′H), 3.96 (m, 2H, Nil-ala and CH-ala), 4.21 (m, 2H, 5′H), 5.02 (bs, 1H, NH2), 5.18 (m, 1H, OCH), 5.56 (m, 1H, 1′H), 5.91 (m, 1H, 3¹H), 5.98 (bs, 1H, NH-cPr), 6.11 (m, 1H, 2′H), 7.25 (m, SH, ArH), 7.51 (d, 1H, 8H); δ_(c) (CDCl₃, 75 MHz) 7.78 (CH₂-cPr), 21.42, 21.48 (CH₃-ala), 24.07 (CH-cPr), 32.91- (CH₂-cPent), 33.05, 33.08 (6′C), 34.97, 35.02 (CH₂-cPent), 46.02, 46.12 (4′C), 50.71 (CH-ala), 59.21, 59.25 (1′C), 69.22, 69.29 (5′C), 78.90 (OCH), 115.23 (5C), 120.55-120.61 (p-Ph), 125.28 (o-Ph), 130.05 (m-Ph), 131.53, 131.59 (3′C), 135.87, 135.97 (8C), 136.73,136.86 (2′C), 151.09, 151.18 (6C and ipso-Ph), 156.71 (4C), 160.44 (2C), 173.71, 173.80 (C═O).

[0545] L-Alanine (phenethyl) ester p-toluene sulfonate salt

[0546] Prepared according to Standard Procedure 2, from L-alanine (1.0 g, 11 mmol), p-TSA monohydrate (2.35 g, 12 mmol), phenethyl alcohol (1.3 ml, 11 mmol) and toluene (65 ml). Thep-toluene sulfonate salt was isolated as an off-white solid (4.0 g, 10.9 mmol, 97%).

[0547] δ_(H) (d₄-CH₃OH, 300 MHz) 1.46 (d, 3H, CH₃-ala, J=7), 2.32 (2, 3H, CH₃, p-TSA), 2.93 (t, 2H, CH₂Ph, J=7), 4.07 (q, 1H, CH-ala, J=7), 4.37 (m, 2H, 0-CH₂) 7.22 (m, 7H, ArH, p-TSA and PhH), 7.78 (d, 2H, ArH, p-TSA); bc (d₄-CH₃OH, 75 MHz) 16.80 (CH₃-ala), 22.06 (CH₃-pTSA), 36.20 (CH₂-Ph), 50.41 (CH-ala), 68.28 (O-CH₂), 127.70,127.83 (o-Ar and o-Ph,p-TSA), 129.81 (p-Ar), 130.13, 130.48 (m-Ar and m-Ph, p-TSA), 139.23 (ipso-ArC), 142.30 (ipso-C-CH₃, p-TSA), 143.83 (ipso-C-S, p-TSA), 171.44 (C═O).

[0548] Pheny(phenethoxy-L-alaninyl)phosphorochloridate

[0549] Prepared according to Standard Procedure 3, from phenyl dichlorophosphate (0.5 ml, 3.3 mmol), dry triethylamine (0.93 ml, 6.7 mmol), L-alanine (phenethyl) ester p-toluene sulfonate salt 9a (1.232 g, 3.3 mmol) and dry DCM (60 ml total). The crude product was obtained as a clear, colourless oil (1.16 g, 94%).

[0550] δ_(P) (CDCl₃, 121 MHz) 8.93, 9.25

[0551] The product was redissolved in dry THF (5 ml) and used as a 0.233 g/ml solution.

[0552] (1S,4R)-4-(2-a mino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-[phenyl(phenethoxy-L-alazuinyl)]phosphate [Cf 1777]

[0553] Prepared according to Standard Procedure 4, from (lS,4R)-4(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (0.2 g, 0.7 mmol), ′BuMgCl (1.0M in THF: 1.4 ml, 1.4 mmol) phenyl(phenethoxy-L-alaninyl) phosphor-ochloridate 9b (3.3 ml of 0.233 g/ml solution, 2.1 mmol) and dry 1HF (8 ml). TLC (8% MeOH in CHCl₃) showed the reaction to be complete after 3 hrs. The crude residue was purified twice by column chromatography, using MeOH:CHCl₃ (4:96) as eluent, to give the product as a pale, yellow oil, which solidified to a cream solid after trituration and coevaporation with diethyl ether (0.181 g, 0.3 mmol, 42%).

[0554] δ_(P) (CDCl₃, 121 MHz) 3.81, 3.86; δ_(H) (CDCl₃, 300M ) 0.65 (m, 2H, CH₂CPr), 0.89 (m, 2H, CH₂-cPr), 1.35 (m, 3H, CH₃-ala), 1.71 (m, 1H, 6¹H,), 2.80 (m, 1H, ⁶ ¹H_(b)), 2.96 (m, 2H, CH2Ph), 3.03 (m, 1H, CH-cPr), 3.17 (m, 1H, 4¹H), 3.91 (m, 2H, NH-ala and CH-ala), 4.18 (m, 2H, OCH), 4.36 (m, 2H, 5′H), 4.99 (bs, 1H, NH₂), 5.56 (m, 1H, 1′H), 5.92 (m, 2H, 3′H and NH-cPr), 6.09 (m, 1H, 2¹H), 7.26 (m, IOH, ArH and PhH), 7.52 (d, 1H, 8H); δ_(c) (CDCl₃, 75 MHz) 6.36 (CH₂-cPr), 19.98, 20.04 (CH₃-ala), 22.65 (CHPr), 33.46, 33.54 (6′C), 33.90 (CH₂-Ph), 44.56, 44.66 (4′C), 49.21 (CH-ala), 57.79, 57.85 (1′C), 64.84 (OCH₂), 67,82 (5′C), 113.79 (5C), 119.11-119.17 (p-Ph), 123.87 (p-Ar), 125.68 (o-Ph), 127.53 (o-Ar), 127.83 (m-Ph), 128.62 (m-Ar), 130.07, 130.14 (3′C), 134.48 (8C), 135.30, 135.39 (2′C), 136.25 (ipso-Ar), 149.63, 149.71 (6C and ipso-Ph), 155.25 (4C), 158.94 (2C), 172.75, 172.45 (C═O).

[0555] L-Alanine (3-phenyl-1-propyl) ester p-toluene sulfonate salt

[0556] Prepared according to Standard Procedure 2, from L-alanine (1.0 g, 11 mmol), p-TSA monohydrate (2.35 g, 12 mmol), 3-phenyl-1-propanol (1.5 ml, 11 mmol) and toluene (65 ml). Removal of the solvent gave the crude product as a yellow oil. Diethyl ether was added and the mixture was cooled for 30 mins. The resulting suspension was filtered to give thep-toluene sulfonate salt as a white solid (4.24 g, 11.2 mmol, 100%).

[0557] δ_(H) (d₄-CH₃OH, 300 MHz) 1.53 (d, 3H, CH₃-ala, J =7), 1.97 (m, 2H, CH₂CH₂Ph), 2.34 (2, 3H, CH₃, p-TSA), 2.67 (t, 2H, CH₂Ph, J=7), 4.10 (q, 1H, CH-ala, J =7), 4.20 (t, 2H, O-CH₂, J=7) 7.22 (m, 7H, ArH, p-TSA and PhH), 7.75 (d, 2H, ArH, p-TSA); δ_(c) (d₄-CH₃OH, 75 Ma) 16.77 (CH₃-ala), 21.93 (CH₃-pTSA), 31.63 (CH₂CH₂-Ph), 33.37 (CH₂-Ph), 50.44 (CH-ala), 67.27 ()—CH₂), 127.26-127.58 (o-Ar and o-Ph, p-TSA), 129.66-130.00 (p-Ar), 130.41 (m-Ar and m-Ph, p-TSA), 142.31 (ipso-ArC), 142.82 (ipso-C-CH₃, p-TSA), 143.82 (ipso-C-S, p-TSA), 171.47 (C═O).

[0558] Phenyl(phenethoxy-L-alaninyl)phosphorochloridate

[0559] Prepared according to Standard Procedure 3, from phenyl dichlorophosphate (0.5 ml, 3.3 mmol), dry triethylamine (0.93 ml, 6.7 mmol), L-alanine (3-phenyl-1-propyl) ester p-toluene sulfonate salt 9a (1.27 g, 3.3 mmol) and dry DCM (60 ml total). Ie crude product was obtained as a clear, pale brown oil (1.16 g, 90%).

[0560] δ_(P) (CDCl₃, 121 MHz) 8.94, 9.27

[0561] The product was redissolved in dry THF (5 ml) and used as a 0.231 g/ml solution.

[0562] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-pu rin-9-yl)-2-cyclopentene-1-methanol O-[phenyl(3-phenyl-1-propoxy-L-alaninyl)]phosphate [Cf 1778]

[0563] Prepared according to Standard Procedure 4, from (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (0.2 g, 0.7 mmol), ′BuMgCl (1.0M in THF: 1.4 ml, 1.4 mmol) phenyl(3-phenyl-1-propoxy-L-alaninyl) phosphorochloridate 10b (3.5 ml of 0.231 g/ml solution, 2.1 mmol) and dry THF (8 ml). TLC (8% MeOH in CHCl₃) showed the reaction to be complete after 4 hrs. The crude residue was purified three times by column chromatography, using MeOH:CHCl₃ (4:96) as eluent, to give the product as a pale, yellow oil, which solidified to an off-white foam after trituration and coevaporation with diethyl ether (0.330 g, 0.5 mmol, 75%). bp (CDCl₃, 121 MHz) 3.89, 3.91; δ_(H) (CDCl₃, 300 MHz) 0.63 (m, 2H, CH₂-cPr), 0.88 (m, 2H, CH2CPr), 1.42 (m, 3H, CH₃-ala), 1.72 (m, 1H, 6¹Ha), 1.98 (CH₂CH₂Ph), 2.69 (CH₂Ph), 2.80 (m, 1H, 6′H_(b)), 3.04 (m, 1H, CH-cPr), 3.18 (m, 1H, 4′H), 4.07 (m, 6H, NH-ala, CH-ala, OCH and 5′H), 5.00 (bs, 1H, NH₂), 5.56 (m, 1′H, 1′H), 5.91 (m, 2H, 3′H and NH-cPr), 6.10 (m, 1H, 2′H), 7.25 (m, 10H, ArH and Phi), 7.52 (d, 1H, 8H); δ_(c) (CDCl₃, 75 MHz) 6.35 (CH₂-cPr), 20.06, 20.12 (CH₃-ala), 22.65 (CH-cPr), 29.02 (CH₂CH₂Ph), 30.97 (CH₂Ph), 33.48, 33.55 (6′C), 44.57, 44.67 (4′C), 49.26 (CH-ala), 57.78, 57.84 (1′C), 63.84 (OCH₂), 67.88 (5′C), 113.83 (5C), 119.10, 119.15 (p-Ph and p-Ar), 123.86 (oPh), 125.09 (o-Ar), 127.33, 127.47 (m-Ph), 128.63 (m-Ar), 130.10, 130.17 (3′C), 134.47, 134.58 (8C), 135.27, 135.37 (2′C), 139.81 (ipso-Ar), 149.65, 149.74 (6C and ipso-Ph), 155.27 (4C), 158.98 (2C), 172.49, 172.58 (C═O).

[0564] L-Alanine (4-phenyl-1-butyl) ester p-toluene sulfonate salt

[0565] Prepared according to Standard Procedure 2, from L-alanine (1.0 g, 11 mmol), p-TSA monohydrate (2.35 g, 12 inuol), 4-phenyl-1-butanol (1.7 ml, 11 mmol) and toluene (65 ml). Removal of the solvent gave the crude product as a clear, colourless oil, which solidified to a white solid after trituration and coevaporation with petrol (60/80) (4.4 g, 11.2 mmol, 100%).

[0566] δ_(H) (d₄-CH₃OH, 300 MHz) 1.55 (d, 3H, CH₃-ala, J=7), 1.74 (m, 4H, —(CH₂)₂CH₂Ph), 2.41 (2, 3H, CH₃,p-TSA), 2.67 (m, 2H, CH₂Ph), 4.12 (q, 1H, CH-ala, J=7), 4.28 (m, 2H, O-CH₂) 7.25 (m, 7H, ArK, p-TSA and PhH), 7.75 (d, 2H, ArR, p-TSA); δ_(c) (d₄-CH₃OH, 75 MHz) 16.65 (CH₃-ala), 21.74 (CH₃-pTSA), 29.18, 29.50 (OCH₂(CH₂)₂CH₂-Ph), 36.72 (CH₂-Ph), 50.27 (CH-ala), 67.74 (O-CH₂), 127.31, 127.36 (o-Ar and o-Ph,p-TSA), 129.79 (p-Ar), 130.25 (m-Ar and m-Ph, p-TSA), 142.14 (ipso-ArC), 143.64, 143.87 (ipso-C-CH₃ and ipso-C-S, p-TSA), 171.47 (C═O).

[0567] Pheny)(4-phenyl-1-butoxy-L-alaninyl)phosphorochloridate

[0568] Prepared according to Standard Procedure 3, from phenyl dichlorophosphate (0.5 ml, 3.3 immol), dry triethylamine (0.93 ml, 6.7 mmol), L-alanine (4-phenyl-1-butyl) ester p-toluene sulfonate salt 11a (1.32 g, 3.3 mmol) and dry DCM (60 ml total). The crude product was obtained as a clear, pale brown oil (1.13 g, 85%).

[0569] δ_(P) (CDCl₃, 121 MHz) 8.89, 9.24

[0570] The product was redissolved in dry THEF (5 ml) and used as a 0.226 g/ml solution.

[0571] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-[phenyl(4-phenyl-1-butoxy-L-alaninyl)]phosphate [Cf 11779]

[0572] Prepared according to Standard Procedure 4, from (1S,4R)A4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-²-cyclopentene-1-methanol (0.2 g, 0.7 mmol), ′BuMgCl (1.0M in THF: 1.4 ml, 1.4 mmol) phenyl(4-phenyl-1-butoxy-L-alaninyl) phosphorochloridate llb (3.7 ml of 0.226 g/ml solution, 2.1 mmol) and dry THF (8 ml). TLC (8% MeOH in CHCl₃) showed the reaction to be complete after 4 hrs. The crude residue was purified by column chromatography, using MeOH:CHCl₃ (4:96) as eluent, to give the product as a clear, colourless oil, which solidified to an off-white foam after trituration and coevaporation with diethyl ether (0.314 g, 0.5 mmol, 69%).

[0573] δ_(P) (CDCl₃, 121 MHz) 3.87, 3.90; δ_(H) (CDCl₃, 300M ) 0.65 (m, 2H, CH₂-cPr), 0.87 (m, 2H, CH₂-cPr), 1.41 (m, 3H, CH₃-ala), 1.71 (m, SH, (CH₂)₂CH₂Ph and 6¹H,), 2.65 (m, 2H, CH₂Ph), 2.80 (m, 1H, 6′H_(b)), 3.04 (m, 1H, CH-cPr), 3.17 (m, 1H, 4¹H), 4.06 (m, 6H, NH-ala, CH-ala, 5′H and OCH₂—) 5.02 (bs, 1H, NH₂), 5.56 (m, 1H, 1¹H), 5.90 (m, 11H, 3′H), 5.98 (bs, 1H, NH-cPr), 6.10 (m, 1H, 2′H), 7.25 (m, 10H, ArH and PhH), 7.52 (d, 1H, 8H); 8c (CDCl₃, 75 MHz) 6.35 (CH₂-cPr), 20.05. 20.11 (CH₃-ala), 22.65 (CHPr), 26.51 (CH₂CH₂CH₂Ph), 27.02 (CH₂(CH₂)₂Ph), 33.48, 33.55 (6′C), 34.32 (CH₂Ph), 44.56, 44.67 (4′C), 49.22, 49.26 (CH-ala), 57.79, 57.83 (1′C), 64.40 (OCH₂), 67.86, 67.94 (5′C), 113.75 (5C), 119.10, 119.15 (p-Ph and p-Ar), 123.85 (o-Ph), 124.88 (o-Ar), 127.33, 127.35 (m-Ph), 128.61 (m-Ar), 130.07, 130.12 (3′C), 134.44, 134.54 (8C), 135.30, 135.39 (2′C), 140.76 (ipso-Ar), 149.64-149.87 (6C and ipso-Ph), 155.26 (4C), 158.98 (2C), 172.53, 172.63 (C═O).

[0574] L-Alanine (2-cyclobexyl ethyl) ester p-toluene sulfonate salt

[0575] Prepared according to Standard Procedure 2, from L-alanine (1.0 g, 11 mmol), P-TSA monohydrate (2.35 g, 12 mmol), 2-cyclohexyl ethanol (1.56 ml, 11 mmol) and toluene (65 ml). Removal of the solvent gave the crude product as a clear, colouriess oil, which solidified to a white solid after trituration and coevaporation with diethyl ether (2.8 g, 7.5 mmol, 67%).

[0576] δ_(H) (d₄-CH₃OH, 300 M) 0.97 (m, 2H, CHl), 1.24 (m, 4H, 2×CH₂), 1.42 (m, 1H, CH-cHx), 1.54 (d, 3H, CH₃-ala, J =7), 1.63 (m, 2H, CHl], 1.75 (m, 4H, 2×CH₂), 2.39 (s, 3H, CH₃, p-TSA), 4.09 (q, 1H, CH-ala, J =7), 4.28 (m, 2H, O-CH₂), 7.25 (d, 2H, ArH, p-TSA), 7.72 (d, 2H, ArH, p-TSA); δ_(c) (d₄-CH₃OH, 75 MHz) 16.65 (CH₃-ala), 21.74 (CH₃-pTSA), 27.68 (CH₂), 27.93 (CH₂), 34.58 (CH₂), 34.62 (CH₂), 36.10 (CH-cHx), 50.27 (CH-ala), 66.05 [O—CH₂(CH₂)₂], 127.36 (o-Ph, p-TSA), 130.24 (m-Ph, p-TSA), 142.13 (ipso-C-CH₃,p-TSA), 143.89 (ipso-C-S,pTSA), 171.49 (C═O).

[0577] Phenyl(2-cyclohexyl ethoxy-L-alaninyl)phosphorochloridate

[0578] Prepared according to Standard Procedure 3, from phenyl dichlorophosphate (0.9 ml, 6.0 mmol), dry triethylamine (1.7 ml, 12.0 mmol), L-alanine (cyclohexyl ethyl) ester p-toluene sulfonate salt 12a (2.24 g, 6.0 mmol) and dry DCM (100 ml total). The crude product was obtained as a clear, colourless oil (1.86 g, 83%).

[0579] δ_(P) (CDCl₃, 121 MHz) 8.96, 9.31

[0580] The product was redissolved in dry IF (5 ml) and used as a 0.372 g/ml solution.

[0581] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-[phenyl(2-cyclohexyl-1-ethoxy-L-alaninyl)]phosphate [Cf 1780]

[0582] Prepared according to Standard Procedure 4, from (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (0.2 g, 0.7 mmol), ′BuMgCl (1.0M in THF: 1.4 ml, 1.4 nmmol) phenyl(cyclohexyl ethoxy-L-alaninyl) phosphorochloridate 12b (2.1 ml of 0.372 g/ml solution, 2.1 mmol) and dry THF (8 ml). TLC (8% MeOH in CHCl₃) showed the reaction to be complete after 2.5 hrs. The crude residue was purified twice by column chromatography, using MeOHCHCl₃ (4:96) as eluent, to give the product as a clear, colourless oil, which solidified to an off-white foam after trituration and coevaporation with diethyl ether (0.302 g, 0.5 mmol, 69%).

[0583] δ_(P) (CDCl₃, 121 MHz) 3.91, 3.94; SH (CDCl₃, 300 MHz) 0.64 (m, 2H, CH₂-cPr), 0.91 (m, 4H, CH₂ and CH₂-cPr), 1.21 (m, 2H, CH₂), 1.41 (m, 3H, CH₃-ala), 1.52 (m, 2H, CH-cHx and 6¹H,), 1.70 (m, 6H, 3×CH₂), 2.80 (m, 1H, 6′H_(b)), 3.04 (m, 1H, CHPr), 3.18 (m, 1H, 4¹H), 4.10 (m, 6H, NH-ala, CH-ala, OCH₂ and 5¹H), 5.03 (bs, 1H, NH2), 5.56 (m, 1H, 1¹H), 5.96 (m, 1H, 3¹H), 5.98 (m, 1H, NH-cPr), 6.10 (m, 1H, 2¹H), 7.25 (m, 5H, Ar), 7.51 (d, 1H1, 8H); δ_(c) (CDCl₃, 75 MHz) 6-35 (Cl₂-cPr), 20.05, 20.12 (CH3-ala), 22.69 (CH-cPr), 25.11 (CH₂), 25.37 (CH2), 32.04, 32.07 (6′C), 33.45, 33.58 (CHcHx), 34.76 (CH₂), 44.58, 44.69 (4′C), 49.28 (CH-ala), 57.78, 57.83 (1′C), 62.88 (OCH₂), 67.86 (5′C), 113.82 (5C), 119.10-119.19 (p-Ph), 123.85 (o-Ph), 128.61 (m-Ph), 130.12 (3∝C), 134.44, 134.54 (8C), 135.28, 135.38 (2′C), 149.66-149.94 (6C and ipso-Ph), 155.28 (4C), 155.99 (2C), 172.57, 172.66 (C═O).

[0584] L-Alanine (3-cyclobexyl-1-propyl) ester p-toluene sulfonate salt

[0585] Prepared according to Standard Procedure 2, from L-alanine (1.0 g, 11 mmol), p-TSA monohydrate (2.35 g, 12 mmol), 3-cyclohexyl-1-propanol (1.7 ml, 11 mmol) and toluene (65 ml). The solvent was removed and diethyl ether was added. The resulting suspension was filtered to give the product as a white solid (3.9 g, 10.1 mmol, 90%).

[0586] δ_(H) (d₄-CH₃OH, 300 MHz) 0.92 (m, 2H, CH₂), 1.23 (m, 61, 3×CH₂), 1.54 (d, 3H, CH₃-ala, J=7), 1.71 (m, 7H, CH-cHx and 3×CH₂), 2.39 (s, 3H, CR₃, p-TSA), 4.10 (q, 1H, CH-ala, J =7), 4.22 (m, 2H, O-CH₂), 7.25 (d, 2H, ArH, p-TSA), 7.72 (d, 2H, ArH, p-TSA); δ_(c) (d₄-CH₃OH, 75 Mz) 16.66 (CH₃-ala), 21.74 (CH₃-pTSA), 27.36 (CH₂), 27.83 (CH₂), 28.11 (CH₂), 34.80 (CH₂), 34.90 (CH₂), 39.03 (ICH-cHx), 50.27 (CH-ala), 68.27 (OCH₂), 127.36 (o-Ph, p-TSA), 130.24 (m-Ph, p-TSA), 142.12 (ipso-C-CH₃, p-TSA), 143.89 (ipso-C-S, p-TSA), 171.49 (C═O).

[0587] Phenyl(3-cyclobexyl-I -propoxy-L-alaninyl)phosphorochloridate

[0588] Prepared according to Standard Procedure 3, from phenyl dichlorophosphate (0.9 ml, 6.0 mmol), dry triethylamine (1.7 ml, 12.0 mmol), L-alaziine (3-cyclohexyl-1-propyl) ester p-toluene sulfonate salt 13a (2.32 g, 6.0 mmol) and dry DCM (60 ml total). The crude product was obtained as a clear, pale yellow oil (2.31 g, 99%).

[0589] δ_(P) (CDCl₃, 121 MHz) 8.99, 9.35

[0590] The product was redissolved in dry THF (5 ml) and used as a 0.463 g/ml solution.

[0591] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-[phenyl(3-cyclobexyl-]-propoxy-L-alaninyl)lphosphate [Cf 1781]

[0592] Prepared according to Standard Procedure 4, from (lS,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (0.2 g, 0.7 mmol), ′BuMgCl (1.0M in THF: 1.4 ml, 1.4 mmol) phenyl(3-cyclohexyl-1-propoxy-L-alaniyl) phosphorochloridate 13b (1.8 ml of 0.463 g/ml solution, 2.1 mmol) and dry THF (8 ml). TLC (8% MeOH in CHCl₃) showed the reaction to be complete after 2.5 hrs. The crude residue was purified by column chromatography, using MeOH:CHCl₃ (4:96) as eluent, to give the product as a clear, colourless oil, which solidified to an off-white foam after trituration and coevaporation with diethyl ether (0.276 g, 0.4 mmol, 62%).

[0593] δ_(P) (CDCl₃, 121 MH) 3.89, 3.91; δ_(H) (CDCl₃, 300 Ma) 0.64 (m, 2H, CH₂cPr), 0.89 (m, 2H, CH₂-cPr), 1.21 (m, 6H, 3×CH₂), 1.41 (in, 3H, CH₃-ala), 1.66 (m, 8H, CH-cHx, 3×CH₂ and 6¹Ha), 2.81 (m, 1H, ⁶′H_(b)), 3.04 (m, 1H, CH-cPr), 3.18 (in, 1H, 4¹H), 4.04 (m, 6H, NH-ala, CH-ala, OCH₂ and 5¹H), 4.98 (bs, 1H, NH2), 5.56 (in, 1H, 1¹H), 5.91 (m, 1H, 3¹H and NHI-cPr), 6.11 (m, 1H, 2¹H), 7.26 (m, 5H, Ar), 7.57 (d, 1H, 8H); bc (CDCl₃, 75 M 6.37 (CH₂-cPr), 20.09, 20.15 (CH3-ala), 22.66 (CH-cPr), 24.85 (CH2), 25.27 (CH₂), 25.55 (CH₂), 29.92 (CH₂), 32.20, 32.33 (6′C), 33.49, 33.57 (CH-cHx), 36.22 (CH₂), 44.58, 44.68 (4′C), 49.27 (CH-ala), 57.78, 57.83 (l′C), 65.01 (OCH₂), 67.84 (5′C), 113.86 (SC), 119.10-119.19 p-Ph), 123.85 (o-Ph), 128.61 (m-Ph), 130.12 (3′C), 134.47, 134.57 (8C), 135.28, 135.38 (2′C), 149.65-149.74 (6C and ipso-Ph), 155.27 (4C), 158.96 (2C), 172.53, 172.64 (Ce).

[0594] L-Alanine (4-cyclohexyl-1-butyl) ester p-toluene sulifonate salt

[0595] Prepared according to Standard Procedure 2, from L-alanine (0.51 g, 5.8 mmol), p-TSA monohydrate (1.21 g, 6.3 mmol), 4-cyclohexyl-1-butanol (1.0 ml, 5.8 mcil) and toluene (65 ml). Thep-toluene sulfonate salt was obtained as a white crystalline solid (2.15 g, 5.4 mmol, 93%).

[0596] δ_(H) (d₄-CH₃OH, 300 MH) 0.92 (m, 2H, CH₂), 1.17 (m, 6H, 3×CH₂), 1.39 (m, 2H, Cl₂), 1.54 (d, 3H, CH₃-ala, J =7), 1.69 (m, 7H, CH-cHx and 3×CH₂), 2.39 (s, 3H, CH₃, p-TSA), 4.10 (q, 1H, CH-ala, J =7), 4.24 (m, 2H, O-CH₂), 7.25 (d, 2H, ArH, p-TSA), 7.72 (d, 2H, ArH,p-TSA); 8c (d₄-CH₃OH, 75 MHz) 16.66 (CH₃-ala), 21.74 (CH₃-pTSA), 24.51 (CH₂), 27.89 (CH₂), 28.18 (CH₂), 30.25 (CH2), 34.90 (CH₂), 38.59 (CH2), 39.27 (CH-cHx), 50.27 (CH-ala), 67.94 (OCH2), 127.36 (o-Php-TSA), 130.23 (m-Ph, p-TSA), 142.15 (ipso-C-CH₃, p-TSA), 143.89 (ipso-C-S, p-TSA), 171.49 (C═O).

[0597] Phenyl(4-cyclobexyl-1-butoxy-L-alaninyl)phosphorochloridate

[0598] Prepared according to Standard Procedulre 3, from phenyl dichlorophosphate (0.45 ml, 3.0 ninol), dry triethylamine (0.8 ml, 6.0 mmol), L-alanine (4-cyclohexyl-1-butyl) ester p-toluene sulfonate salt 14a (1.2 g, 3.0 mmol) and dry DCM (60 ml total). The crude product was obtained as a clear, brown oil (1.36 g, >100%).

[0599] δ_(P) (CDCl₃, 121 MHz) 8.91, 9.28

[0600] The product was redissolved in dry THF (5 ml) and used as a 0.272 g/ml solution.

[0601] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-[phenyl(4-cyclohexyl-1-butoxy-L-alaninyl)lphosphate [Cf 1782]

[0602] Prepared according to Standard Procedure 4, from (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol 0.2 g, 0.7 mmol), ′BuMgCl (1.0M in THF: 1.4 ml, 1.4 mmol) phenyl(3-cyclo-hexyl-1-propoxy-L-alaninyl) phosphorochloridate 14b (3.1 ml of 0.272 g/ml solution, 2.1 mmol) and dry THF (8 ml). TLC (8% MeOH in CHCl₃) showed the reaction to be complete after 2.5 hrs. The crude residue was purified twice by column chromatography, using MeOH:CHCl₃ (4:96) as eluent, to give the product as a clear, colourless oil, which solidified to an off-white foam after trituration and coevaporation with diethyl ether (0.341 g, 0.5 mmol, 75%). 8p (CDCl₃, 121 MHz) 3.89, 3.91; ⁸H (CDCl₃, 300 MHz) 0.65 (m, 2H, CHz-cPr), 0.86 (m, 2H, CH2-cPr), 1.21 (m, 8H, 4×CH₂), 1.41 (m, 3H, CH₃-ala), 1.65 (m, 8H, CH-cHx, 3×CH₂ and 6¹H_(b)), 2.81 (m, 1H, 6′H_(b)), 3.04 (m, 1H, CH-cPr), 3.19 (m, 1H, 4′H), 4.04 (m, 6H, NH-ala, CH-ala, OCH₂ and 5¹H), 4.96 (bs, 1H, NH₂), 5.56 (m, 1H, 1′H), 5.92 (m, 1H, 3′H and NH-cPr), 6.11 (m, 1H, 2¹H), 7.26 (m, 5H, Ar), 7.52 (d, 1H, 8H); δ_(c) (CDCl₃, 75 MHz) 6.37 (CH₂-cPr), 20.10, 20.16 (CH₃-ala), 22.00 (CH₂), 22.65 (CH-cPr), 25.34 (CH₂), 25.64 (CH₂), 27.77 (CH₂), 32.28 (CH-cHx), 33.48, 33.56 (6′C), 36.45 (CH₂), 44.58, 44.68 (4′C), 49.24 (CH-ala), 57.79, 57.84 (1′C), 64.69 (OCH₂), 67.84, 67.94 (5′C), 113.86 (5C), 119.10-119.19 p-Ph), 123.86 (o-Ph), 128.62 (m-Ph), 130.11,130.17 (3′C), 134.47,134.57 (8C), 135.28, 135.39 (2′C), 149.65-149.74 (6C and ipso-Ph), 155.26 (4C), 158.96 (2C), 172.54, 172.64 (C═O).

[0603] Phenyl(methoxy-L-valinyl)phosphorocbloridate

[0604] Prepared according to Standard Procedure 3, from phenyl dichlorophosphate (0.45 ml, 3.0 mmol), dry triethylamine (0.8 ml, 6.0 mmol), L-valine methyl ester hydrochloride salt (0.5 g, 3.0 mmol) and dry DCM (60 ml total). The crude product was obtained as a clear, colourless oil (0.922 g, >100%).

[0605] δ_(P) (CDCl₃, 121 MHz) 8.99, 9.37

[0606] The product was redissolved in dry TEF (5 ml) and used as a 0.184 g/ml solution.

[0607] (1S,4R)-4-(2-amino-6-cyclopropy laminao-9H-pu rin-9-yl)-2-cyclopentene-1-methanol O-[phenyl(methboxy-L-valinyl)phosphate [Cf 1686]

[0608] Prepared according to Standard Procedure 4, from (1S,4R)-4-(2-amino4-cyclopropylwnino-9H-purin-9-yl)-2-cyclopentene-1-methanol (0.2 g, 0.7 mmol), ′BuMgCl (1.0M in THF: 1.4 ml, 1.4 mmol), phenyl(methoxy valinyl)phosphorochloridate 15a (3.5 ml of 0.184 g/ml solution, 2.1 mmol) and dry THF (5 ml). The reaction mixture was stirred for 16 hrs, after which time a further 1.5 ml of the solution of 15a was added. The reaction mixture was stirred for a fuirther 4 hrs. The crude residue was purified by column chromatography, using MeOH:DCM (5:95) as eluent, to give the product as a clear, colourless oil, which solidified to a white foam after trituration and coevaporation with diethyl ether (0.161 g, 0.3 mmol, 41%).

[0609] δ_(P) (CDCl₃, 121 MHz) 4.65, 4.74; BH (CDCl₃, 300 MHz) 0.66 (m, 2H, CH₂-cPr), 0.94 [m, 8H, CH₂-cPr and CH(CH₃)₂], 1.71 (m, 1H, 6¹H.), 2.06 [m, 1H, CH(CH₃)₂], 2.81 (m, 1H, ⁶′H_(b)), 3.04 (m, 1H, CH-cPr), 3.18 (m, 1H, 4¹H), 3.52 (m, 1H, CH-val), 3.70 (d, 3H, OCH₃), 3.83 (m, 1H, NH-val), 4.22 (m, 2H, 5¹H), 4.86 (bs, 2H, NH₂), 5.56 (m, 1H, 1′H), 5.74 (bs, 1H, N1H-cPr), 5.93 (m, 1H, 3¹H), 6.11 (m, 1H, 2¹H), 7.27 (m, 5H, ArH), 7.52 (d, 1H, 8H); δ_(c) (CDCl₃, 75 MHz) 6.37 (CH₂-cPr), 16.36, 16.45 [CH(CH₃)₂], 22.65 (CH-cPr), 31.08, 31.16 [CH(CH₃)₂], 33.61 (6′C), 44.60, 44.70 (4′C), 51.05, 51.10 (OCH3), 57.78 (1′C), 58.96, 59.01 (CH-val), 67.90 (5′C), 113.91 (5C), 119.03-119.13 (o-Ph), 123.80 (p-Ph), 128.58 (m-Ph), 130.05, 130.14 (3′C), 134.47 (8C), 135.27, 135.39 (2′C), 149.66-149.84 (6C and ipso-Ph), 155.28 (4C), 158.96 (2C), 172.10, 172.19 (C═O); m/z (FAB) 556.2428 (MH⁺, C₂₆H₃₅N₇O₅P requires 556.2437).

[0610] Phenyl(methoxy-L-leucinyl)phosphorochloridate

[0611] Prepared according to Standard Procedure 3, from phenyl dichiorophosphate (0.41 ml, 2.8 mmol), dry triethylamine (0.77 ml, 5.5 mmol), L-leucine methyl ester hydrochloride salt (0.5 g, 2.8 nimol) anid dry DCM (60 ml total). The crude product was obtained as a clear, pale yellow oil (1.062 g, >100%).

[0612] δ_(P) (CDCl₃, 121 MHz)9.33, 9.51

[0613] The product was redissolved inl dry THF (5 ml) and used as a 0.212 g/ml solution.

[0614] (1S, 4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-[phenyl(methoxy-L-leucinyl)phosphate [Cf1718]

[0615] Prepared according to Standard Procedure 4, from (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-pun-9-yl)-2-cyclopentene-1-methanol 0.2 g, 0.7 mmol), ′BuMgCl (1.0M in THF: 1.4 ml, 1.4 mmol), phenyl (methoxy-L-leucinyl) phosphorochloridate 16a (3.2 ml of 0.212 g/ml solution, 2.1 mmol) and dry THF (10 ml). TLC (8% MeOH in CHCl₃) showed the reaction to be complete after 2 hrs. The crude residue was purified twice by column chromatography, using MeOH: CHCl₃ (4:96) as eluent, to give the product as a clear, colourless oil, which solidified to a white foam after trituration and coevaporation with diethyl ether (0.211 g, 0.4 mmol, 53%).

[0616] δ_(P) (CDCl₃, 121 MHz) 3.98, 4.06; 8H (CDCl₃, 300 MHz) 0.64 (m, 2H, CH₂CPr), 0.89 [m, 8H, CH₂-CPr and CH(CH₃], 1.51 (m, 2H, CH₂leu), 1.69 [(m, 2H, CH(CH₃)₂ and 6′H_(a)], 2.80 (m, 1H, .6′H_(b)), 3.04 (m, 1H, CH-cPr), 3.16 (m, 1H, 4′H), 3.67 (m, 1H, CH-leu), 3.69 (d, 3H, OCH₃), 3.98 (m, 1H, NH-leu), 4.19 (m, 2H, 5¹H1), 4.97 (bs, 2H, NH₂), 5.55 (m, 1H, 1′H), 5.91 (m, 1H, NH-cPr and 3′H), 6.09 (m, 1H, 2′H), 7.25 (m, 5H, ArH), 7.51 (d, 1H, 8H); δ_(c) (CDCl₃, 75 Mz) 6.37 (CH₂Pr), 20.69, 20.82 (CH₃-1eu), 22.69 (CH-cPr), 23.28, 23.41 [CH(CH₃)₂], 33.54 (6′C), 42.6042.81 (CH₂-leu), 44.59,44.70 (4′C), 51.19, (OCH₃), 52.07, 52.16 (CH-leu), 57.80 (I° C), 67.91, 67.98 (5′C), 113.88 (5C), 118.99-119.14 (o-Ph), 123.80 (p-Ph), 128.58 (m-Ph), 130.06, 130.14 (3′C), 134.53 (8C), 135.27, 135.34 (2′C), 149.68-149.76 (6C and ipso-Ph), 155.28 (4C), 158.97 (2C), 173.12, 173.23 (Ce); m/z(FAB) 570.2610 (MH⁺, C₂₇H₃₇N₇O₅P requires 570.2594).

[0617] Phenyl(methoxy-L-prolinyl)phosphorochloridate

[0618] Prepared according to Standard Procedure 3, from phenyl dicllorophosphate (0.54 ml, 3.6 mmol), dry tfiethylamine (1.0 ml, 7.2 nimol), L-proline methyl ester hydrochloride salt (0.6 g, 3.6 mmol) and dry DCM (60 ml total). The crude product was obtained as a clear, colourless oil (1.24 g, >100%).

[0619] δ_(P) (CDCl_(3, 121) MHz) 9.02, 9.22

[0620] The product was redissolved in dry THF (5 ml) and used as a 0.248 g/ml solution.

[0621] (1S4R4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-[pheny](methoxy-Lproinyl)phosphate lCf 1719]

[0622] Prepared according to Standard Procedure 4, from (1S,4R)-4-(2-amino6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (0.2 g, 0.7 miol), ′BuMgCl (1.0M in TBT: 1.4 ml, 1.4 mmol), phenyl(methoxy-L-prolinyl) phosphorochloridate 17a (2.6 ml of 0.248 g/ml solution, 2.1 mmol) and dry THF (10 ml). TLC (8% MeOH in CHCl₃) showed the reaction to be complete after 20 hrs. The crude residue was purified twice by column chromatography, using MeOH: CHCl₃ (4:96) as eluent, to give the product as a clear, colourless oil, which solidified to a white foam after trituration and coevaporation with diethyl ether (0.168 g, 0.3 mmol, 44%). Bp (CDCl_(3, 121) MHz) 2.83, 2.90; BH (CDCl₃, 300M ) 0.65 (m, 2H, CH2-cPr), 0.90 (m, 2H, CH₂-cPr), 1.92 (m, 5H, CH₂CH₂-pro and 6′H_(b)), 2.83 (m, 1H, 6′H_(b)), 3.04 (m, 1H, CH-cPr), 3.17 (m, 1H, 4′H), 3.45 (m, 2H, N-CH₂-pro), 3.70 (d, 3H, OCH₃), 4.13 (m, 1H, CH-pro), 4.30 (m, 2H, 5¹H), 4.87 (bs, 2H, NH₂), 5.56 (m, 1H, l¹H), 5.73 (s, 1H, NH-cPr), 5.91 (m, 1X, 3¹H), 6.12 (m, 1X, 2′H), 7.27 (m, 5H, ArH), 7.55 (d, 1H, B8); bc (CDCl_(3, 75) MHz) 6.42 (CH₂-cPr), 22.62 (CH-cPr), 23.91, 24.02 (CH₂-pro), 30.38, 30.49 (CH₂-pro), 33.54 (6′C), 44.61, 44.72 (4′C), 46.89 (N-CH2), 51.07, 51.19 (OCH₃), 57.71, 57.80 (1′C), 58.84, 58.92 (CH-pro), 67.67, 67.75 (5′C), 113.87 (5C), 118.90-119.22 (o-Ph), 123.64, 123.73 (p-Ph), 128.55, 128.59 (m-Ph), 130.00 (3′C), 134.46 (8C), 135.42, 135.63 (2′C), 149.81, 149.90 (6C and ipso-Pli), 155.20 (4C), 158.87 (2C), 172.72, 173.23 (C═O); m/z (FAB) 554.2283 (MH⁺, C₂₆H₃₃N₇O₅P requires 554.2281).

[0623] Phenyl(dibenzyloxy-L-aspartinyl)phosphorochloridate

[0624] Prepared according to Standard Procedure 3, from phenyl dichlorophosphate (0.45 ml, 3.0 mmol), dry triethylamine (0.8 ml, 6.0 mmol), L-aspartate dibenzyl ester p-toluene sulfonate salt (1.46 g, 3.0 mmol) and dry DCM (60 ml total). The crude product was obtained as a clear, yellow oil (0.8024 g, 55%).

[0625] δ_(P) (CDCl₃, 121 M)9.43, 9.58

[0626] The product was redissolved in dry THF (5 ml) and used as a 0.16 g/ml solution.

[0627] (1S,4R)-4-(2-amino6-cyclopropylamin o-9H-purin-9-yl)-2-cyclopeotenie-1-methanol O-[phenyl(dibenzyloxy-L-aspartinyl)phosphate [Cf 1720]

[0628] Prepared according to Standard Procedure 4, from (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol (0.157 g, 0.55 mmol), ′BuMgCl (1.0M in THF: 1.1 ml, 1.1 mmol), phenyl(dibenzyloxy-1-aspartinyl) phosphorochloridate 18a (5.0 ml of 0.16 g/ml solution, 1.6 mmol) and dry THF (10 ml). TLC (8% MeOH in CHCl₃) showed the reaction to be complete after 1.5 hrs. The crude residue was purified twice by column chromatography, using MeOH: CHCl₃ (3:97) as eluent, to give the product as a clear, colourless oil, which solidified to an off-white foam after trituration and coevaporation with diethyl ether (0.284 g, 0.4 mmol, 70%). Sp (CDCl₃, 121 ) 3.68, 4.24; SH (CDCl₃, 300M ) 0.63 (in, 2H, CH₂-cPr), 0.85 (m, 2H, CH₂Pr), 1.63 (m, 1H, 6¹H.), 2.71 (m, 1H, 6′H_(b)), 3.06 (m, 2H, CH-cPr and 4′H), 4.14 (m, 2H, CH-asp, NH-asp), 4.34 (m, 2H, 5′H), 4.98 (bs, 2H, NH2), 5.06 (d, 2H, OCH₂Ph), 5.13 (d, 2H, OCH₂Ph), 5.53 (m, 1H, 1′H), 5.88 (in, 2H, NH-cPr and 3¹H), 6.01 (m, 1H, 2′H), 7.25 (m, 1H, ArH), 7.49 (d, 1H, 8H); δ_(c) (CDCl₃, 75 MHz) 6.35 (CH₂-cPr), 22.64 (CH-cPr), 33.40 (6′C), 37.44, 37.60 (CH₂-asp), 44.50, 44.57 (4′C), 50.20, 50.33 (CH-asp), 57.79 (1′C), 65.77 (OCH₂Ph), 66.65 (OCH₂Ph), 67.86, 68.00 (5′C), 113.85 (5C), 119.09-119.34 (o-Ph), 123.92 (p-Ph), 127.34-127.55 (m-Ph and nap-Bn), 128.61 (o-Bn), 130.06 (3′C), 134.00 (ipso-Bn), 134.03 (ipso-Bn), 134.61 (8C), 135.23, 135.27 (2′C), 149.47-149.91 (6C and ipso-Ph), 155.28 (4C), 158.95 (2C), 169.22, 169.43, 170.00, 17029 (C═O).

[0629] (1S,4R)-4-(2-:kmino-6-cyclopropylamineo9H-purin-9-yl-2-cyclopentene-1-methanol O-(phenyl (2-methylpropyl)oxyalaninyl phosphate) CF1672

[0630] This was prepared by Standard Procedure 4. 70% yield.

[0631] δ_(P) 3.87, 3.91.

[0632] δ_(H) 0.64 (2H, m, CH_(a)H_(b), CH₁, H_(b), cyclopropyl), 0.92 (8H, m, CH_(a), H_(b), CH_(a), H_(b), cyclopropyl, CH(CH₃)₂), 1.42 (3H, m, CH₃ alaninyl), 1.71 (1H, m, 6′-H_(a)H_(b)), 1.92 (1H, m, CH(CH₃)₂), 2.81 (1H, m, 6′-H_(a)H_(b)), 3.03 (1H, m, CH₂ cyclopropyl), 3.19 (1H, m, 4′-H), 3.87 (3H, m, CH alaninyl, CH₂CH(CH₃)₂), 4.09 (1H, m, NH alaninyl), 4.20 (2H, m, 5′-H), 4.91 (2H, br s, NH2), 5.53 (1H, br m, 1′-H), 5.80 (1H, br s, NH-cyclopropyl), 5.92 (1H, m, 3′-H), 6.12 (1H, m, 2′-H), 7.31 (5H, in, Ph-H), 7.48 (1H, br d, 8H)

[0633] δ_(c) 5.45 (CH₂cyclopropyl×2), 17.01 (CH(CH₃)₂), 19.23, 19.29 (Me alaninyl), 21.74 (CH-cyclopropyl), 25.72 (CH(CH3)₂), 32.58, 32.64 (6′-C), 43.66, 43.76 (4′-C), 48.35 (CH alaninyl), 56.90 (1′-C), 66.88, 66.96, 67.03 (5′-C), 69.57, 69.60 (CH₂CH(CH₃)₂), 118.17, 118.20, 118.24, 118.27 (o-Ph, 5-C), 122.94 (p-Ph), 127.70 (m-Ph), 129.19, 129.24 (3′-C), 134.35, 134.45 (8-C, 2′-C), 148.81, 148.72 (i-Ph), 149.62, 149.76 (6-C), 154.34 (4-C), 158.91, 158.96 (2-C), 171.68, 171.58 (C(O) alaninyl).

[0634] MS m/e 570.2505 (M⁺, C₂₇H₃₆N₇O₅P requires 570.2515).

[0635] HPLC t_(R) 33.11 min (0% CH₃CN (0 min), 80% CH₃CN (35 min), 80% CH₃CN (45 min), 0% CH₃CN (55 min)).

[0636] (1S ,4R)-442-amino6-cyclopropylamino-9H-purin-9-y)-2-cyclopentene-1-methanol O-(phenyl (2,2-dimethylpropyl)oxyalIninyl phosphate) CF1673

[0637] This was prepared by Standard Procedure 4.94% yield.

[0638] δ_(P) 3.88, 3.94.

[0639] δ_(H) 0.61 (2H, m, CH_(a)H_(b), CH_(a),H_(b), cyclopropyl), 0.85 (2H, br m, CH_(a),H_(b), CH_(a), H_(b), cyclopropyl), 0.91 (9H, s, C(CH₃)₃ ), 1.41 (3H, m, CH₃ alaninyl), 1.70 (1H, m, 6′-H_(a)H_(b)), 2.78 (1H, m, 6′-H_(a)H_(b)), 3.03 (1H, m, CH cyclopropyl), 3.18 (1H, m, 4′-H), 3.81 (3H, m, CH alaninyl, CH₂CH(CH₃)₂), 4.09 (1H, m, NH alaninyl), 4.20 (2H, m, 5′-H), 4.97 (2H, br s, NH₂), 5.52 (1H, br m, 1′-H), 5.86 (1H, br s, NH-cyclopropyl, 3′-H), 6.08 (1H, m, 2′-H), 7.25 (5H, m, Ph-H), 7.48 (1H, br d, 8H).

[0640] δ_(c) 7.89 (CH2-cyclopropyl×2), 21.74, 21.77 (Me alaninyl), 26.81 (C(CH₃)₃), 24.21 (CH-cyclopropy), 31.90 (C(CH₃)₃), 35.06 (6′-C), 46.10, 46.20 (4′-C), 50.79, 50.83 (CH alaninyl), 59-42 (1′-C), 66.35 (5′-C), 69.34, 69.41, 69.49 (CH₂C(CH₃)₃), 116.41 (5-C), 120.62,120.66, 120.68, 120.72 (o-Ph), 125.39 (p-Ph), 130.15 (7n-Ph), 131.61, 131.65 (340-C), 136.82, 136.90 (8-C, 2′-C), 151.16, 151.25 (6-C, i-Ph), 156.78 (4-C), 158.91, 160.44 (2-C), 174.09, 174.20 (C(O) alaninyl).

[0641] ES⁺m/e 584.2640 (MH⁺, C₂₈H₃₉N₇O₅P requires 584.2672).

[0642] HPLC t_(R) 34.97 min (0% CH₃CN (0 min), 80% CH₃CN (35 min), 80% CH₃CN (45 min), 0% CH₃CN (55 min)).

[0643] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl (3-methylbutyl)oxyalaninyl phosphate) CF1674

[0644] This was prepared by Standard Procedure 4. 47% yield.

[0645] δ_(P) 3.87, 3.89:

[0646] δ_(H) 0.57 (2H, m, CH_(a)H_(b), CH_(a),H_(b) cyclopropyl), 0.80 (8H, m, CH_(a)H_(b), CH_(a), H_(b), cyclopropyl, CH(CH₃)₂ ), 1.30 (3H, m, CH₃ alaninyl), 1.42 (2H, m, OCH₂CH₂), 1.62 (2H, m, 6′-H_(a)H_(b), CH(CH₃)₂), 2.70 (1H, m, 6′-H₃H_(b)), 2.92 (1H, br s, CH cyclopropyl), 3.07 (1H, m, 4′-H), 3.88 (3H, m, CH alaninyl, OCH₂CH₂), 4.07 (3H, m, NE alaninyl, 5′-H), 4.91 (2H, br s, NH2), 5.48 (1H, br m, 1′-H), 5.83 (2H, br s, NH-cyclopropyl, 3′-H), 6.03 (1H, m, 2′-H3, 7.18 (5H, m, Ph-H), 7.42 (1H, br d, 8H).

[0647] δ_(c) 7.81 (CH₂-cyclopropyl×2), 21.49, 21.56 (Me alaninyl), 22.79, 22.83 (CH(CH₃)₂), 24.10 (CH(CH₃)₂), 25.38 (CH-cyclopropyl), 34.91, 34.99 (OCH₂CH2), 37.54 (6′-C), 46.01, 46.11 (4′-C), 50.70 (CH alaninyl), 59.25, 59.29 (1′-C), 64.63, 64.66 (OCH₂CH₂), 69.22, 69.30, 69.38 (5′-C), 116.17 (5-C), 120.53, 120.55, 120.59, 120.61 (o-Ph), 125.28 (p-Ph), 130.05 (m-Ph), 131.54, 131.60 (3′-C), 135.96 (8-C), 136.70, 136.81 (2′-C), 151.09, 151.17 (6-C, i-Ph), 156.68 (4-C), 160.34 (2-C), 173.94, 174.05 (C(O) alaninyl).

[0648] ES+m/e 584.2664 (MH⁺, C₂₈H₃₉N₇O₅P requires 584. 2672).

[0649] HPLC t_(R) 38.51 min (0% CH₃CN (0 min), 80% CH3CN (35 min), 80% CH₃CN (45 min), 0% CH₃CN (55 min)).

[0650] (1S,4R)-4-(2-amino-6-cyclopropylamino-9-H-purin-9-yl)2-cyclopentene-1-methanol O-(phenyl (cycloheptanyl)oxyalaninyl phosphate) CF1752

[0651] This was prepared by Standard Procedure 4.41% yield.

[0652] δ_(P) 3.96, 3.98.

[0653] δ_(H) 0.68 (2H, m, CH_(a)H_(b), CH_(a),H_(b), cyclopropyl), 0.99 (2H, m, CH_(a),H_(b), CH_(a), H_(b), cyclopropyl), 1.36 (5H, m, CH₃ alaninyl, 5″-H_(a),H_(b),6″-H_(a)H_(b)), 1.80 (1 1H, m, 6′-H_(a),H_(b), 2″-H, 3″-H, 4″-H, 7″-H, 5″-H_(a)H_(b), 6″-H_(a)H_(b)), 2.80 (1H, m, 6′-H_(a),H_(b)), 3.12 (1H, br s, CH cyclopropyl), 3.22 (1H, m, 4′-H), 3.97 (2H, m, CH alaninyl, NH alaninyl), 4.20 (2H, m, 5′-H), 4.95 ( 1H, m, O-CH), 5.18 (2H, br s, NH₂), 5.57 (1′H, br m, 1′-H), 5.90 (1H, m, 3′-H), 6.12 (1H, m, 2′-H), 6.25 (1′H, br s, NH cyclopropyl), 7.25 (SH, m, Ph-H), 7.51 (1H, br d, 8H).

[0654] δ_(c) 15.08 (CH₂-cyclopropyl×2), 28.76, 28.82 (Me alaninyl), 30.40, 30.44 (3″-C, 6″-C), 24.10 (CH(CH₃)₂), 31.57 (CH-cyclopropyl), 35.87 (4″-C, 5″-C), 41.26, 41.29, 41.31, 41.36 (6′-C), 42.24 (2″-C, 7″-C), 53.32, 53.42 (4′-C), 58.08 (CH alaninyl), 61.15 (1′-C), 66.62 (5′-C), 116.17 (5-C), 127.81, 127.85, 127.88, 127.91 (o-Ph), 132.54 (p-Ph), 137.32, 137.49 (m-Ph), 138.75 (3′-C), 143.21 (8-C), 144.13, 144.22 (2′-C), 158.40, 158.49 (6-C, i-Ph), 164.42 (4-C), 167.41 (2-C), 180.47, 180.51,180.59 (C(O) alaninyl).

[0655] ES+m/e 632.2719 (M[Na]⁺, C₃₀H₄₀N₇O₅Nap requires 632.2726).

[0656] HPLC t_(R) 41.92 min (0% CH₃CN (0 min), 80% CH₃CN (35 min), 80% CH₃CN (45 min), 0% CH₃CN (55 min)).

[0657] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopeutene-1-methanol O-(phenyl diethoxyaspartyl phosphate) CF1714

[0658] This was prepared by Standard Procedure 4.54% yield.

[0659] δ_(P) 3.76,4.19.

[0660] δ_(H) 0.62 (2H, m, CH_(a)H_(b), CH_(a),H_(b), cyclopropyl), 0.88 (2H, m, CH_(a)H_(b), CH_(a), H_(b), cyclopropyl), 1.25 (6H, m, CH₃—CH₂—O aspartyl×2), 1.68 (1H, m, 6′-H_(a)H_(b)), 2.75 (2H, m, —(CO)—CH_(a)H_(b), aspartyl, 61-H_(a)H_(b)), 2.97 (2H, m, CH cyclopropyl, -(CO)-CHaRb aspartyl), 3.16 (1H, m, 4′-H), 4.15 (8H, m, CH aspartyl, CH₂—O aspartyl×2, NH aspartyl, 5′-H), 4.90 (2H, br s, NH₂), 5.52 (1H, br m, 1′-H), 5.80 (1H, br s, NH-cyclopropyl), 5.90 (1H, m, 3′-H), 6.08 (1H, m, 2′-H), 7.21 (5H, m, Ph-H), 7.48 (1H, br d, 8H).

[0661] δ_(c) 8.65 (CH₂-cyclopropyl×2), 15.31 (CH₃-CH₂-O aspartyl×2), 24.92 (CH-cyclopropyl), 35.72 ((CO)-CH₂ aspartyl), 39.74, 39.91 (6′-C), 46.82, 46.90 (4′-C), 52.41, 52.47 (CH aspartyl), 60.11 (1′-C), 62.22 (CH₃—CH₂—O(CO)CH₂ aspartyl), 63.15 (CH₃—CH₂—C(CO)CH 15 aspartyl), 70.14, 70.27, 70.35 (5′-C), 116.12 (5-C), 121.33, 121.40, 121.49, 121.55 (o-Ph), 126.15 p-Ph), 130.86 (m-Ph), 132.36 (3′-C), 136.90 (8-C), 137.54 (2′-C), 151.81, 151.85 (6-C, i-Ph), 157.39 (4-C), 161-01 (2-C), 171.67, 171.81 (C(O)CH₂ aspartyl), 172.38, 1172.48, 172.52, 172.62 (C(O) aspartyl).

[0662] ES+m/e 614.2393 (MH⁺, C₂₈H₃₇N₇O₇P requires 614.2492).

[0663] HPLC IR 30.37 mn (0% CH₃CN (0 min), 80% CH₃CN (35 min), 80% CH₃CN (45 min), 0% CH₃CN (55 min)).

[0664] (1S,4R)-4-(2-amino-6-cyclopropylamino9H-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl methoxymethionyl phosphate) CF1715

[0665] This was prepared by Standard Procedure 4.49% yield.

[0666] δ_(P) 3.90, 4.03.

[0667] δ_(H) 0.61 (2H, m, CH_(a)H_(b), CH_(a), H_(b), cyclopropyl), 0.86 (2H, m, CH_(a)H_(b), CH_(a),H_(b), cyclopropyl), 1.71 (1H, m, CH-CH_(a)CH_(b) methioninyl), 1.90 (1H, m, CH-C_(a),CH_(b) methioninyl), 2.01 (3H, d, CH₃—S—), 2.30 (1H, m, ⁶′-H_(a)H_(b)), 2.47 (2H, m, 5′-CH₂), 2.78 (1′H, m, ⁶′-H_(a),H_(b)), 2397 (1H, br m, CH cyclopropyl), 3.14 (1H, m, 4′-H), 3.70 (3H, d, CH₃—O—), 3.80 (1H, m, CH methioninyl) 4.17 (31H, m, NH methioninyl, 5′-H), 4.89 (2H, br s, NH2), 5.49 (1H, m1′-H), 5.80 (1H, br s, NH-cyclopropyl), 5.90 (1H, m, 3¹H), 6.08 (1H, ma, 2-H), 7.24 (5H, m, Ph-H), 7.43 (1H, br d, 8H).

[0668] δ_(c) 6.52 (CH₂-cyclopropyl×2), 14-42, 14.47 (CH₃—S−), 22.81 (CH-cyclopropyl), 28,63, 28.78 (S-CH₂), 32.62, 32.73,32.81 (CH-CH₂- methioninyl), 33.65 (67-C), 44.73,44.83 (4′-C), 51.67 (CH methioninyl), 57.99 (1′-C), 68.13, 68.20,68.27 (5′-C), 114.03 (5-C), 119.15, 119.22, 119.24, 119.30 (o-Ph), 124.05, 124.10 (p-Ph), 128.80 (m-Ph), 130.26, 130.30 (3′-C), 134.72 (8-C), 135.42, 135.47 (2′-C), 149.76, 149.80, 149.84, 149.89 (i-Ph), 150.08 (6-C), 155.38 (4-C), 159.06 (2-C), 172.25, 172.28, 172.32, 172.36 (C(O)).

[0669] ES+mt/e 588.2053 (0% C₂₆H₃₄N₇O₅PS requires 588.2080).

[0670] HPLC t_(R) 29.64 min (0% CH₃CN (0 min), 80% CH₃CN (35 min), 80% CH₃CN (45 min), 0% CH3CN (55 min)).

[0671] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2cyclopentene-1-methanol O-(phenyl methoxytryptophanyl phosphate) CF1750

[0672] This was prepared by Standard Procedure 4.70% yield.

[0673] δ_(P) 3.88,4.01.

[0674] δ_(H) 0.68 (2H, m, CH_(a)H_(b), CH_(a),H_(b) cyclopropyl), 0.92 (2H, m, CHaHT CH_(a), H_(b) cyclopropyl), 1.53 (1H, m, 6′-H_(a)H_(b)), 2.68 (1H, m, 6′-Hafb), 2.99 (2H, br m, CH cyclopropyl, 4′-H), 3.22 (2H, m, CH₂-Trp), 3.66 (3H, d, CH₃-O-), 3.93 (3H, m, NH Tip, 5′-H), 4.35 (1H, m, CH Trp), 4.94 (2H, br s, NH2), 5.49 (1H, m, 1′-H), 5.87 (2H, m, NH-cyclopropyl, 3′-H), 5.97 (1H, m, 2′-H), 7.01 (1H, m, 6″-H), 7.26 (7H, m, Ph-H, 4″-H, 5″-H), 7.46 (1H, m, 7″-H), 7.52 (1H, m, 2″-H), 8.63 (1H, br d, 8H).

[0675] ≢7 _(c) 7.81 (CH₂-cyclopropyl×2), 24.10 (CH-cyclopropyl), 34.86, 34.91 (6′-C), 45.81, 45.90, 46.00 (4′-C), 52.97 (CH Trp), 59.24, 59.29 (1′-C), 69.14, 69.20 (5′-C), 109.86, 110.11 (3″-C), 111.72 (7″-C), 118.91 (5-C), 119.95, 120.04 (4″-C, 5″-C), 120.40, 120.47, 120.57, 120.63 (o-Ph), 122.49, 122.56 (6″-H), 123.70 (2″-C), 125.23, 125.29 (P-Ph), 127.79, 127.98 (9″-C), 130.04 (m-Ph), 131.27 (3′-C), 136.08 (8-C), 136.50, 136.55, 136.76, 136.87 (2′-C, 8″-C), 151.05, 151.14, 151.17, 151.26 (i-Ph, 6-C), 156.68 (4-C), 160.35 (2-C), 173.58, 173.66 (C(O)).

[0676] ES+m/e 643.2432 (MH⁺, C₃₂H₃₆N₈O₅P requires 643.2546).

[0677] HPLC t_(R) 31.46 minl (0% CH₃CN (0 min), 80% CH₃CN (35 mm), 80% CH₃CN (45 ), 0% CH₃CN (5 min)).

[0678] (1S,4R)-4-(2-anmino-6-cyclpropylamino9H purin-9-yl)-2-cyopentene1-methanol O-(phenyl methoxyisoleucinyl phosphate) ClF1751

[0679] This was prepared by Standard Procedure 4.60% yield. ps δ_(P) 4.48, 4.54.

[0680] δ0.68 (2H, m, CH_(a)H_(b), CH_(a), H_(b),cyclopropyl), 0.91 (8H, m, CH_(a), H_(b), CH_(a),H_(b), cyclopropyl, CH₃×2 isoleucinyl), 1.15 (1H, m, CH_(a)CH_(b) isoleucinyl), 1.45 (1H, m, CH_(a)CH_(b) isoleucinyl), 1.75 (2H, m, 6′-H_(a)H_(b), CH₃CH), 2.83 (]H, m, 6′-H_(a)H_(b)), 3.05 (1H, br m, CH cyclopropyl), 3.19 (1H, m, 4′-H), 3.62 (1H, m, NH isoleucinyl), 3.71 (3H, d, CH₃—O—), 3.88 (1H, m, CH isoleucinyl), 4.21 (2H, m, 5′-H), 4.91 (2H, br s, NH₂), 5.55 (1H, m, 1′-H), 5.81 (1H, br s, NHcyclopropyl), 5.93 (1H, m, 3′-H), 6.12 (1H, m, 2′-H), 7.28 (5H, m, Ph-H), 7.52 (1H, br d, 8H).

[0681] δ_(c) 7.82 (CH₂-cyclopropyl×2), 11-89 (CH₃CH₂), 15.72 (CH₃CH), 24.08 (CH-cyclopropyl), 25.04, 25.13 (CH₃CH₂), 34.99 (6′-C), 39.49, 39.56, 39.64 (CH₂CH), 46.04, 46.14 (4′-C), 52.46, 52.50 (CH isoleucinyl), 59.24, 59.44, 59.54 (1′-C), 69.34 (5S-C), 116.12 (5-C), 120.47, 120.53, 120.58 (o-Ph), 125.27 (p-Ph), 130.03 (m-Ph), 131.50, 131.57 (3′-C), 136.04 (8-C), 136.84, 136.74 (2′-C), 151.10, 151.18, 151.27 (i-Ph, 6-C), 156.69 (4-C), 161.06, 161.09, 161.35, 161.41 (2-C), 173.48, 173.53 (C(O)).

[0682] ES+mIe 570.2496 (MH⁺, C₂₇H₃₇N₇O₅P requires 570.2594).

[0683] HPLC IR 32.83, 33.14 min (0% CH₃CN (0 nin), 80% CH₃CN (35 min), 80% CH₃CN (45 min), 0% Cl3CN (55 min)).

[0684] (1S,4R)-4-(2-amino6-cyclopropylamino9H-purin-9-yl)-2-cyclopletene-1-methanol O-(phenyl dimethoxyglutamyl phosphate) CF1749

[0685] This was prepared by Standard Procedure 4.38% yield.

[0686] δ_(P) 3.99.

[0687] δ_(H) 0.68 (2H, m, CH_(a)H_(b), CH_(a),H_(b), cyclopropyl), 0.91 (2H, m, CH_(a)H_(b), C CH_(a),H_(b), cyclopropyl), 1.73 (1H, m, ⁶′-H_(a), H_(b)), 2.12 (1H, m, C(O)CH₂CH_(a),H_(b)), 2.38 (2H, m, C(O)CH₂), 2.82 (1H, m, 6′-H_(a)H_(b)), 3.05 (1H, m, CH cyclopropyl), 3.18 (1H, n, 4′-H), 3.68 (3H, s, MeOC(O)CH₂), 3.72 (3H, s, MeOC(O)CH), 3.85 (1H, m, NH glutyl), 4.10 (1H, m, CH glutyl), 4.21 (2H, m, 5′-H), 4.95 (2H, br s, NH2), 5.57 (1H, br m, 1′-), 5.88 (1H, br s, NH-cyclopropyl), 5.95 (1H, m, 3′-H), 6.10 (1H, m, 2′-H), 7.25 (5H, m, Ph-H), 7.54 (1H, br s, 8H).

[0688] δ_(c) 7.82 (CH₂-cyclopropyl×2), 24.12 (CH-cyclopropyl), 29.66, 29.73, 29.88 (C(O)CH₂CH2), C(O)CH₂CH₂), 34.91 (6′-C), 46.02, 46.12 (4′-C), 52.19 (CH₃OC(O)CH₂CH₂), 54.17, 54.28 (CH₃OC(O)CH₂), 54.17 (CH glutyl), 59.31 (1′-C), 69.50 (5′-C), 115.42 (5-C), 120.48, 120.51, 120.55, 120.58 (o-Ph), 125.39 (p-Ph), 130.09, 130.22 (m-Ph), 131.55, 131.60 (3′-C), 136.13 (8-C), 1136.68, 136.77 (2′-C), 150.98, 151.05, 151.13 (6-C), 151.76 (i-Ph), 156.65 (4-C), 160.99, 161.02, 161.08, 161.12 (2-C), 173.33, 173.43 (C(O)×2 glutyl).

[0689] ES+m/e 600.2216 (MH⁺, C₂₇H₃₅N₇07P requires 600.2335).

[0690] HPLC IR 27.25 min (0% CH₃CN (0 min), 80% CH₃CN (35 min), 80% CH₃CN (45 min), 0% CH₃CN (55 min)).

[0691] (1S,4R)-4(2-aminocyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl (methoxya-ethylglycinyl phosphate) CF1783

[0692] This was prepared by Standard Procedure 4.44% yield.

[0693] δ_(P) 4.10.

[0694] δ_(H) 0.59 (2H, m, CH_(a)H_(b), CH_(a), H_(b), cyclopropyl), 0.83 (5H, br m, CH_(a)H_(b), CH_(a),H_(b), cyclopropyl, CH₃-CH₂), 1.68 (3H, m, CH₃—CH₂, 6′-H.), 2.69 (1H, m, ⁶′-H_(a),H_(b)), 2.91 (1H, m, 4′-H), 3.06 (1H, m, CH cyclopropyl), 3.58 (3H, d, J 3.0, MeO), 3.90 (211, m, NH glycinyl, CH glycinyl), 4.07 (2H, m, 5′-H), 5.02 (2H, br s, NH2), 5.42 (1H, m, 1′-H), 5.75 (1H, m, 3′-H), 5.98 (1H, m, 2′-H), 6.03 (1H, m, NH cyclopropyl), 7.18 (5H, m, Ph-H), 7.41 (1H, br d, 8H).

[0695] δ_(c) 7.76 (CH₂-cyclopropyl×2), 9.68, 9.76 (CH₃CH₂), 24.12 (CH-cyclopropyl), 28.05 20 (CH₃CH₂), 35.01 (6′-C), 46.02, 46.13 (4′-C), 52.70, 52.73 (CH₃O), 56.02 (1′-C), 59.25 (CH-ala), 69.38 (5′-C), 116.10 (5-C), 120.48, 120.50, 120.55, 120.57 (o-Ph), 125.27 (p-Ph), 130.04 (m-Ph), 131.51 (3′-C), 135.86 (8-C), 136.86 (2′-C), 151.08, 151.13, 151.22 (6-C, i-Ph), 156.67 (4-C), 160.40 (2-C), 173.84, 173.87, 173.92 (C(O) alaminyl).

[0696] ES+m/e 564.2094 (M[Na]⁺, C₂₅H₃₂N₇O₅NaP requires 564.2100).

[0697] HPLC t_(R) 16.82, 16.84 min (0% CH₃CN (0 min), 80% CH₃CN (15 mm), 80% CH₃CN (25 min), 0% CH₃CN (35 min)).

[0698] (1S S4R)-4-(2-amino-6-cyclopropylaraino-9H-purin-9-yl)-2-cyclopentene1-methanol O-(phenyl (methoxy-a-phenyl(RS)glycinyl phosphate) CF1784

[0699] This was prepared by Standard Procedure 4. 46% yield.

[0700] δ_(P) 3.18,3.28,3.42,4.29.

[0701] Proton and Carbon NMR gave complex spectra, consistent with the racemised product.

[0702] ES+nm/e 612.2086 (M[Na⁺, C₂₉H₃₂N₇O₅NaP requires 612.2100).

[0703] HPLC t_(R) 17.63, 18.50 min (0% CH₃CN (0 min), 80% CH₃CN (15 min), 80% CH₃CN (25 mi), 0% CH₃CN (35 min)). (1:1.08 racemnisation by HPLC)

[0704] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl (methoxy-α-butylglycinyl phosphate) CF1786

[0705] This was prepared by Standard Procedure 4. 51% yield*.

[0706] δ_(P) 4.10, 4.16.

[0707] δ_(H) 0.51 (2H, m, CH_(a), H_(b), CH_(a), H_(b), cyclopropyl), 0.72 (5H, br m, CHaHB, CH_(a), H_(b). cyclopropyl, CH₃-CH₂), 1.18 (4H, m, CH₃-CH₂-CH2-), 1.54 (3H, m, CH₂-CHrO , 6′-H_(a)H_(b)), 2.73 (1H, m, 6′-H_(a)H_(b)), 2.93 (111 m, 4′-H), 3.09 (]H, m, CH cyclopropyl), 3.52 (1H, m, CH glycinyl), 3.62 (3H, s, MeO), 3.87 (1H, m, NH glycinyl), 4.12 (2H, m, 5′-H), 4.75 (2H, br S, NH2), 5.45 (1H, m, 1′-H), 5.79 (2H, br s, NH-cyclopropyl, 3′-H), 6.00 (1H, m, 2′-H), 7.20 (5H, m, Ph-H), 7.42 (1H, br d, 8H).

[0708] δ_(c) 7.76 (CH₂-cyclopropyl×2), 14.23 (CH₃CH₂), 22.56 (CH₃CH₂), 24.14 (CH-cyclopropyl), 27.43, 27.50 (CH₃CH₂CH₂), 34.50, 34.58 (CH₂CH20), 35.01 (6′-C), 46.02, 46.12 (4-C), 52.66, 52.68 (CH₃O), 54.87, 54.94 (1′-C), 59.20 (CH-ala), 69.30, 69.37 (5′-C), 115.18 (5-C), 120.29, 120.42, 120.50, 120.57 (o-Ph), 125.21 ip-Ph), 130.00 (m-Ph), 131.51, 131.54 (3′-C), 135.86 (8-C), 136.71, 136.76 (2′-C), 151.12, 151.16, 151.20, 151.25 (6-C, i-Ph), 156.73 (4-C), 160.49, 160.96 (2-C), 174.19, 174.26 (C(O) glycinyl).

[0709] ES+m/e 592.2428 (M[Na]⁺, C₂₇H₃N₇O₅NaP requires 592-2413).

[0710] HPLC IR 18.34, 18.41, min and 16.64 min (6:1) (0% CH₃CN (0 min), 80% CH₃CN (35 min), 80% CH₃CN (45 min), 0% CH₃CN (55 min)).

[0711] (1S,4R)-4-2-amino6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl (methoxy-α-propylglycinyl phosphate) CF1785

[0712] This was prepared by Standard Procedure 4.50% yield.

[0713] δ_(P) 4.14,4.21.

[0714] δ_(H) 0.62 (211, m, CH_(a),H_(b), CH_(a),H_(b), cyclopropyl), 0.86 (5H3, br m, CH_(a)H_(b), CH_(a), H_(b), cyclopropy], CH₃—CH₂), 1.32 (2H, m, CH₃-CH₂-), 1.63 (3H, m, CH₃-CR₂, 6′-H_(a),H_(b)), 2.79 (1H, m, 6′-H_(a)H_(b)), 3.03 (1H, m, 4′-H, 3.18 (1H, m, CH cyclopropyl), 3.71 (3H, d, J 3.0, MeO), 3.97 (1H, m, CH glycinyl), 4.15 (3H, m, 5′-H, NH glycinyl), 5.09 (2H, br s, NH₂), 5.55 (1H, m, 1′-H), 5.90 (1H, m, 3′-H), 6.08 (2H, m, 2′-H, NH cyclopropyl), 7.23 (5H, m, Ph-H), 7.52 (1H, br d, 8H).

[0715] δ_(c) 7.55 (CH₂-cyclopropyl×2), 13.98 (C1H₃CH₂), 18.62, 18.70 (CH₃CH₂), 24.15 (CH-cyclopropyl), 35.00 (6′-C), 36.89, 36.96 (CH₂CH₂O), 46.02, 46.12 (4′-C), 52.68 (CH3O), 54.70, 54.77 (1′-C), 59.21 (CH-ala), 69.31, 69.38 (5′-C), 115.24 (5-C), 120.45, 120.51; 120.57 (o-Ph), 125.22 (p-Ph), 130.01 (m-Ph), 131.54 (3′-C), 135.89 (8-C), 136.72, 136.78 (2′-C), 151.11, 151.16, 151.20, 15125 (6-C, i-Ph), 156.72 (4-C), 160.45, 160.95 (2-C), 174.18, 174.25 (C(O) alaninyl).

[0716] ES+m/e 578.2259 (M[Na]⁺, C₂₆H₃₄N₇O₅NaP requires 578.2257).

[0717] HPLC IR 17.57 ml (0% CH₃CN (0 min), 80% CH₃CN (35 mL), 80% CH₃CN (45 min), 0% CH₃CN (55 ml)).

[0718] (1S,4R)-4-(2-amino6cyclopropyl2 mino-9H-purin-9-yl)-2-cyclopentene1-methanol O-((P-(2 2-dimethoxypropionic acid methyl ester)-phenyl)methoxyalaninyl phosphate) CF1671

[0719] This was prepared by Standard Procedure 4.24% yield.

[0720] δ_(P) 3.72, 3.84.

[0721] δ_(H) 0.56 (2H, m, CH_(a), H_(b), CH_(a),H_(b), cyclopropyl), 0.79 (2H, m, CH_(a),H_(b), CH_(a), H_(b), cyclopropyl), 1.30 (3H, m, CH₃ alaninyl), 1.63 (1H, m, 6′-H_(a)H_(b)), 2.70 (1H, m, 6′-H.Eb), 2.95 (1H, br s, 4′-H), 3.07 (3H, m, CH cyclopropyl, Ph-CH₂-), 3.26 (6H, S, (OMe)₂), 3.52 (3H, s, C(OMe)₂COOMe), 3.61 (3H, s, COOMe alaninyl), 3.84 -4.08 (4H, m, CH alaninyl, NH alaninyl, 5′-H), 4.99 (2H, br s, NH₂), 5.46 (1H, br m, 1′-H), 5.81 (1H, br s, 3′-H), 6.02 (2H, m,3′-H, NH-cyclopropyl), 6.02 (1H, m, 2′-H), 7.02 (4H, m, Ph-H), 7.45 (1H, br d, 8H).

[0722] δ_(c) 7.77 (CH₂cyclopropyl×2), 21.37 (Me alaninyl), 24.01 (CH-cyclopropyl), 34.89 (6′-C), 39.55 (Ph-CH₂), 45.97, 46.09 (4′-C), 50.53 ((MeO)₂, CH₃OO alaninyl), 52.65 (C(OMe)₂COOMe), 59.28 (1′-C), 69.29 (5′-C), 103.27 (C(OMe)₂),120.31, 120.38 (o-Ph), 122.94 p-Ph), 131.35 (m-Ph), 131.39 (3′-C), 136.79 (8-C, 2′-C), 150.14,150.05 (i-Ph, 6-C), 152.12 (4-C), 160.24 (2-C), 169.08 (C(OMe)₂COOMC), 174.36, 174.46 (C(O) alaiinyl).

[0723] ES+m/e 696.2531 ([M]⁺, C₃₀H₄₀N₇O₉NaP requires 696.2523).

[0724] HPLC IR 29.02 min (0% CH₃CN (0 min), 80% CH₃CN (35 miin), 80% CH3CN (45 min), 0% CH₃CN (55 min)).

[0725] (1′S,4R)-4-(2-amino-6cyclopropylamino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-((p-methoxyphenyl)methoxyalaninyl phosphate) CF1815

[0726] This was prepared by Standard Procedure 4.23% yield.

[0727] δ_(P) 4.23, 4.28.

[0728] δ_(H) 0.72 (2H, m, CH_(a)H_(b), CH_(a),H_(b), cyclopropyl), 1.0 (2H, m, CH_(a)H_(b), CH_(a), H_(b) cyclopropyl), 1.48 (3H, m, CH₃ alaninyl), 1.82 (1H, in, 6-1H_(a)H_(b)), 2.80 (1H, m, 6′-H_(a)H_(b)), 3.11 (1H, br s, 4′-H), 3.25 (1H, m, CH cyclopropyl), 3.67 (1H, m, NH alaninyl), 3.77 (3H, s, COOMe alaninyl), 3.89 (3H, s, MeO-Ar), 4.14 (1H, m, CH alaninyl), 4.30 (2H, m, 5′-H), 4.94 (2H, br S, NH₂), 5.65 (1H, br m, 1′-H), 5.83 (1H,br s, NH-cyclopropyl), 6.00 (1H, m, 3′-H), 6.17 (1H, m, 2′-H), 6.92 (2H, m, m-Ar), 7.23 (2H, m, o-Ar), 7.63 (1H, s, 8H).

[0729] δ_(c) 7.81 (CH₂-cyclopropyl×2), 21.46, 21.52 (Me alaninyl), 24.00 (CH-cyclopropyl), 34.96 (6′-C), 46.04, 46.14 (4′-C), 50.64 (CH300 alaninyl), 52.89 (CH-alaninyl), 56.02 (CH₃O-Ar), 59.28 (1′-C), 69.30 (5′-C), 114.98 (m-Ph, 5-C), 121.42, 121.46, 121.52 (o-Ph), 131.52, 131.56 (3′-C), 135.98, (2′-C), 136.76, 136.87 (i-Ph), 144.61 (8-C), 156.71 (4-C), 157.01 (p-Ar), 161.40, 160.99 (2-C), 174.39, 174.50 (C(O) alaninyl).

[0730] HPLC IR 16.28 (0% CH₃CN (0 min), 80% CH3CN (15 min), 80% CH₃CN (25 min), 0% CH₃CN (35 min)).

[0731] (1S,4R)-4-(2-amino&cyclopropylamino-9H-purin-9-yl)-2-cyclopentene1-methanol O-((p-propoxyph enyl)methoxyalaninyl phosphate) CF1816

[0732] This was prepared by Standard Procedure 4.56% yield.

[0733] δ_(P) 4.33, 4.41.

[0734] δ_(H) 0.62 (2H, m, CH_(a),H_(b), CH_(a),H_(b), cyclopropyl), 0.82 (2H, m, CH_(a)H_(b), CH_(a),H_(b), cyclopropyl), 1.03 (311, t, J 6.0, CH₃-CH₂), 1.39 (311, m, CH₃ alaninyl), 1.66 (1H, m, ⁶′-H_(a)H_(b)), 1.80 (2H, h, J 6.0, CH₃-CH9₂), 2.79 (1H, m, ⁶′-H_(a)H_(b)), 3.01 (1I1, br s, 4′-H), 3.12 (1H, m, CH cyclopropyl), 3.72 (3H, s, COOMe alaninyl), 3.89 (2H, t, J 6.0, CH₂-O), 4.04 (2H1, m, CH alaninyl, NH alaninyl), 4.17 (211, m, 5′-H), 5.10 (21H, br s, NH2), 5.52 (1H, br m, 1′-H), 5.51 (1H, br s, NH-cyclopropyl), 5.89 (11H, m, 3′-H), 6.04 (1H, m, 2′-H), 6.81 (21 m, m-Ar), 7.11 (2H, m, o-Ar), 7.51 (1H, s, 8H).

[0735] δ_(c) 7.77 (CH₂-cyclopropyl×2), 10.91 (CH₃-CH₂), 21.39, 21.46 (Me alaninyl), 22.97 (CH₃-CH₂), 24.14 (CH-cyclopropyl), 34.96 (6′-C), 46.02, 46.13 (4′-C), 50.57, 50.65 (CH₃OO alaninyl), 52.85, 52.87 (CH-alainyl), 53.89 0 59.25 (1′-C), 69.16, 69.24, 69.33 (5′-C), 70.30 (CH₂-O), 115.24,115.26 (5-C), 115.57 (m-Ph), 121.37, 121.40, 121.43, 121.46 (o-Ph), 131.51, 131.57 (3′-C), 135.93, (2′-C), 136.77, 136.85 (i-Ph), 144.47, 144.55 (8-C), 156.54, 156.73 (4-C), 160.45 (p-Ar), 160.91 (2-C), 174.48, 174.59 (C(O) alaninyl).

[0736] HPLC t_(R) min (0% CH₃CN (0 min), 80% CH₃CN (15 min), 80% CH3CN (25 min), 0% CH₃CN (35 min)).

[0737] (1S,4R)-4-(2-amino-6-cyclopropylamino⁹H-purin-9-yl)-2-cyclopentene-1-methanol O-[4-bydroxyacetophenone(methoxy-L-alaninyl)]-phosphoramidate Cf 1794

[0738] This was prepared by Standard procedure 4. The crude residue was purified twice by column chromatography, using MeOH:CHCl₃ (3%:97) and MeOH:EtOAc (5:95) as eluent, to give the product as a white foam (30 mg, 17 mmol, 15%).

[0739] δ_(P) 3.496.

[0740] δ_(SH) 0.66 (m,2H,CH2-cPr), 0.85 (m,2H,CH2-cPr), 1.33 (m, 3H, CH3-CH), 1.7 (m, 1H, H′6), 2.53 (s, 3H, CH3-COPh), 2.8 (m, 1H, H′6), 2.9 (m, 1H, CH-cPr), 3.1 (m, 1H1, H′4), 3.6 (s, 3H, CH₃-O), 3.9 (m, 1H, CH3-CH), 4.1 (m, 2H, H′5), 4.9 (m, 2H, NH₂), 5.5 (m, 1H,′1), 5.85 (m, 1H, H′3), 6.1 (m, 2H, H′2,NHcPr) 7.2 (dd, 2H, o-Ar), 7.5 (m, 1H, H8), 7.8 (dd, 2H, p-Ar)

[0741] δ_(c) 6.371 (CH₂cPr), 20 (CH-CH3aa), 21.671 (NHCH3), 25 (CH3CO), 33.458 (C′6), 44.55 (C¹4),49.5 (CHaa), 51.4 (OCH3), 57.9 (C′1), 67.9 (C′5), 113.787 (C5), 120 (o-Ar), 122.22 (p-Ar), 128.743 (m-Ar), 130 (C′3), 134.53 (C′2), 135.31 (C8), 150.31 (i-Ar), 155.18 (C6), 156.342 (C2), 158.8 (C4), 173.004 (COOCH3), 198 (CO-Ar).

[0742] HPLC t_(r): 15.976 min (0% CH₃CN (0 min), 80% CH₃CN (15 min), 80% CH₃CN (25 min), 0% CH₃CN (35 min)).

[0743] (1S,4R)-4-(2-amino-6cyclopropylamino-9H-purin-9-yl)-2-cyclopentene1-methanol O-[4D-butylphenyl-(methoxy-L-alaninyl)-phosphate Cf 1795

[0744] The crude residue was purified twice by column chromatography, using MeOH:CHCl₃ (3%:97) and MeOH:CH₂Cl₂ (5:95) as eluent, to give the product as a white foam ( 15 mg, 0.025 mmol, 4%),

[0745] δ_(P) 3.934.00.

[0746] δ_(H) 0.66 (m,2H,CH2-cPr), 0.85 (m,2H,CH2-cPr), 1.1 (m,3H, CH₃-CH₂),1.2 (m,4H, CH₂-CH₂), 1.33 (m, 3H, CH3-CH), 1.7 (m, 1H, H′6),2.5 (m, 2H, CH₂-Ar), 2.8 (m, 1H, H′6),2.9 (m, 1H, CH-cPr), 3.1 (m, 1H, H′4),3.6 (s, 3H, CH3-O),3.9 (m, 1H, CH3—CH), 4.1 (m, 2, H′5),4.9 (m, 2H, NH2),5.5 (m, 1H′1), 5.85 (m, 1H, H′3), 6.1 ( m, 2H, H′2,NHCPr), 7.2

[0747] δ_(c) (dd, 211, o-Ar), 7.5 (m, 1H, H8),7.8 (dd, 2H,p-Ar). ⁶c 6.371 (CH2cPr), 14.345 (CH₃—CH₂), 21.49 (CH-CH3aa), 22.66 (CH₂-CH₃), 21.671 (NHCH3), 30.127 (CH2-CH2-CH12), 33.458 (C′6), 34.047.(CH2-Ar), 44.55 (C′4), 49.5 (CHaa), 51.4 (OCH3), 57.9 (C′1), 67.9 (C′5), 113.787 (C5), 120 (o-Ar), 122.22 (p-Ar), 128.743 (m-A), 130 (C′3),134.53 (C2),135.31 (C8),146.58 (i-Ax) 155.18 (C6),156.342 (C2),158.8 (C4),173.004 (COOCH)

[0748] HPLC t_(r): 19.591 mn (0% CH₃CN (0 mm), 80% CH₃CN (15 inn), 80% CH₃CN (25 min), 0% CH₃CN (35 min)).

[0749] (1S,4R)-4i(2-aminicyclopropylamino9H-purin-9-yl)-2-cyclopentene-1-methanol O-[phenylphenyl-(methoxy-L-alaninyl)]-phosphate Cf 1788

[0750] The crude residue was purified three times by column chromatography, using MeOH:CHCl₃ (3:97) and MeOH:CH₂Cl₂ (5:95) and MeOH:AcOEt (3:97) as eluent, to give the product as a yellow foam (35 mg, 0.058 mmol, 8%).

[0751] δ_(P) 3.94-3.96.

[0752] δ_(H) 0.66 (m,2H,CH²-cPr), 0.85 (m,2H,CH2Pr), 1.33 (m, 3H, CH3—CH), 1.7 (m, 1H, H′6), 2.8 (m, 11H, H′6), 2.9 (m, 1H, CH-cPr), 3.25 (m, 1H, H′4), 3.6 (s, 3H, CH3-O), 4.1 (m, 1H, CH3-CH), 4.25 (m, 2H, H′5), 4.9 (m, 2H, N1H2), 5.5 (m, 1H,H′1), 5.85 (m, 1H, H′3), 6.15 (m, 2H, H′2,NHcPr), 7.35 (m, 9H, Ar), 7.6 (m, 1H, H8).

[0753] δ_(c) 6.371 (CH2cPr), 21.49 (CH-CH3aa), 21.671 (NHCH3), 33.458 (C′6), 46.14 (C4), 50.671 (C1Haa), 52.9 (OCH3),59.9 (C′1), 65.9 (C′5),115.787 (C5),120 (o-Ar), 122.22 (p-Ar), 128.743 (m-Ar), 130 (C′3), 134.53 (C′2), 135.31 (C8), 145.25 (i-Ar), 155.18 (C6), 156.342 (C2),158.8 (C4),173.004 (COOCH3).

[0754] HPLC t_(r): 19.147 min (0% CH₃CN (0 mn), 80% CH₃CN (15 min), 80% CH₃CN (25 min), 0% CH₃CN (35 min)).

[0755] (1S,4R)-4-(2-amino-⁶-cyclopropyaImino-9H-purin-9-yl)-2-cyclopentene-1-methanol O-[phen oxyphenyl-(methoxy-L-alaninyl)]-phosphate Cf 1787

[0756] The crude residue was purified twice by column chromatography, using MeOH:CHCl3 (3:97) and MeOH:CH₂Cl₂ (5:95) as eluent, to give the product as a yellow foam ( 35 mg, 0.058 mmol, 8%).

[0757] δ_(P) 4.2124.184.

[0758] δ_(H) 0.66 (m,2H,CH2-cPr), 0.85 (m,2H,CH2-cPr), 1.33 (m, 3H, CH3-CH), 1.7 (m, 1H, H′6), 2.8 (m, 1H, H′6), 2.9 (m, 1H, CH-cPr), 3.25 (m, 1H, H4), 3.6 (s, 3H, CH3-O), 4.1 (m, 1H, CH3-CH), 4.25 (m, 2H, H′5), 4.9 (m, 2H, NH2), 5.5 (m, 1H,H′1), 5.85 (m, 1′H, H′3), 6.15 (m, 2H, H′2,NHcPr), 7.35 (m, 9H, Ar), 7.6 (m, 1H, H8).

[0759] δ_(c) 6.371 (CH2cPr), 21.49 (CH-CH3aa), 21.671 (NHCH3), 33.458 (C′6), 46.14 (C′4), 50.671 (CHaa), 52.9 (OCH3), 59.9 (C′1), 65.9 (C′5), 115.787 (CS), 120 (o-Ar), 122.22 p-Ar2), 128.743 (m-Ar), 130 (C′3), 134.53 (C′2), 135.31 (C8), 153.83 (i-Ar₂, m-Arl), 155.18 (C6), 156.342 (C2),158.8 (C4), 173.004 (COOCH3).

[0760] HPLC t_(r): 18.830 min (0% CH₃CN (0 Min), 80% CH₃CN (15 min), 80% CH₃CN (25 min), 0% CH₃CN (35 min))

[0761] (1S,4R)-4-(2-amino-6cyclopropy]amino9H-purin-9-yl)-2-cyclopentene-1-methanol O-phenyl methoxy-α,α-cyclopentylglycinyl]phosphate Cf1763

[0762] This was prepared by Standard procedure 4 in 77% yield.

[0763]³¹ p (CDCl₃) 3.02,3.09

[0764]¹H (CDCl₃) 0.56-0.61 (2H,m, CH₂ (cpro)), 0.81-0.89 (2H, m, CH2 (cpro)), 1.58-1.78 (SH, m, CCH₂CH₂CH₂CH₂C, and H6′), 1.87-2.18 (4H, m, CCH₂CH₂CH₂CH₂C), 2.64-2.74 (1H, m, H6′), 2.83-3.09 (2H, m, CH(cpro), H4′), 3.60-3.62 (3H, s, OCH₃(ala)), 4.044.19 (2H, m, H5′), 5.20 (2H, bs, NH2), 5.42-5.47 (1H, n, HI′), 5.77-5.83 (1H, m, H3′), 5.98-6.02 (1H, m, H2′), 6.20 (NH(cpro)), 7.06-7.27 (SH, m, Ar), 7.42-7.48 (1H, s, H8). 1³C (CDCl₃) 8.02 (CH₂(cpro)), 24.37, 24.41 (CCH₂CH₂CH₂CH₂C), 34.73 (C6′), 38.48, 38.68,38.79, 38.87 (CCH₂CH₂CH₂CH₂C), 46.05, 46.15 (C4′), 52.99 (OCH₃(ala)), 59.56, 59.60 (Cl′), 67.16 (C (aa), 69.28, 69.37 (C5′), 114.76 (CS), 120.46, 120.52 (o-Ph), 125.22 (p-Ph),130.04 (m-Ph), 131.19 (C3′), 136.72 (C8), 137.13, 137.20 (C2′), 151.27, 151.31, 151.36,151.40 (C6), 155.56 (C4), 158.95 (C2),175.96, 176,00 (CO).

[0765] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-pu rin-9-yl)-2-cyclopentene-1-methanol O-[phenyl methoxy-α,α-cylohexylglycinyl] phosphate Cf1764

[0766] This was prepared by Standard procedure 4 in 15% yield.

[0767]³¹ p (CDCl₃) 2.89, 3.00

[0768]¹H (CDCl₃) 0.74 (2H,m, CH₂ (cpro)), 1.01-1.03 (2H, m, CH₂ (cpro)), 1.29-2.23 (11H, m, CCH₂CH₂CH₂CH₂CH₂C, and H6′), 2.72-2.83 (1H, m, H6′), 3.17 (1H, bs, CH(cpro)), 3.35-3.43 (1H, m, H4′), 3.69-3.70 (3H, s, OCH₃(aa)), 4.164.29 (2H, m, H5′), 5.52-5.66 (1H, m3 HI′), 5.79 (1H, bs, NH(cpro)), 5.85-5.90 (1H, m, H3′), 6.08-6.10 (1H, m, H2′), 7.15-7.35 (5H, m, Ar), 7.37-7.63 (1H, d, H8).

[0769]^(—)C (CDCl₃) 8.30 (CH₂(cpro)), 21.49, 21.68, 21.84, 22.02, 22.11 (CCH2CH 2CH₂CH₂C), 25.14, 25.47, 25.72 (CCH₂CH₂CH₂CH₂CH₂C ), 34.37, 34.59 (C6′), 46.06, 46.16 (C4′), 52.75, 53.12 (OCH₃(aa)), 59.95, 60.19 (Cl′), 69.22 (CS′), 120.41, 120.47 (o-Ph), 125.22 (p-Ph), 130.04 (m-Ph), 130.72, 130.82 (C3′), 137.41 (C8), 137.56 (C2′), 151.33, 151.43 (C6), 175.37 (CO).

[0770] (1S,4R)-4-(2-amino-6-cycIopropylamino-9H-purin-9-yl)-2-cyclopentenel-methanol O-[phenyl meth oxya,a-cylopropylglycinyll phosphate Cf 1762

[0771] This was prepared by Standard procedure 4 in 69% yield.

[0772]³¹ P (CDCl₃) 3.84

[0773]¹H (CDCl₃) 0.68(2H,m, CH₂ (cpro)), 0.90-0.92 (2H, m, CH₂ (cpro)), 1.16-1.49 (4H3 m, CCH2CH7C(aa)), 1.66-1.72 (1H, m, H6′), 2.72-2.82 (1H, m, H6′), 3.08-3.15 (2H, m, CH(cpro), H4′), 3.61-3.63 (3H, d, OCH₃(aa)), 4.244.26 (2H, m, H5′), 5.24 (2H, bs, NH2), 5.53 (1H, bs, H1′), 5.87(1H, m, H3′), 6.07 (1H, m, H2′), 6.42-6.45 (1H, bs, NH(cpro)), 7.15-7.35 (SH, m, Ar), 7.56-7.61 (1H, d, HB).

[0774]¹³C (CDCl₃) 7.92 (CH₂(cpro)), 18.38 (CH₂ (aa)), 35.20 (C6′), 52.88 (OCH3(aa)), 59.45 (Cl′), 69.32 (C5′), 120.52 (o-Ph), 125.29 (p-Ph), 130.04 (m-Ph),137.03 (C2′), 151.13 (C6),160.96, 160.98 (C2), 174.35 (CO).

[0775] (1S,4R)-4-(2-amino-6-cyclopropylamino-9H-purin-9-yl)-2-cyclopentene1-methanol O-[p-(methoxycarbonyl)phenyl methboxy-L-alaninyll phosphate Cf1766

[0776] This was prepared by Standard procedure 4 in 37% yield.

[0777] 31P (CDCl₃) 3.54, 3.58

[0778]¹H (CDCl₃) 0.66-0.69 (2H,m, CH₂ (cpro)), 0.88-0.94 (2H, m, CH₂ (cpro)), 1.38-1.43 (3H, t, CH₃(ala)), 1.70-1.81 (1H, m, H6′), 2.76-2.89 (1H, m, H6′), 3.07 (1H, m, CH(cpro)), 3.21 (1H, mn, H4′), 3.71-3.73 (3H, d, OCH₃(ala)), 3.94 (3H, s, COOCH₃), 3.98-4.12 (1H, m, CH(ala)), 4.20-4.31 (2H, m, H5′), 5.19 (2H, bs, NH2), 5.54-5.57 (1H, m, H1′), 5.91-5.96 (1H, in, H3′), 6.09-6.14 (1H, m, H2′), 6.21 (1H, bs, NH(cpro)), 7.27-7.32 (2H, m, ArO,2H), 7.53-7.54 (1H, d, H8), 8.02-8.06 (2H, m, COAr,2H).

[0779]¹³C (CDCl₃) 7.75 (CH₂(cpro)), 21.22, 21.29, 21.46 (CH₃(ala)),24.16 (NHCH), 34.83 (C6′), 45.97, 46.07 (C4′), 50.59 (CH(ala)), 52.57, 59.32 (OCH₃ (ala), OCH₃(Ph)), 59.27, 59.32 (Cl′), 69.43 (C5′), 115.07, 115.11 (C5), 120.28, 120.31, 120.34, 120.38 (o-Ph), 127.07 (p-Ph), 131.58, 131.66 (m-Ph), 131.88 (C3′), 135.94, 136.04 (C2′), 136.61, 136.73 (C8), 151.31 (C6), 156.52 (C2), 160.97 (C4), 171.57 (CO), 174.30,174.39 (CO).

[0780] (1S,4R)-4-(2-amino-6-cyclopropylamino9H-purin-9-yl)-2-cyclopentene-1-methanol O-[p-(trifluoromethylthio)phenyl methoxy-L-alaninyl]phosphate Cf 1769

[0781] This was prepared by Standard procedure 4 in 34% yield.

[0782]³¹ P (CDCl₃) 3.67, 3.88

[0783]¹H (CDCl₃) 0.81 (2H,bs, CH₂ (cpro)), 1.06-1.08 (2H, m, CH2 (cpro)), 1.50-1.54 (3H, t, CH₃(ala)), 1.83-1.93 (1I1, m, H6′), 2.87-2.99 (1H, m, H6′), 3.23-3.31 (1H, m, CH(cpro)), 3.82-3.84 (3H, d, OCH₃(ala)), 4.1 44.15 (1H, mi, CH(ala)), 4.32-4.40 (2H, m, H5′), 5.65 (3H, bs, H1′, NH₂), 6.01-6.04 (11, m, H3′), 6.19-6.23 (1H, m, H2′), 6.64 (1H, bs, NH(cpro)), 7.37-7.43(2H, m, Ar), 7.67 (1H, d, H8), 7.73-7.76 (2H, m, Ar). 7C (CDC)₃) 8.16 (CH₂(cpro)), 21.39, 21.45 (CH₃(ala)), 34.45 (C6′), 46.09 (C4′), 50.66 (CH(ala)), 53.01 (OCH₃ (ala)), 59.87 (Cl′), 69.34 (C5′), 77.47, 77.67 (CF₃S ?), 121.64, 121.69 (o-Ph), 127.07 (p-Ph), 136.99, 137.14 (C2′), 138.56 (C8), 153.36, 153.45 (C6), 160.93 (C4), 174.27 (CO).

[0784] (1S,4R)-4-(2-aminotcyclopropy]2 mino9H-purin-9-yl)2-cyclopentene-1-methano O-[p-(2-methoxyvinyl)phenyl methoxy-L-alaninyl] phosphate Cf 1767

[0785] This was prepared by Standard procedure 4 in 38% yield.

[0786] 31p (CDCl₃) 3.70, 3.74

[0787]¹H (CDCl₃) 0.58-0.61 (2H,bs, CH₂ (cpro)), 0.81-0.85 (2H, m, CH₂ (cpro)), 1.30-1.36 (3H, t, CH₃(ala)), 1.61-1.72 (1H, m, H6′), 2.33 (31H, s, CH₃CO), 2.70-2.79 (1H, m, H6′), 2.99 (1H, bs, CH(cpro)), 3.13(1H, bs, 1H4′), 3.64-3.65 (3H, d, OCH₃(ala)), 3.924.01 (1H, m, CH(ala)), 4.114.21 (2H, m, H5′), 5.14 (3H, bs, H1′, NH2), 5.47-5.49 (1H, m, HI′), 5.82-5.87 (1H, m, H3′), 6.01-6.06 (1H, m, H12′), 6.12 (1H, bs, NH(cpro)), 6.57-6.63 (1H, dd, CH3COCH═CH), 7.14-7.46 (6H, m, H8, Ar, CH₃COCH═).

[0788] 1³C (CDC]₃) 7.95 (CH₂(cpro)), 21.45 (CH₃(ala)), 28.02 (CH₃CO), 34.69 (C6′), 46.11 (C4′), 50.64 (CH(ala)), 52.99 (OCH₃ (ala)), 59.53 (Cl′), 121.03, 121.10, 121.17 (o-Ph), 127.39 (p-Ph), 130.13 (CH₃COCH═CH), 131.44, 131.55 (C3′), 136.76 (C2′), 142.59 (CH₃COCH═CH), 152.72 (C6),174.26,174.36 (CO(ala)), 198.70 (COCH₃).

[0789] (1S,4R)-4-(2-amino-6cyclopropylamin o-⁹H-purin-9-yl)-2-cyclopentene-1-methanol O-[p-(2-phenylcarbonylvinyl)phenyl methoxy-L-alaninyll phosphate Cf 1771

[0790] This was prepared by Standard procedure 4 in 26% yield.

[0791]³¹p (CDCl₃) 3.75,3.79

[0792]¹H (CDCl₃) 0.61-0.66 (2H,m, CH₂ (cpro)), 0.85-0.91 (2H, m, CH₂ (cpro)), 1.39-1.44 (3H, m, CH3(ala)), 1.67-1.86 (1H, m, H6′), 2.77-2.87 (1H, m, H6′), 3.04-3.05 (1H, bs, CH(cpro)), 3.19-3.21 (1H, bs, H4′), 3.72-3.73 (3H, d, OCH₃(ala)), 4.024.13 (1H, m, CH(ala)), 4.194.29 (2H, m, H5′), 5.17 (3H, bs, H1′, NH₂), 5.53-5.58 (1H, n, HI′), 5.90-5.95 (11H, m, H3′), 6.09-6.15 (2H, m, H12′, NH(cpro)), 7.24-8.08 (12H, m, Ar-, CH=C H, -Ar-, H8).

[0793]¹³C (CDCl₃) 7.85 (CH₂(cpro)), 21.35, 21.41, 21.48 (CH₃(ala)), 24.22 (CH(NH)), 34.80 (C6′), 46.01 (C4′), 50.67 (CH(ala)), 52.97 (OCH₃ (ala)), 59.37 (Cl′), 69.40 (C5′), 115.07 (C5), 121.01, 121.07, 121.14 (o-Ph), 128.92, 129.06 (p-Ph), 133.27 (C3′), 136.13, 136.23 (C2′), 138.53 (C8), 152.77, 152.86 (C6), 156.31 (C2), 160.97, 160.99 (C4), 174.31, 174.41 (CO(ala)), 190.76 (CO (Ar)).

[0794] (1S,4R)-4-(2-amino6-cyclopropylamin o-9H-purin-9-yl)-2-cyclopentene-1-methanol O[p-(2,2-dicyanovinyl)phenyl methoxy-L-alaninyl] phosphate Cf 1768

[0795] This was prepared by Standard procedure 4 in 10% yield.

[0796]³¹P (CDCl₃) 4.54, 4.65

[0797]¹H (CDCl₃) 0.61-0.66 (2Hsm, CH₂ (cpro)), 0.85-0.91 (2H, m, CH₂ (cpro)), 1.34-1.41 (3H, CH₃(ala)), 1.67-1.83 (1H, m, H6′), 2.77-2.88 (1H, m, H6′), 2.95-2.97 (1H, m, H(cpro)), 3.23 (1H, bs, H4′), 3.68-3.70 (3H, d, OCH₃(ala)), 3.99-4.03 (1H, m, CH(ala)), 4.22-4.32 (2H, m, H5′), 5.49-5.53 (11H, m, H1′), 5.99-6.03 (1H, m, H3′), 6.166.22 (1H, m, H2′), 6.94-6.97 (1H, dd, Ar-CH=CH), 7.36-7.41 (Ar), 7.64-7.65 (1H, d, H8), 7.92-8.16 (Ar).

[0798]¹³C (CDCl₃) 6.56 (CH₂(cpro)), 19.85 (CH₃(ala)), 23.33 (CH(cpro)), 34.23 (C6′), 46.07 (C4′), 50.47, 50.53 (OCH₃ (ala)), 51.78 (CH(ala)), 59.51 (Cl′), 69.19, 69.29 (C5′), 113.84, 114.08 (C5), 121.14, 121.21, 121.27 (o-Ph), 128.49 (p-Ph), 130.74, 130.85 (m-Ph), 132.84 (C3′), 136.01 (C2′), 136.88, 136.99 (C8), 156.47 (C2), 160.99, 161.03 (C4), 174.27 (CO).

[0799] (1 S,4R)-4-(2-amino-⁶-cyclopropylamino9H-purin-9-yl)-2-cyclopentene-1-methanol O-[o(carboxylate ethyl ester)phenyl methoxy-L-alaninyl]phosphate Cf1798

[0800] This was prepared by Standard procedure 4 in 24% yield.

[0801]³¹P (CDCl₃) 4.03, 4.16

[0802]¹H (CDCl₃) 0.64-0.70 (2H,m, CH₂ (cpro)), 0.92-0.93 (2H, d, CH₂ (cpro)), 1.38-1.47 (6H, m, CH₃(ala), CH₃CH₂O), 1.73-1.83 (1H, m, H6′), 2.78-3.24 (3H, m, H6′, H4′, CH(cyclo)), 3.64-3.72 (3H, s, OCH₃(ala)), 4.084.20 (1H, m, CH(ala)), 4.234.45 (4H, m, H5′, CH₂CH₃), 5.21 (2H, bs, NH2), 5.55-560 (1H, m, H1′), 5.89-5.93 (1H, m, H3′), 6.13-6.18 (1H, m, H2′), 7.23-7.61 (1H, m, H8), 7.88-7.92 (1H, d, Ar).

[0803]³¹C (CDCl₃) 7.95 (CH₂(cpro)), 14.65 (CH₃CH₂), 21.33, 21.39, 21.68, 21.74 (CH₃(ala)), 24.30 (NHCH), 34.80 (C6′), 46.04, 46.14 (C4′), 50.49 (CH(ala)), 52.74, 52.83 (OCH₃ (ala)), 59.45 (Cl′), 61.76, 61.82 (CH₂CH₃), 69.43, 69.51, 69.64 (C5′), 114.92 (C5), 122.93, 123.09, 123.60, 123.67125.26 (Ar), 131.34 (Ar), 131.77, 131.86 (C3′), 134.00 (Ar), 136.48 (C2′), 137.05 (C8), 150.20, 150.28 (C6), 155.88 (C2), 160.78, 160.86 (C4), 174.28, 174.39, 174.55, 174.65 (CO).

EXAMPLE A

[0804] (1R, 4S)-9-14-(hydroxymethyl)-2-cyclopenten-2-yl] guanine5′-[phenyl-(methozy-L-alaninyl)]-phosphate.

[0805] C₂₁H₂₅O₆N₆P₁, MW=488.45.

[0806] R. Vince and M. Hua, J. Med. Chem. 1990, 33, 17-21, which is hereby incorporated by reference, describes a procedure for the sysnthesis of (1R,4S)-9-{4-(hydroxymethyl)-2-cyclopenten-1-yl]guanine.

[0807] (1R,4S)-9-[4-(hydroxymethyl)-2-cyclopenten 1-yl]guanine (400 mg, 1.618mmol) was dried by azeotroping with anhydrous pyridine (4×10 ml), kept under N₂(g), and suspended in anhydrous THF (30 m1l). tBuMgCl (1.0M solution in THF) (1.6 ml, 1.618mmol) was added dropwise and the resulting darker suspension vigorously stirred for 10 min. Phosphorochloridate (4.79 ml, 2.43mmol) was added dropwise, and the reaction mixture stirred at room temperature for 69 hrs. After this time, the suspended solid was partially in solution but a solid was still observed on the sides of the flask. More phosphorochloridate was added (4.79 ml, 2.43 mmol), and the reaction mixture stirred for a fuirther 55 hrs before being quenched by the addition of sat.NH₄Cl solution (0.25 m). After stirring for a further 10 mins, the solvent was removed under reduced pressure to give the crude product as a yellow gum which was solubilised in MeOH, dried over MgSO₄ (s), filtered and the filtrate reduced to dryness. The residue was solubilised in MeOH, silica added, and then the solvent removed to give the product preabsorbed onto silica which was loaded onto a silica column and eluted with 8% MeOH in CHCl₃. The product was further purified by gradient elution from 5→9 MeOH in DCM on a biotage flash-40 column, and after evaporation of the appropriate fractions, the product was obtained as a white foam (70 mg, 8.6%).

[0808] The compound had the formula

[0809]³¹ P NMR (MeOH-d₄): δ5.18, 4.86 (1:1).

[0810]¹H NMR: δ7.67 (1H), 7.37-7.30 (2H), 7.21-7.14 (3H), 6.17-6.10 (1H), 5.97-5.94 (1H), 5.53-5.48 (1H), 4.28-4.15 (2H), 4.00-3.87 (1′H), 3.66 (3H), 3.18 (1H), 2.83-2.71 (1H), 1.82-1.66 (1H), 1.36-1.29 (3H).

[0811]¹³C NMR: δ174.4*, 158.5, 154.1, 151.7, 151.1*, 136.9*, 136.5, 130.7, 129.7, 125.0, 120.4*, 116.8, 68.9*, 59.8, 51.7, 50.5*, 46.0*, 34.2,19.3*.

[0812] MS ES⁺: m/z 488.86 (100%) (M)⁺, 500.04 (12%)(M+Na)⁺, 507.96 (25%)(M+K)⁺.

[0813] MS FAB: calculated m/z 489.165146, found m/z 489.164677.

In Vitro Testing

[0814] Cells were infected with HIV-1 as previously described [Balzarini et al. AIDS (1991), 5, 21-28]. Briefly, 5×10⁵ cells per milliliter were infected with HIV-1 or HV-2 at 100 CClD₅₀ (50% cell culture infective dose) per milliliter of cell suspension. Then 100 μL of the infected cell suspension was transferred to microtiter plate wells and mixed with 100 μL of the appropriate dilutions of the test compounds. After 4 days giant cell formation was recorded microscopically in the HIV-infected cell cultures [CEM]. The 50% effective concentration (EC₅₀) and 50% cytoxic concentration (CCso) were defined as the compound concentrations required to reduce by 50% the number of giant cells or viable cells in the virus-infected and mock-infected cell cultures, respectively.

[0815] In the following Tables data columns are, in order:

[0816] HIV1 CEM: EC₅₀ in μM for inhibition of HIV-1 in CEM cells.

[0817] HIlI CEM: EC₅₀ in μM for inhibition of HIV-2 in CEM cells.

[0818] CC50 CEM: CC₅₀ in μM for toxicity to CEM cells.

[0819] Table I below contains in vitro data comparing the biological activity of compound cf1490 with its non-phosphorarmidated counterpart, Abacavir, and with the compound of comparative Example A and its non-phosphoramidated counterpart. Abacavir is currently used in the treatment of patients with HIV infection. TABLE I EC₅₀/μM EC₅₀/μM HIV-1 HIV-2 CC₅₀/μM Fold Compound CEM CEM CEM Improvement 1490 0.07 0.09 13.1 30.2 Abacavir 1.9 3 78 Example A 1.3 0.85 123 1.9 Nonphosphoramidated 2 2.3 157 counterpart of Example A

[0820] As can be seen in Table I compound cf 1490 embodying the present invention shows a much enhanced potency (27 to 33 fold) with respect to HIV in vitro than the known non-phosphoraridated Abacavir. The fold improvement in Table I is the mean increase in potency of the phosphoramidate compound versus its parent nucleoside for HIV 1 and HIV 2.

[0821] The surprising nature of this result is demonstrated having regard to Comparative Example A and its non-phosphoramidated counterpart. The structure of the non-phosphoramidated counterpart of Example A isprimafacie similar to that of Abacavir. The phosphoramidate of Example A, however, shows a potency with respect to HIV which is merely comparable to that of its nonphosphoramidated counterpart, whose structural formula is:

[0822] Table II below compares the in vitro potency data of the compound 1490 with known equivalent data disclosed in PCT/GB96/00580 for known phosphoramidated compounds. The data in each case were obtained by the in vitro assay descibed above under “In vitro testing” TABLE II EC₅₀/μM EC₅₀/μM HIV-1 HIV-2 CC₅₀/μM Compound CEM CEM CEM 1490 0.07 0.09 13.1 951 0.1 0.07 5.5 1078 0.55 0.65 209 1093 0.016 0.035 2.57

[0823] Each of compounds 951, 1078 and 1093 is a phosphoramidate of a nucleoside analogue.

[0824] Compound 951 is 2′, 3′-dideoxy -2′, 3′-didehydrothymidine 5′-(phenyl exthoxyalaninyl) phosphoramidate.

[0825] Compound 1078 is 2′, 3′-dideoxy -2′, 3′-didehydrothymidine 5′-(phenyl dimethoxyaspartyl) phosphoramidate.

[0826] Compound 1093 is 2′, 3′-dideoxy adenosine 5′-(phenyl methoxyalaninyl) phosphoramidate.

[0827] As can be seen from Table II the compound 1490 demonstrates a high degree of potency with respect to HIV.

[0828] Potency and toxicity data on an expanded tange of compounds is presented in Table III, in which:

[0829] Cpd and Init refer to the compound reference numbers;

[0830] X refers to the aryl (phosphate) moiety;

[0831] Y refers to the group;

[0832] Z refers to the bonding in the five membered sugar ring:=is unsaturated pentene; H is saturated.

[0833] B in each case is “1592” which refers to the base present in Abacavir.

[0834] The data columns are, in order:

[0835] HIV 1 CEM: EC₅₀ in μM for inhibition of HIV1 in CEM cells

[0836] HIV2 CEM: EC₅₀ in μM for inhibition of HIV-2 in CEM cells

[0837] HIV2CEM.TK- EC₅₀ μM for inhibition of IV-2 in CEM=cells

[0838] CC50 CEM: CC₅₀ μM for toxicity to CEM cells

[0839] EC50 MSV: EC₅₀ μM for inhibition of MSV

[0840] MCC MSV: minimum cytotoxic concentration in MSV essay. HIV2 HIV2 CC50 EC50 Cpd Init X Y Z B HIV1 CBM CBM CEM. TK. CEN MSV MCCMSV 1490 SH PhO MaAlaNH = 1592 0.05 0.05 13.1 1.6 >4 1540 SH CH AlaNH = 1592 1.2 0.95 115 1582 SH PhO BzAlaNH = 1592 0.083 0.11 • 12.5 1583 SH PhO Me-D-AlaNH = 1592 1.38 4.5 • 64.3 1584 SH PhO Me(Me2Gly)NH = 1592 0.067 0.06 • 8.91 1585 SH PhO MePheNH = 1592 1.42 2.13 • 36.1 1587 SH PhO EtAlaNH = 1592 0.07 0.06 • 12.1 1588 SH PhO MeGlyNH = 1592 1.78 2 • ≧100 1589 SH PhO Me2AspNH = 1592 1.42 1.9 • 44.2 1595 SH HO D-AlaNH = 1592 1.2 1.2 0.8 213 1620 SH p-ClPhO MeAlaNH = 1592 0.014 0.063 0.013 4.7 1645 SH PhO tBuAlaNH = 1592 3.7 6 33 11.7 >20 1646 SH PhO PrAlaNH = 1592 0.093 0.12 9 2 >4 1647 SH PhO BuAlaNH = 1592 0.085 0.17 8.23 0.62 >4 1661 SH PhO IPrOAlaNh = 1592 0.5 0.85 9.18 2.75 ≧20 1671 AS p-MeOCOC(OMe2)CPh MeAlaNH = 1592 0.1 0.12 12.1 9.2 >20 1672 AS PhO IPrCH2AlaNH = 1592 0.09 0.1 14.4 1.98 >4 1673 AS PhO tBuCH2AlaNH = 1592 0.15 0.18 8.07 2.92 >4 1674 AS PhO IPrCH2CH2AlaNH = 1592 0.25 0.25 10.7 2.04 >4 1880 AHA PhO MeAlaNH H 1592 12.5 17.5 237 ≧100 >100 1685 SS PhO 3-pentyl Ala NH = 1592 1.6 2 12.5 19.7 10.1 >20 1666 SS PhO Meval NH = 1592 3.5 4 3.5 54.1 11.8 >20 1687 SS PhO tBuCH2CH2AlaNH = 1592 0.2 0.2 0.14 10.2 2.22 >4 1702 AHA — — H 1592 ≧50 ≧50 179 ≧100 >100 1706 SH PhO nPnAlaNH = 1592 0.065 0.08 16.4 1.45 >4 1707 SH PhO cHxAlaNH = 1592 0.33 0.25 10.2 2.84 >4 1708 SH PhO cHxCH2AlaNH = 1592 0.15 0.16 15.1 1.3 >4 1709 SH PhO Me(CHxCH2Gly)NH = 1592 1.2 2 16 1.72 >4 1710 SH 4-Br-PhO MeAlaNH = 1592 0.0055 0.049 5.78 0.51 >0.8 1713 AS 4MOOC(MeO)2CCH2 MeAlaNH = 1592 0.053 0.065 14 10.8 >20 1714 AS PhO dIEtASP = 1592 0.55 2.1 23.1 7.18 >20 1715 AS PhO MeMET = 1592 1.15 2.73 48.9 10.2 >20 1718 SS PhO MeLeuNH = 1592 0.85 1.48 22 8.84 >20 1719 SS PhO MeProN = 1592 4 5.5 19.4 11.6 ≧100 1720 SS PhO Bn2AspNH = 1592 1721 SS PhO IPr(CH2)3AlaNH = 1592 0.05 0.14 12.5 2.2 >4 1722 SS PhO cPentCH2AlaNH = 1592 0.13 0.48 15.2 1737 SH p-F-PhO MeAlaNH = 1592 1738 SH p-I-PhO MeAlaNH = 1592 1739 SH PhO nHxAlaNH = 1592 1749 AS PhO Me2GluNH = 1592 3.5 5.33 36.9 1750 AS PhO MeTrpNH = 1592 3 3.67 18.3 1751 AS PhO MeIleNH = 1592 7 5.33 24.2 1752 AS PhO cHeptAlaNH = 1592 1.3 1.05 6.32

Acid stability

[0841] Compounds were tested for their stability towards acid-mediated hydrolytic decomposition employing a test designed to simulate stomach conditions. Each compound was incubated in dilute HCl of pH1 for 24 hours at 25° C. 0.3 mg of compound were added to IniL of O.1N HCl at 25° C. HPLC was run immediately for time=0 and at intervals up to approximately 24 hours.

[0842] The results for compound 1587, and for comparative compounds labelled 1001 and 1093 and described in PCT/GB96/00580, are given in table IV below. TABLE IV Time Compound left Compound (hr) (%) 1587 0 100 22 77 1001 0 0 17 0 1093 0 100 13 0

[0843] Compound 1001 disappeared immediately (<Imin). Compound 1093 degraded after less than 13 hours. The majority of compound 1587 remained in tact after 22 hours.

[0844] Each of compounds 1001 and 1093 is a phosporamidate of an adenosine analogue. 20 Compound 1001 is 2′, 3′-dideoxy -2′, 3′-didehydroadenosine-5′-(phenylmethoxyalaninyl) phosphate. Compound 1093 is 2′, 3′-dideoxy adenosine 5′-(phenyl methoxyalaninyl) phosphate.

[0845] The results given in Table V above demonstrate the acid stability of a compound embodying the present invention compared to known compounds.

BioloLoical stability

[0846] Compound 1587 of the present invention and the two comparative compounds 1001 and 1093 identified above were tested for their stability towards biological decomposition. Each compound was incubated in normal heparinised human plasma at 37° C. for 4 hours. At selected time points (0, 15, 30 min, and 1, 2, 4 hours) duplicate samples were removed and deproteinated by acetonitrile extraction. Drug concentrations were then determined by LC/MS/MS analysis using standard methods. The results are shown in Table V below. TABLE V Compound % Remaining at 4 hours Half-life (hours) 1587 91 26 1001 52 4.6 1093 50 4.2

[0847] Under the conditions of the test the data in Table V shows a 6-fold stability advantage of compound 1587 over each of compounds 1001 and 1093.

EXAMPLE 1

[0848] (1S,4R)-442-Amino-6-cyclopropylamino-9(purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl ethoxy-L-alaninyl) phosphate Succinate Salt

[0849] (a) Phenylethoxv-L-alaninyl phosphorochloridate

[0850] L-alanine ethyl ester hydrochloride (3.0 g, 0.02 moles) was suspended in dry methylene chloride (40 mL). To this suspension was added phenyl phosphorodichloridate (2.9 ml, 0.02 mol) and the mixture was cooled to −80 ° C. N,N-Diisopropylethylamine (Aldrich, 6.8 mL, 0.04 mol) was added to the reaction in aliquots (1-2 mL) over a 1 h time period. Reaction allowed to wann slowly to room temperature while stirring for 2 h. Organic solvent was removed in vacuo and the residue treated with diethyl ether (100 mL). The diethyl ether solution was filtered to remove insoluble inorganics and concentrated in vacuo to give the product as a colourless syrup. This product was used without further purification in part b.

[0851] (b) (1S.4R)-4-(2-amino-6-cycloironylamino-9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(phenl ethoxy-L-alaninyl)phosphate

[0852] (1S4R)-4-(2-amino-6-cyclopropylamino-9(H)-purin-9-yl)-2-cyclopentene-1-methanol (1.5 g, 5.2 mmol) was dried by addition of dioxane and concentration in vacuo. To the dried nucleoside was added anhydrous pyridine (10 mL) and tethydrofiran (20 mL). Subsequently, tert-butyl magnesium chloride (6 mL, 1M solution in tetrahydrofiran, 6 mmol) was added slowly. The reaction was stirred for 20 min and a solution of phenyl ethoxy-L-alaninyl phosphorochloridate (part a, 3 g, 0.01 mol in 20 mL tetrahydrofiran) was added. The reaction was stirred at room temperature for 10 h and subsequently concentrated in vacuo to a brown syrup. This syrup was dissolved in methylene chloride (100 mL) the methylene chloride extracted with water (2×100 mL), dried MgSO4), filtered and concentrated to a brown solid foam. This solid foam was purified by flash chromatography using 5% methanol in chloroform as eluent to give 1.7 g (60%) of, after purification, a 4:6 mixture of the phosphate isomers as a white solid foam. ¹H-NMR (CDCl₃): δ7.47 (2 x s, 1H), 7.10-7-46 (m, 5H), 6.07 (m, 1H), 5.9 (m, 1H), 5.78 (s, 1H), 5.5 (m, 1H), 4.84 (s, 2H), 4.1 (m, 4H), 4.00 (m, 1H), 3.64 (m, 1H), 3.14 (m, 1H), 3.0 (m, 1), 2.78 (m, 1H), 1.68 (m, 1H), 1.36 (2xd, 3H), 1.22 (2xt, 3H), 0.86 (m, 2H), 0.6 (m, 2H);

[0853]³¹ P-NMR (CDCl₃): δ3.05, 3.02.

[0854] Anal. Calcd. for C₂₅H₃₂N₇O₅P×1/4CHCl₃: C, 53.07; H, 5.70; N, 17.15. Found: C, 52.81; H, 5.95; N, 16.91.

[0855] (c) (1S,4R)-4-(2-Amino-6-cyclonropylamino-9()-,purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl ethoxy-L-alaninyl) phosphate Succinate Salt

[0856] (1S,4R)-4-(2-amino-6-cyclopropylamino-9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl ethoxy-L-alaninyl)phosphate (part 1b, 376 mg, 0.7 mmol) was dissolved in ethanol. To this solution was added succinic acid (82 mg, 0.7 mmol) and the resulting solution evaporated to dryness. The residue was dissolved in acetonitrile (10-20 mL) with heating. Precipitate formed upon cooling. The mixture was stored in the refrigerator overnight and solid collected by filtration to give 330 mg (72%) of a 4:6 mixture of the phosphate isomers as a solid; ¹H-NMR (DMSO-d₆): δ12.14 (s, 2H), 7.58 (s, 1H), 7.1-7.4 (m, 6H), 5.9-6.1 (m, 3H), 5.85 (broad s, 2H), 5.42 (m, 1H), 3.95-4.15 (m, 4H), 3.8 (m, 1H), 3.05 (m, 2H), 2.65 (m, 1H), 2.4 (s, 4H), 1.63 (m, 1H), 1.4 (2xd, 3H), 1.12 (t, 3H), 0.5-0.7 (m, 4H); 3P-NMR (DMSO-d,6): 5; 4.00 and 3.68; high resolution mass spectrum: calcd for C₂₅H₃₂N₇O₅P (M+H)⁺(m/z) 542.2281, found 542.2282.

[0857] Anal. Calcd. for C₂₅H₃₂N₇O₅P C₄H₆O₄1/2H₂O: C, 52.09; H, 5.87; N, 14.66. Found: C, 52.13; H, 5.72; N, 14.61.

EXAMPLE 2

[0858] (1S,4R)-4-(2-amino-6cyclopropylamino-9(H)-purin-9-yl)-2-cyclopentene1-methanol O-(phenyl methoxy-L-alaninyl)phosphate Succinate Salt

[0859] (a) Phenylmethoxy-L-alaninyl phosphorochloridate.

[0860] L-alanine methyl ester hydrochloride (10 g, 0.072 mol) was suspended in dry methylene chloride ( 100 mL). To this suspension was added phenyl phosphorodichloridate (10.7 g; 7.6 mL) and the mixture was cooled to −80 ° C. Subsequently N,N-Diisopropylethylamine (Aldrich, 25 ml) was added to the reaction in aliquots (1-2 mL) over a 1 h time period. The solution was stirred for 30 min at −80° C., then allowed to warm slowly to room temperature while stirring for 2 h. Organic solvent was removed in vacuo and the residue treated with diethyl ether (100 mL). The diethyl ether solution was filtered to remove insoluble inorganics and concentrated in vacuo to give the product as a colorless syrup:

[0861]³¹ P-NMR (CDCl₃) 8 8.61; 8.37 ppm. This product was used without further purification in

EXAMPLE 2b

[0862] (b) (1S,4R)S-(2-aIino-6-cyclopropylino-9M-purin-9-yl-2-cyclopentee-1-metanol O-(phenyl methoxy-L-alaninyl)phosphate

[0863] (1S4R)-4(2-amino-6-cyclopropylamino-9H)-purin-9-yl)-2-cyclopentene-1-methanol (5.5 g, 0.018 moles) was dried by addition of dioxane and concentration in vacuo. To the dried nucleoside was added anhydrous tetrahydrofuiran (30 mL) and pyridine (40 ni). Subsequently tert-butyl magnesium chloride (23 mL, 1M solution in tetrahydrofuran, 1.3 equivalents) was added slowly. The reaction was stirred for 20 min and a solution of phenylmethoxy-L-alaninyl phosphorochloridate (12 g, 0.043 moles, 2.5 equivalents in 20 mL THF) was added. The reaction was stirred at room temperature for 12 h and subsequently concentrated in vacuo to a brown syrup. This syrup was dissolved in methylene chloride (100 mL) the methylene chloride extracted with water (2×100 mL), dried (MgSO₄), filtered and concentrated to a brown foam. This foam was purified by flash chromatography using 5% methanol in chloroform as eluent to give 6.9 g (75%) of a mixture of the phosphate isomers of the title compound as a white solid foam. ¹H-NMR

[0864] (CDCl₃): δ7.5 (2 x s, 1H), 7.1-7.4 (m, 5H), 6.1 (m, 1H) 5.9 (m, 2H), 5.5-5.6 (m, 1H), 4.9 (bs, 2H), 4.2 (m, 2H), 4.05 (m, 1H), 3.7 (s, 3H), 3.6-3.8 (m, 1H) 3.17 (m, 1H), 3.0 (a, 1H), 2.8 (m, 1H), 1.7 (m, 1l ), 1.4 (2 x d, 3H), 0.9 (m, 2H), 0.6 (m, 2H); 3NMR (CDl₃): δ3.07, 3.02.

[0865] Anal. Calcd. for C₂₄H₃₀N₇O₅P×2/5 CHCl₃: C, 50.94; H, 5.33; N, 17.00. Found: C, 50.83; H, 5.39; N, 16.94.

[0866] (c) (1S,4R)-4-(2-amino-6-cyclopropyamino-9(H)-purin-9-yl)-2-cyclopentne-1-methanol O-(phenyl methoxy-L-alaninyl)phosphate Succinate Salt

[0867] (1S,4R) 4-2-amino-6-cyclopropylamino-9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl methoxy-L-alaninyl)phosphate (part b, 100 mg, 0.19 mmol) was dissolved in methanol. To this solution was added succinic acid (22 mg, 0.19 Cmol) and the resulting solution evaporated to dryness. The residue was dissolved in acetonitrile (GOEL) with heating. Precipitate formed upon cooling. The mixture was stored in the refrigerator overnight and solid collected by filtration to give 70 mg (57%) of a mixture of the phosphate isomers as a solid; ¹H-NMR (DMSO-di): 6 12.15 (s, 2H, D₂O exchangeable), 7.61 (s, 1H), 7.36 (3H, becomes 2H on D₂O exchange), 7.20 (3H), 5.9-6.1 (m, 3H), 5.88 (broad s, 2H, D₂O exchangeable), 5.44 (m, 1H), 4.0-4.2 (m, 2H), 3.85 (m, 1H), 3.60 (s, 3H), 3.05 (2H), 2.65 (m, 1H), 2.44 (s, 4H), 1.64 (m, 1H), 1.23 (m, 3H), 0.5-0.7 (m, 4H);

[0868]³¹ P-NMR (DMSO-d₆): δ3.99 and 3.66;

[0869] Anal. Calcd. for C₂₄H₃₀N₇O₅P C₄H₆O₄·1/2H₂O: C, 51.38; H, 5.70; N, 14.98. Found: C, 51.36; H, 5.66; N, 14.99.

EXAMPLE 3

[0870] (1S,4R)-4-(2-Aminio-6cyclopropylamino-9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl ethoxy-L-alaninyl) phosphate Fumarate Salt

[0871] (1S,4R)-4-(2-amino-6-cyclopropylamino-9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl ethoxy-L-alaninyl)phosphate (198 mg, 0.37 mmol) was dissolved in ethanol. To this solution was added fiumaric acid (43 mg, 0.37 mmol) and the resulting solution evaporated to dryness. The residue was dissolved in acetonitrile (10 mL) with heating. Precipitate formed upon cooling. The mixture was stored in the refiigerator overnight and solid collected by filtration to give 185 mg (75%) of a 4:6 mixture of the phosphate isomers as a solid; ¹H-NMR (DMSO-d₆): δ7.6 (s, 1H), 7.1-7.4 (m, 6H), 6.64 (s, 2H), 5.9-6.1 (m, 3H), 5.87 (broad s, 2H), 5.44 (m, 1H), 3.95-4.15 (m, 4H), 3.84 (m, 1H), 3.05 (m, 2H), 2.65 (m, 1H), 1.63 (m, 1H), 1.23 (in, 3H), 1.15 (t, 3H), 0.5-0.7 (m, 411);

[0872]³¹ P-NMR (DMSO-d₆): δ; 4.00 and 3.67.

[0873] Anal. Calcd. for C₂₅H₃₂N₇O₅P·C₄H₄O₄·1/2H₂O: C, 52.25; H, 5.59; N, 14.71. Found: C, 52.25; H, 5.51; N, 14.49.

EXAMPLE 4

[0874] (1S,4R)-4-(2-Amino-6-cyclopropylamino-9(H)-purin-9-yl)-2-cyclopenten1-methanol O-(phenyl ethoxy-L-alaninyl) phosphate Glutarate Salt

[0875] ( S,4R)-4-(2-amino-6-cyclopropylaInino-9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl ethoxy-L-alaninyl)phosphate (part 1b, 200 mg, 0.38 mmol) was dissolved in ethanol. To this solution was added glutaric acid (50 mg, 0.38 mmol) and the resulting solution evaporated to dryness. The residue was dissolved in acetonitrile (10 mL) with heating. The mixture was stored in the refiigerator overnight and solid collected by filtration to give 130 mg (50%) of a 67:33 mixture of the phosphate isomers as a solid; ¹H-NMR (DMSO-d₆): δ7.6 (s, 1H), 7.1-7.4 (m, 6H), 5.9-6.1 (m, 3H), 5.87 (broad s, 21), 5.44 (m, 1H), 3.95-4.2 (m, 4H), 3.8 (m, 1H), 3.1 (m, 2H), 2.65 (m, 1H), 2.25 (t, 4H), 1.7 (m, 3H), 1.23 (m, 3H), 1.15 (t, 3H), 0.5-0.7 (m, 4H);

[0876]³¹ P-NMR (DMSO-d₆): δ; 4.00 and 3.68.

[0877] Anal. Calcd. for C₂₅H₃₂N₇O₅P C₅HBO₄-1/2H₂O: C, 52.78; H, 6.05; N, 14.36. Found: C, 52.97; H, 6.07; N, 14.33.

EXAMPLE 5

[0878] (1S,4R)-4-(2-Amino-6-cyclopropylamino-9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl ethoxy-L-alaninyl) phosphate D-Tartrate Salt

[0879] (1S,4R)-4-(2-amino-6-cyclopropylamino-9(H)purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl ethoxy-L-alarunyl)phosphate (157 mg, 0.29 mmol) was dissolved in ethanol. To this solution was added D-tartaric acid (44 mg, 0.29 mmol) and the resulting solution evaporated to dryness. The residue was dissolved in acetonitrile (10 mL) with heating. The mixture was stored in the refrigerator overnight and solid collected by filtration to give 112 mg of a 53:47 mixture of the phosphate isomers as a solid; ¹H-NMR (DMSO-d₆): δ7.6 (s, 1H), 7.1-7.4 (m, 6H), 5.8-6.2 (i 5H), 5.44 (m, 1H), 4.3 (s, 2H), 3.95-4.2 (in, 4H), 3.8 (m, 1H), 3.35 (broad s, 2H), 3.1 (m, 2H), 2.65 (m, 1H), 1.7 (m, 1H), 1.23 (m, 3H), 1.15 (t, 3H), 0.5-0.7 (m, 4H);

[0880]³¹ P-NMR (DMSO-d₆): δ; 4.00 and 3.67.

EXAMPLE 6

[0881] (1S,4R)-4-(2-amino6-cyclopropylamino9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl metioxy-L-alaninyl)phosphate Diastereomers

[0882] An approximately 1:1 mixture of diastereomers of (1S,4R)-4-(2-Amino-6-cyclopropylamino-9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl methoxy-L-alaninyl)phosphate was prepared using similar methodology as above: ¹H-NMR (CDCl₃): δ7.5 (2 x s, 1H), 7.1-7.4 (m, 5H), 6.1 (m, 1H), 5.9 (m, 2H), 5.5-5.6 (m, 1H), 4.9 (bs, 2H), 4.2 (m, 2H), 4.05 (m, 1H), 3.7 (s, 3H), 3.6-3.8 (m, 1H) 3.17 (m, 1H), 3.0 (m, 1H), 2.8 (m, 1H), 1.7 (m, 1H), 1.4 (2 x d, 3H), 0.9 (m, 2H), 0.6 (m, 2H);

[0883]³¹ P-NMR (CDCl₃): δ3.07, 3.02.

[0884] Anal. Calcd. for C₂₄H₃₀N₇O₅P×2/5 CHCl₃: C, 50.94; H, 5.33; N, 17.00. Found: C, 50.83; H, 5.39; N, 16.94.

[0885] The phosphate isomers were separated with Supercritical Fluid Chromatography using a Chiralpak AS column, 25% methanol in carbon dioxide as the eluent, flow rate 2 mILn, temperature 40° C., and pressure 3000psi. The first isomer to elute had a RT of 2.9 min and was 100% enantiopure; evaporation of solvents gave the isomer as a white solid foam: ¹H-NMR (CDCl₃): δ7.50 (s, 1H), 7.3-7.4 (m, 2H), 7.15-7.25 (m, 3H), 6.11 (m, 1H), 5.91 (m, 1H), 5.86 (s, 1H), 5.55 (m, 1H), 4.89 (s, 2H), 4.24 (m, 2H), 4.05 (m, 1H), 3.72 (s, 3H), 3.65 (m, 1H), 3.20 (m, 1H), 3.02 (m, 1H), 2.83 (m, 1H), 1.72 (m, 1H), 1.37 (d, 3H), 0.89 (m, 2H), 0.62 (m, 2;

[0886]³¹ p-NMR (CDCl₃): 3 3.07.

[0887] Anal. Calcd. for C₂₄H₃₀N₇O₅P×1/7CHCl₃: C, 53.25; H, 5.58; N, 18.00. Found: C, 53.27; H, 5.69; N, 17.72.

[0888] The second isomer to elute had a RT of 6.7 min and was 100% enantiopure; evaporation of solvents gave the isomer as a white solid foam: ¹H-NMR (CDCl₃): 3 7.52 (s, 1li, 725-7.4 (m, 2H), 7.15-7.22 (m, 3H), 6.11 (m, 1H), 5.94 (m, 1H), 5.85 (s, 1H), 5.55 (m, 1H), 4.88 (s, 2H), 4.22 (m, 2H), 4.04 (m, 1H), 3.75 (s, 3H), 3.7-3.75 (m, 1H), 3.17 (m, 1H), 3.04 (m, 1H), 2.80 (m, 1H), 1.73 (m, 1H), 1.42 (d, 3H), 0.89 (m, 2H), 0.67 (m, 2H);

[0889]³¹ P-NMR (CDCl₃): δ3.0.

[0890] Anal. Calcd. for C₂₄H₃₀N₇O₅P×1/5 CHCl₃: C, 52.71; H, 5.52; N, 17.78. Found: C, 52.61; H, 5.67; N, 17.53.

EXAMPLE 7

[0891] (1S,4R)-4-(2-Amino-6-cyclopropylamino-9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl Nl-methylamino-L-alaninyl) phosphate Sodium Salt

[0892] (1S,4R)-4-(2-Amino-6-cyclopropylamino-9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl methoxy-L-alaninyl)phosphate (0.060 g, 0.11 mmoles) was suspended in solution of 40% aqueous methylamine (60 ml) and stirred at room temperature for 18 hours. The volatiles were removed by spin evaporation in vacuo and the residue was dissolved in water (50 ml), extracted with dichloromethane (2×50 ml) and purified by anion exchange chromatography on a Sep-Pak® Vac 35cc Accell™ Plus QMA cartridge (Waters Corp., P/N WAT054725) (HCO3- form) with an aqueous ammonium bicarbonate buffer (0 -0.5Mgradient, 1 L). The appropriate fractions were combined and the volatiles were remove by spin evaporation in vacuo. The residue was twice dissolved in deionized water and spin evaporated in vacuo to give (1S,4R)-4-(2-amino-6-cyclopropylamino-9(H), puiin-9-yl)-2-cyclopentene-1-methanol O-(phenyl N-methylamino-L-alaninyl) phosphate as the ammonium salt. This salt was dissolved in deionized water and passed through a Sep-Pak®Vac 20 cc Accell™ Plus CM cartridge (Waters Corp., PIN WAT054675) (Na⁺ form) using deionized water. The appropriate fractions were combined and lyophilized to give 0.026 g (46% yield) of (1S,4R)-4-(2-amino-6-cyclopropylamino-9(H)-purin-9-yl)2 cyclopentene-1-methanol O-(phenyl N-methylamino-L-alaninyl) phosphate sodium salt 2.2 hydrate as a white solid:: MS (ES) m/e 449 (MH⁻).

[0893] Anal. Calcd. for C₁₈H₂₆N₈NaO₄P·2.2 H₂O: C, 42.22; H, 5.98; N, 21.88. Found: C, 42.36; H, 5.77; N, 21.66.

EXAMPLE 8

[0894] (1S,4R)-4-(2-Amino-6-cyclopropylamino-9(M-purin-9-y i)-2-cyclopentene-1-methanol O-(phenyl N-cyclopropylamino-L-alaninyl) phosphhate Sodium Salt

[0895] (1S,4R)-4-(2-Aniino-6-cyclopropylamino-9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl N-cyclopropylaminno-L-alaninyl) phosphate sodiurm salt was prepared by a method analogous to that used to prepare (1S,4R)-4-(2-amino-6-cyclopropylamino 9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl N-methylamino-L-alaninyl) phosphate sodium salt except that the 40% aqueous methylamine solution was replaced by a solution of cyclopropylamine (5 ml, 72 mmoles) in deionized water (50 ml). Lyophilization ofthe combined fractions gave 35 mg (58% yield) of (1S,4R)-4-(2-amino-6-cyclopropylamino-9(H)-putin-9-yl)-2-cyclopentene-1-methanol O-(phenyl N-cyclopropylamino-L-alaninyl) phosphate sodium salt 2.5 hydrate as a white solid: MS (ES⁻) m/e 475 (MH⁻).

[0896] Anal. Calcd. for C₂₀H₂₈N₈NaO₄P·2.5 H₂O: C, 44.20; H, 6.12; N, 20.61. Found: C, 44.27; H, 5.81; N, 20.49.

EXAMPLE 9

[0897] (1S,4R)-4-(2-Amino-6-cyclopropylamino-9(H)-purin-9-yl)2-cyclopentene-1-methanol O-(phenyl N,N-dimethylamino-L-alaninyl) phosphate Sodium Salt

[0898] (1S,4R)-4 -(2 -Amino-6-cyclopropylamino-9(H)-purin-9-yl)-2cyclopentene-1-methanol O-(phenyl N-dimethylaimino-L-alaninyl) phosphate sodium salt was prepared by a method analogous to that used to prepare (1S,⁴R)-4(2-amino-6-cyclopropylamino-9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl N-methylanino-L-alaninyl) phosphate sodium salt except that the 40% aqueous methylamine solution was replaced by a 40% aqueous dimethylamine solution (50 ml). Lyophilization of the combined fractions gave 39 mg (59% yield) of (1S,4R)-4-(2-amino-6-cyclopropylamino-9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl N,N-dimethylamino-L-alaminyl) phosphate sodium salt trihydrate as a white solid: MS (ES⁻) m/e 463 M).

[0899] Anal. Calcd. for C₁₉H₂₈N₈NaO₄P ·3.0 H₂O: C, 42.22; H, 6.34; N, 20.73. Found: C, 42.40; H, 6.01; N, 20.51

EXAMPLE 10

[0900] (1S,4R)-4-(2-Amino-6-cyciopropylamino-9(-purin-9-yl)-2-cyclopentene-1-methanol O-(L-alaninyl) phosphate Disodium Salt

[0901] (1S ,4R)-4-(2-Amino-6-cyclopropylanino-9H)-purin9-yl)-2- cylopentene-1-methanol O-(phenyl methoxy-L-alaninyl)phosphate (0.5 g, 0.95 mmoles) was suspended in solution of triethylamine (30 ml) and deionized water (30 ml) and stirred at room temperature for 18 hours. The volatiles Were removed by spin evaporation in vacuo and the residue was dissolved in water (50 ml), extracted with dichloromethane (2×50 ml) and purified by anion exchange chromatography on a Sep-Pak® Vac 35 cc Accell™ Plus QMA cartridge (Waters Corp., P/N WAT054725) (HCO₃ ⁻ form) with an aqueous ammonium bicarbonate buffer (0 -0.5Mgradient, 1 L). The appropriate fractions were combined and the volatiles were remove by spin evaporation in vacuo. The residue was twice dissolved in deionized water and spin evaporated in vacuo to give (1S,4R)-4-2-amino6-cyclopropylamino-9(H)-purin-9-yl)-2cyclopentene-1-methanol O-(L-alaninyl) phosphate as the ammonium salt. This salt was dissolved in deionized water and passed tluough a Sep-Pak® Vac 20 cc Accell™ Plus CM cartridge (Waters Corp., P/N WAT054675) (Na⁺ form) using deionized water. The appropriate fractions were combined and lyoplhilized to give 0.430 g (86% yield) of (1S,4R)-4-(2-amino-6-cyclopropylamino-9(H)-purin-9-yl)-2-cyclopentene-1-methaniol O-(L-alaninyl) phosphate disodium salt 2.5 hydrate as a white solid: MS (ES⁻) m/e 436 M⁻)

[0902] Anal. Calcd. for C₁₇H₂₂N₇Na₂O₅P 2.5 H₂O: C, 38.79; H, 5.17; N, 18.63. Found: C, 38.62; H, 5.11; N, 18.43.

Anti-Hepatitis B Virus Activity

[0903] Compounds of Example 1 to 10 were tested for anti- Hepatitis B Virus activity according to the method described by Jansen, R. et al., Antimicrobial Agents and Chemotherapy, Vol.37, No. 3, pp.441-447, 1993. Representative IC₅₀ values were in the range of 0.017μM -3.0 μM.

[0904] The solubility and solution/solid state stability of three salt forms of (1S, 4R)-4-[2-amino-5(cyclopropylamino)-9(H)-purin-9-yl]-2-cyclopentene-1-methanol O-(phenyl ethoxy-L-alaninyl) phosphate

[0905] The salts have handling and formulation advantages in that they are stable, free-flowing crystalline solids that do not change composition, even at elevated temperature and humidity. The free base of (1S, 4R)-4-[2-amino-6-(cyclopropylamino)-9(H)-purin-9-yl]-2-cyclopentene-1-methanol O-(phenyl ethoxy-L-alaninyl) phosphate in contrast, is a hygroscopic, amorphous solid foam that could not be crystallized. 0.1 N HCl PBS HPMC/Tween Solid State Solid Solubility Stability Solubility Stability Solubility Stability Stability Form Type* (mg/mL) (%) (mg/mL) (%) (mg/mL) (%) (%) Free Amorphous >5 69.1 0.054 98.5 0.04 97.6 93.7 Base Hygroscopic Glutarate crystals >5 69.3 0.084 99.9 >0.25, <1 98.6 98.9 Fumarate crystals >5 70.0 0.086 98.5 0.22 98.3 97.1 Succinate crystals >5 66.0 0.069 99.8 >0.25, <1 98.8 99.6

[0906] The free bases of the phosphoramidates of 2′, 3′-dideoxy adenosine and 2′,3′-dideoxy-2′, 3′-didehydroadenosine are hygroscopic amorphous foams or gums. However, their instability to acid prevents advantageous utilization of complexes Dith acids to form salts with improved physical properties; exposure to acids degrades these compounds rapidly. (1S, 4R)-4-[2-amino-⁶-(cyclopropylamino)-9H)-purin-9-yl]-2-cyclopentene-1-methanol (abacavir) has enhanced stability to acid, compared to nucleosides containing labile glycosidic bonds between heterocycle and sugar. Thus phosphoramidate protides of abacavir fonn stable salts that have been found to have advantageous physical properties suitable for pharmaceutical development. 

1. A compound of the formula (I):

wherein Ar is an aryl group R¹ and R² are each independently selected from the group comprising H, alkyl and aryl groups, X is selected from the group comprising O, NH, NR⁴ and S wherein R⁴ is selected from the group comprising alkyl and aryl; R⁵ is selected from the group comprising H, alkyl and aryl groups, wherein when R¹ and R⁵ are each alkyl they may be linked to form a 5- or 6- membered ring; and R³ is selected from the group comprising H. alkyl, aryl, heterocyclic and polycyclic groups, or a pharmaceutically acceptable derivative or metabolite thereof.
 2. A compound according to claim I wherein Ar is phenyl or substituted phenyl.
 3. A compound according to any one of claims 1 to 2 wherein R³ is selected from the group comprising C₃, —C₂H₅ and CH₂Ph.
 4. A compound of the formula (II):

wherein R¹, R², R³, R⁵ and X have the meanings ascribed in claim 1 .
 5. A compound according to any one of claims 1 to 4 wherein R¹ and R² are the same or different and are H, —CH₃ or —CH₂CH₃.
 6. A compound according to any one of claims 1 to 4 wherein R¹ is H and R² is 3 or CH₂—Ph.
 7. A compound according to any one of claims 1 to 6 wherein the C atom bearing R¹ and R² is chiral.
 8. A compound according to any one of claims 1 to 6 wherein the compound has L chirality with respect to the C atom bearing R¹ and R².
 9. A compound according to any one of claims 1 to 8 wherein X is O.
 10. A compound selected from: (1S,4R)-4-[2-wnino-6cyclopropylamino)-9H-puSdn-9-yl]-2-cyclopentene-1-methanol O-[phenyl methoxy-L-alaninyl3 phosphate (1S14R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-L-alannyl3 phosphate diammonium salt (1S,4R)-4-[2-amino-6-(cyclopropylo)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[phenyl benzyloxy-L-alaiinyl]phosphate (1S,4R)-4-[2-anino-⁶-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[phenyl methoxy-D-alaninyl]phosphate (1S,4R)-4 2-amino-6-(cylopropyla no)-9H-purin-9-yll-2-cyclopentcne-1-methanol O-[phenyl methoxy-α,α-dimethylglycinyl]phosphate (1S ,4R)-4-[2-amino-6(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[phenyl methoxy-L-phenylalaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene 1-methanol O-[phenyl ethoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yll-2-cyclopentene-1-methanol O-[phenyl methoxyglycinyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-metanol O-[phenyl L-aspartyl dimethyl ester]phosphate, (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[4-chlorophenyl methoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-pufin-9-yll-2-cyclopentene-1-methanol O-[phenyl tertbutyloxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropya no)-9H-purin-9-yl]-2-cyclopentene-S-metanol O-[phenyl n-propoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[Phenyl n-butyloxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[Phenyl 1-propoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2c-yclopentene-1-methanol O-[(p-(2″, 2″-dimethoxypropionic acid methyl ester) phenyl) methoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylammo)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[phenyl (2-methylpropyl)oxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene 1-methanol O-[phenyl (2,2-dimethylpropyl)oxy-L-alaninyl]phosphate (1S,4R)-4-amino-6-(cyclopropylamino)-9H-purin-9-yl]2-cyclopentene-1-methanol O-[phenyl 3-methylbutyloxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopertene-1-methanol O-[phenyl 3-pentyloxy-L-alaninyl]phosphate (1S,4R)-4-2-amino-6-(cyclopropylamino)-9H-purin-9-yl],-2-cyclopentene-1-methanol O-[phenyl methoxy-L-valinyl]phosphate (1S,4R)-4-12-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[phenyl 3,3-dimethyl-1-butyloxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[Phenyl n-pentyloxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[Phenyl cyclohexyloxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[Phenyl cyclohexanemethoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[Phenyl methoxy-3-cyclohexane-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[4-bromophenyl methoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[phenyl diethoxy-L-aspartyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[phenyl methoxy-L-methionyl]phosphate (1S,4R)-4-[2-amino6-(cyclopropylaznino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[phenyl methoxy-L-leucinyl]phosphate (1s,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[phenyl methoxy-L-prolinyl]phosphate. (1S,4R)-4-[2-amino-6(cycloproylamino)-9H-purin-9-yl]-2-cyclopentene-1-methylene-[phenyl dibenzyloxy-L-aspartinyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[phenyl 4-methyl-1-pentyloxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-(cyclopropylamino)-9H-purin-9-yl -2-cyclope tene-1-methanol O-[phenyl cyclopentylmethoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[4-fluorophenyl methoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[4-iodophenyl methoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopopylamino)-9H-puiin-9-yl]-2-cyclopentene-lmethanol O-[phenyl dimethoxy-L-glutamyl]phosphate (1s,4R)-4-[2-amino6-(CYClopropylamiflio)-9H-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl methoxy-L-tryptophanyl]phosphate (1S,4R) 4-[2-amino-6-(cyclopropyl0o)-9H-purin-9-yl]--cyclopentene-1-metanol O-(phenyl methoxy-L-isoleucinyl]phosphate (1S (1S,4R)-4-[2-amino6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[phenyl cycloheptanyloxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylaminlo)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[phenyl cyclobutylmethoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[phenyl cyclopropylmethoxy-L-alaninyl]phosphate (1S,4R)$[-amino-6cycloproylamino)-9H-purin-9-yl]-2 syclpentene-1-methanol O-[phenyl cyclobutyloxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[phenyl cyclopentyloxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-i-methanol O-[phenyl phenethoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[phenyl 3-phenyl-1-propoxy-L-alaninyl]phosphate (1S,4R)-4-m2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2 myclopentene-1-methanol O-[phenyl 4-phenyl-1-butoxy-L-alaninyl]phosphate (1S4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-metanol O-[phenyl 2-cyclohexyl-1-ethoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclope itene-1-methlanol O-[phenyl 3-cyclohexyl-1-propoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9yl]-2-cyclopentene-1-methanol O-[phenyl 4cyclohexyl-1-butoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[phenyl methoxy-α-ethyl-L-glycinyl]phosphate (1S,4R)-4-[2-amino-6-cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O[phenyl methoxy-α-phenyl(RS)glycinyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9yl]-2-cyclopentene-1-methanol O-[phenyl methoxy-α-propyl-L-glycinyl]phosphate) (1S,4R)-4-12-anino6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopente-1-methanol O-([phenyl methoxy-α-butyl-L-glycinyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[p-phenoxyphenyl methoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[p-phenylphenyl methoxy-L-alaninyl)]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[4-hydroxyacetophenone methoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[4-butylphenyl methoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[p-methoxyphenyl methoxy-L-alaniyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2cyclopentene-1-methanol O-[p-propoxyphenyl methoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6(cycopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[phenyl methoxy-α,α-cyclopentylglycinyl]phosphate (1S,4R)-4-[2amino-6-(cyclopropylamino)-9H-purin-9-yl]-2Cyclopentene-1-methanol O-[phenyl methoxy-α,α-cylohexylglycinyl]phosphate (1S,4R)-[4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[phenyl methoxy-α,α-cylopropylglycinyl)]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yll-2-cyclopentene-1-methanol O-[phenyl (methoxycarbonyl)phenyl methoxy-L-alaninyl ]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[p-(trifluoromethylthio)phenyl methoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-&(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[p-(2-methoxyvinyl)phenyl methoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-puwin-9-yl]-2-cyclopentene-1-methanol O-[p-(2-phenylcarbonylvinyl)phenyl methoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-64cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[p-(2,2-dicyanovinyl)phenyl methoxy-L-alaninyl]phosphate (1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol O-[o-(carboxylate ethyl ester)phenyl methoxy-L-alaninyl]phosphate (1S,4R)-4-(2-amino-6-(cyclopropylamiino-9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl ethoxy-L-alaninyl) phosphate succinate salt (1S,4R)-4-(2-amino6yclopropylamino-9(H)-purin-9yl)-2-cyclopentene-1-methanol O-(phenyl methoxy-L-alaninyl) phosphate succinate salt (1S,4R)-4-(2-amino-6-cyclopropylamino-9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl ethoxy-L-alaniyl) phosphate fiimarate salt (1S,4R)-4(2-amino-6-cyclopropylamino-9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl ethoxy-L-alaninyl) phophate glutarate salt (1S,4R)-4-(2-amino-6-cyclopropylamino-9(H)-purlin-9-yl)-2-cyclopentene-1-methanol O-(phenyl ethoxy-L-alaninyl) phosphate D-tartrate salt (1S,4R)-4-(2-amino-6-cyclopropylamino-9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl methoxy-L-alaninyl) phophate diastereoisomers (1S,4R)-4-(2-amino6-cyclopropylamino-9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl N-methylamino-L-alaniinyl) phosphate sodium salt (1S,4R)-4-(2-amino-6-cyclopropylamino-9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl N-cyclopropylamino-L-alaninyl) phosphate sodium salt (1S,4R)-4(2-amino-6-cyclopropylamino-9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(phenyl N,N-dimethylamino-L-alaninyl) phosphate sodium salt (1S,4R)-4-(2-amino-6-cyclopropylamino-9(H)-purin-9-yl)-2-cyclopentene-1-methanol O-(L-alaninyl) phosphate disodiwn salt.
 11. A compound according to any one of claims 1 to 10 for use in a method of treatment, prophylaxis or diagnosis.
 12. Use of a compound according to any one of claims 1 to 10 in the manufacture of a medicament for the treatment or prophylaxis of a viral infection.
 13. Use of a compound according to claim 12 wherein the viral infection comprises HIV.
 14. Use of a compound according to claim 12 wherein the viral infection comprises HIV.
 15. A method of prophylaxis or treatment of viral infection comprising administration to a patient in need of such treatment an effective dose of a compound according to any one of claims 1 to 10 .
 16. A method according to claim 15 wherein the viral infection is HV.
 17. A method according to claim 15 wherein the viral infection is HBV.
 18. A method according to any one of claims 15 to 17 comprising administering orally to a patient an effective dose of the compound.
 19. A pharmaceutical composition comprising a compound according to any one of claims 1 to 10 in combination with a pharmaceutically acceptable excipient.
 20. A composition according to claim 19 in a form for oral administration.
 21. A process for the preparation of a compound according to any one of claims 1 to 10 comprising reacting a compound having the formula

with a compound of formula 